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PART I
Introduction and thesis outline
 
CHAPTER 1.1
General introduction
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1
For a very long time he was ubiquitous, but unknown. Then he became recognized, but 
forgotten. Now, he is well known, but disappearing.
In short, these three sentences could be the historical description of Helicobacter pylori 
(H. pylori), the spiral shaped gram-negative bacterium colonizing the stomach in about 
half of the world’s population. 
This thesis focuses on its epidemiology in a multi-ethnic Western society, in which subjects 
from high and low prevalence countries are living together. Although colonizing the 
stomach, H. pylori has been associated with extra-gastric diseases, like asthma and allergy, 
pregnancy complications and obesity. Because of the adaptive immunological activity of 
the stomach in terms of both T and B-cell function, it is thought that the strong, lifelong 
interaction between H. pylori and the gastric mucosa influences the maturation of the 
immune system. In this context, the “disappearing microbiota” hypothesis states that 
the loss of our ancient indigenous microbiota contributes to the epidemic rise in diseases 
like asthma, allergy and obesity (1). H. pylori, as a member of the ancient indigenous 
microflora, can be used as a proxy for this modern phenomenon. In this thesis we focus 
on the epidemiological relationship between H. pylori and asthma/allergy, and obesity. 
We further assess the association between H. pylori and pregnancy related complications. 
Most of above mentioned studies are embedded in a population-based prospective cohort 
study in Rotterdam, the Netherlands, called the Generation R study. In this study pregnant 
women and their children have been followed from early pregnancy onwards, until they 
will reach adulthood. The study is designed to identify environmental and genetic causes 
of normal and abnormal growth, development and health during fetal life, childhood 
and adulthood (2). Enrolment was aimed in the first trimester, but was allowed until birth 
of the child. In total, 9,778 mothers with a delivery date between April 2002 and January 
2006 were enrolled in the study. Data collection during each trimester of pregnancy 
included physical examination, biological samples, fetal ultrasound examinations, and 
self-administered questionnaires. Information from midwife and hospital registries was 
obtained. During the pre-school period, which refers to the period from birth to 4 years 
of age, information was mainly obtained by means of postal questionnaires. At the age 
of 6 years, blood samples were collected, and information on presence of pulmonary 
symptoms and disease was obtained by questionnaire. Additional detailed hands-on 
assessments were performed in a dedicated research centre to measure e.g. length and 
weight. 
The thesis further focuses on the potential long-term consequence of H. pylori colonization 
at higher age. Chronic active gastritis caused by H. pylori colonization eventually leads 
to intestinal type gastric cancer in a small part of infected subjects. Recognition and 
surveillance of its precursor lesions may prevent patients form invasive cancer. In one 
study we follow-up a cohort of these patients. 
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This thesis is divided in four parts. In part I most of the main topics are introduced, 
followed by the aims and outline of this thesis. Part II and part III enclose the original 
studies on the epidemiology of H. pylori, its association with extra-gastric diseases, 
and the follow-up of premalignant gastric lesions. The main findings of this thesis are 
summarized and discussed in part IV. 
CHAPTER 1.2
Current pharmacotherapy options for gastritis
Wouter J. den Hollander, Ernst J. Kuipers
Expert Opinion on Pharmacotherapy 2012; 13(18):2625-36
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ABSTRACT 
Introduction: Gastritis is a broad term, which is used for different conditions by clinicians, 
endoscopists and pathologists. Classification strategies have led to more congruence 
between specialists. The histological evaluation of the gastric mucosa is mandatory for 
diagnosing and classifying gastritis. Main etiologic factor is infection with H. pylori. The 
clinical importance of gastritis lays in the fact that it predisposes to more pronounced 
damage to the gastric mucosa, in particular peptic ulcer disease, and eventually atrophic 
gastritis, intestinal metaplasia, and gastric malignancy, both adenocarcinoma and MALT 
lymphoma. 
Areas covered: This review covers the current pharmacotherapy options for different 
forms of gastritis. The main focus is on H. pylori-induced gastritis. Thereafter, other forms 
of gastritis like autoimmune gastritis and NSAID-related gastropathy are covered. 
Expert opinion: The emerging problem of antibiotic resistance requires an accurate 
knowledge of local eradication rates. Standard triple therapy should be abandoned 
in regions with high clarithromycin resistance. In these areas sequential or quadruple 
therapy is best initial treatment. Further research should focus on non-invasive and 
effective techniques of susceptibility testing, making a tailored approached available 
and cost-effective. Primary prevention of NSAID-related gastropathy can be enhanced 
by better education for clinicians and patients, so that both right prescription of gastro-
protective agents as therapy adherence will improve. 
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1. INTRODUCTION ON GASTRITIS
Gastritis is in clinical practice a confusing term owing to different definitions used by 
clinicians, endoscopists, and pathologists. Clinicians often use the term as a descriptor 
for patients with acute symptoms of vomiting, presumably of infectious or toxic 
origin, with or without diarrhea (‘gastro-enteritis’). Usually, there is no indication for 
endoscopy and the condition is self-limiting. Acute hemorrhagic or erosive gastritis is 
caused by acute chemical or irritant injury. Endoscopists however use the term ‘gastritis’ 
to describe endoscopic signs of inflammation and irritation of the gastric epithelium, 
including vascular injection, erythema, and edema. Finally, pathologists reserve the term 
for histological signs of inflammation of the mucosa, with ‘acute’ gastritis referring to 
polynuclear infiltration and ‘chronic’ gastritis referring to mononuclears, and ‘acute and 
chronic gastritis’ to a mixed infiltrate (see Table 1 for different forms of gastritis). 
Table 1 Different forms of gastritis and gastropathy
Acute gastritis Uncommon
Acute Helicobacter pylori gastritis
Acute hemorrhagic and erosive gastropathy 
Eosinophilic gastritis
Lymphocytic gastritis
Infectious gastritis, other than H. pylori
- Viruses (CMV, EBV, Herpes virus)
- Bacteria (streptococci, E.coli, 
enterobacteria)
- Mycobacteria
- Fungi (Candida)
- Parasites (Cryptosporidiosis)
Crohn’s disease
Sarcoidosis
Isolated granulomatous gastritis
Common
Helicobacter pylori gastritis
Chemical gastritis/gastropathy
- NSAIDs/ aspirin use
- Bile reflux
- Alcohol
Autoimmune atrophic gastritis
CMV: Cytomegalovirus; EBV: Epstein-Barr virus; NSAID: Non-steroidal anti-inflammatory drug.
Twenty years ago, the need for conformity in definition increased as it became clear that 
there was no obvious correlation between dyspepsia, endoscopic signs of gastritis, and 
histological gastritis was found (3). Often signs of edema, reddening, and swelling of the 
mucosa were found by endoscopy, suggesting gastritis. However, macroscopic features 
observed during gastroscopy were poorly related to histological signs of gastritis (4, 5), 
unless the gastric mucosa either had a typical miniature cobblestone appearance, named 
nodular gastritis (particularly found in children with H. pylori infection), or grossly 
enlarged folds, termed hypertrophic gastritis (6, 7). Since then, endoscopic imaging has 
strongly improved in terms of image resolution, magnification, and light techniques 
such as narrow band imaging (NBI). These improvements have enabled the experienced 
endoscopists to improve on identification of patients with different conditions of the 
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gastric mucosa, such as inflammation, atrophy, and metaplasia. Further techniques such 
as magnification endoscopy are useful in specific situations, such as the evaluation of 
dysplasia, but are not used in routine daily practice (8). These endoscopic improvements 
have for now not made histology redundant. The histological evaluation of the gastric 
mucosa remains mandatory for diagnosing and classifying gastritis. This review will focus 
on the combination of endoscopic and histological gastritis, not on the acute clinical 
picture of nausea and vomiting clinically defined as gastritis. 
1.1 Definitions and histological classification 
In 1990 a new classification of endoscopic and histological signs of gastritis was 
presented: the Sydney System. Until now, this histologic score system is still important 
and widely used (9). It comprises an endoscopic and a histological division, the latter 
being the most important part. Topography of gastritis was considered to be the core of 
the classification: gastritis limited to the antrum, the corpus, or a pangastritis. If known, 
the etiology can be added as prefix. Morphology of the gastric mucosa is divided into 
five graded variables: chronic inflammation (presence of mononuclear cells), activity of 
gastritis (presence of neutrophils), atrophy defined as loss of specialized glands, intestinal 
metaplasia, and the presence of H. pylori (9). Each of these variables is graded as absent, 
mild, moderate or severe. In 1997 an update of this Sydney system was published (10). 
A recommendation to include biopsies from the angulus of the stomach beyond antrum 
and corpus was added. Moreover, a ‘visual analogue scale’ was presented to increase the 
interobserver consistency in grading of the five morphologic variables. 
In 2007 a further gastritis classification was introduced, the Operative Link on Gastritis 
Assessment (OLGA) (11). Rationale for this project was that the histology report till then 
failed to establish a link between gastritis phenotype and risk of malignancy. The OLGA 
system stages a patient into different cancer risk groups, based on the combination of 
antrum and corpus atrophy scores. Stage I comprises the lowest atrophy score and stage 
IV the highest. The stages III and IV are associated with an increased cancer risk compared 
with the lower stages (12). From a clinical perspective, this system was a significant step 
forward. To improve clinical usefulness and reduce interobserver variation as much 
as possible, a system modification, the OLGIM system, was later proposed based on 
replacement of antral and corpus atrophy scores by scores of intestinal metaplasia at 
the same locations (see Table 2) (13). OLGA and OLGIM are both staging systems that 
provide useful information on prognosis and need for follow-up strategies (14). A recent 
guideline on management of premalignant gastric lesions recommends use of these 
systems to define surveillance management for subgroups of patients with different risks 
of progression to gastric cancer (15).   
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Table 2 OLGIM staging system(13). Replacement of IM by atrophy results in the OLGA frame(110).
Corpus
Antrum 
(including 
incisura 
angularis)
IM score No IM (score 0) Mild IM (1) Moderate IM (2) Severe IM (3)
No IM (score 0) Stage 0 Stage I Stage II Stage II
Mild IM (1) State I Stage I Stage II Stage III
Moderate IM (2) Stage II Stage II Stage III Stage IV
Severe IM (3) Stage III Stage III Stage IV Stage IV
OLGIM, operative link on gastric intestinal metaplasia assessment; IM, Intestinal metaplasia; OLGA, 
operative link for gastritis assessment
1.2 Etiology
Although gastritis was known for decades by clinicians as a very common condition, the 
causative agent for the vast majority of gastritis cases was not recognized until 1982 
(16). With the almost ubiquitous prevalence at older age, gastritis was for long even 
considered a normal process of aging. The detection of H. pylori as cause of chronic 
gastritis therefore totally altered the former concepts. This turned the most common 
type of gastritis into a potentially curable disease. 
H. pylori is a gram-negative bacterium, which colonizes more than half of the world’s 
population. Owing to a remarkably high urease activity the bacterium can survive in the 
acid environment of the stomach (17, 18). Urease converts urea present in the gastric 
lumen into alkaline ammonia and carbon dioxide. The prevalence of H. pylori widely varies 
geographically, and is highest in developing countries. In Western countries, however, 
prevalences have been declining over recent decades to below 40% – supposedly as 
a result of improved hygiene and sanitation and the active elimination by antibiotics 
(18). In parallel to the declining infection rate, incidences of H. pylori-related diseases 
also have shown a major decline (19, 20). Acquisition of infection usually occurs in early 
childhood, and is mainly transmitted within families (21). One recent study found that 
during the last decades the decline in acquisition in children has slowed down, suggesting 
a stabilization of the previously decreasing trend (22). Colonization will induce gastritis 
in virtually all infected people, and will persist in adults unless eradication by antibiotics. 
H. pylori is a noninvasive bacterium, but it nevertheless stimulates a robust inflammatory 
and immune response (23). The bacterium disrupts the mucous layer, making the mucosa 
more vulnerable to acid peptic damage. In addition, the host immune response in 
reaction to H. pylori further aggravates tissue injury. Level of immune response, tissue 
damage and development of H. pylori related diseases is influenced by bacterial, host, 
and environmental factors. In H. pylori-positive patients the life-time risk for developing 
ulcer disease is about 10-20% and for developing gastric cancer about 1-2% (18).
This discovery of H. pylori has also led to the recognition of other distinctive forms of 
gastritis (10). In autoimmune atrophic gastritis an immune response in the oxyntic mucosa 
is directed against parietal cells and intrinsic factor. Parietal cell destruction results 
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in hypochlorhydria and ultimate achlorhydria, hypergastrinemia, and loss of pepsin 
activity (24). Serum anti-parietal cell and anti-intrinsic factor antibodies can be found. 
Inflammation is typically found in the fundus-corpus mucosa. This may eventually lead 
to vitamin B12 deficiency with pernicious anemia. Some studies have shown a possible 
association between H. pylori infection and autoimmune gastritis (25, 26). However, 
confirmation of this association needs further large cohort studies of H. pylori-positive 
subjects (13). 
A chemical or reactive gastritis/gastropathy can occur due to chemical irritants and 
drugs. Some people prefer to consider this mucosal injury as a reactive gastropathy, 
since evident signs of an inflammatory process are lacking (27). For example bile reflux 
and NSAIDs/aspirin may cause mucosal damage (10). NSAIDs inhibit gastrointestinal 
mucosal cyclooxygenase (COX) activity. As consequence, synthesis of mucosal protective 
prostaglandins is suppressed, resulting in mucosal damage and eventually in many 
patients mucosal erosions and ulcera. NSAID/aspirin use is therefore a major risk factor 
for gastrointestinal bleeding, with serious morbidity and mortality. Bile reflux gastritis 
results from regurgitation of bile into the stomach owing to an operative stoma, an 
incompetent pyloric sphincter, cholecystectomy, or abnormal duodenal motility (28, 29). 
Rare forms of gastritis include eosinophilic gastritis and lymphocytic gastritis. In 
eosinophilic gastritis the esophagus and intestine can also be involved. Although 
the exact etiology is still unknown, it is thought that there may be involvement of 
environmental factors in diet that play a critical role (30). Damage to the gastrointestinal 
wall is caused by eosinophilic infiltration and degranulation (31). Abdominal pain and 
diarrhea are common complaints. Lymphocytic gastritis is associated with celiac disease 
and possibly with H. pylori infection (10, 32). This rare condition is characterized by a 
dense lymphocytic infiltration of surface and pit gastric epithelium. 
1.3 Symptoms and clinical outcomes
The majority of patients with gastritis do not report any complaints. Dyspepsia, a chronic 
or recurrent pain centered in the upper abdomen, is often reason for diagnostics to 
H. pylori and related diseases (33). The association between H. pylori and non-ulcer 
dyspepsia however is arbitrary. Benefits of H. pylori eradication for relief of dyspepsia 
symptoms differed in several studies, yet were the highest in regions with a high 
prevalence of peptic ulcer disease (33-35). In a systematic review of these trials, H. pylori 
eradication was in comparison with placebo associated with a 10% higher chance of cure 
of dyspeptic symptoms (35).
Although gastritis does not give rise to specific complaints, it may have long-term 
consequences. H. pylori gastritis can lead to mucosal disruption leading to gastric and 
duodenal ulcers (21). It is estimated that 10-20% of H. pylori-positive subjects develop 
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1
peptic ulcer disease during their lifetime, with duodenal ulcer being more common at 
younger age, and gastric ulcer more at older age. Besides H. pylori, chemical irritants or 
drugs also give mucosal erosions, which may lead to ulceration and in addition bleeding 
or perforation. Eradication of H. pylori results in an evident decrease in ulcer recurrence 
rate (36).
Furthermore, H. pylori has since 1994 been classified as type I carcinogen by the WHO, 
because of convincing evidence that chronic H. pylori gastritis increases the risk of 
development of gastric cancer. Chronic H. pylori-induced gastritis eventually leads to 
atrophic gastritis, because of destruction of gastric glands and replacement by fibrosis 
and intestinal-type epithelium (18). In this sequence intestinal metaplasia may progresses 
to dysplasia, which eventually ends in intestinal-type gastric adenocarcinoma in 1-2% of 
infected patients (37). Epidemiological studies have suggested that the vast majority of 
gastric adenocarcinomas are thus related to H. pylori infection. H. pylori-positive subjects 
also have a significant increased risk for the development of gastric MALT lymphoma 
(38). Exact prevalence is unknown, but it occurs in less than 1% of H. pylori-positive 
patients and is declining (39). In approximately 75% of the patients with early stage 
MALT lymphoma eradication induces long-term remission of the lymphoma (40).
Both ulcer disease and gastric cancer can present with widely different features, like 
dyspepsia, bleeding, anaemia, and weight loss. If ‘alarm’ symptoms (i.e. weight loss, 
dysphagia, overt GI bleeding, abdominal mass, and iron deficient anaemia) are present, 
a prompt endoscopy is required. Without these symptoms a test-and-treat strategy for 
H. pylori is recommended (41). 
2. PHARMACOTHERAPY OPTIONS FOR GASTRITIS
2.1 Current treatment of H. pylori-induced gastritis
2.1.1 Indications
Testing for H. pylori is only justifiable if a positive test will be followed by eradication 
treatment. The rationale for eradication should be the prevention or treatment of H. 
pylori-related diseases, which can develop as a result of the chronic active gastritis. Ideally, 
H. pylori eradication is only indicated when either the lesions it causes are reversible or 
progression is stopped. To date, evidence for all possible indications is not available. 
Generally accepted indications are peptic ulcer disease (active or in past), previous gastric 
cancer without total gastrectomy, and MALT lymphoma (see Table 3). Other reasons 
for treatment include chronic atrophic gastritis, uninvestigated dyspepsia, functional 
dyspepsia, and first-degree relatives of patients with cancer (41). Currently accepted 
indications for eradication vary among countries. Recently, the European Helicobacter 
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Study Group has published a new consensus report on management of H. pylori infection 
(41). Compared to the American College of Gastroenterology guideline there is a slight 
difference in their recommendations for testing and treatment of H. pylori infection (17). 
For example, the European in contrast to the American guideline recommends testing 
for H. pylori in case of atrophic gastritis, unexplained iron deficiency anemia, idiopathic 
thrombocytopenic purpura and vitamin B12 deficiency (41). 
Table 3 Indications for H. pylori eradication
Generally accepted Optional
Chronic active gastritis
Peptic ulcer disease (active or in past)
Previous gastric cancer without total gastrectomy
MALT-lymphoma
Chronic atrophic gastritis
Uninvestigated dyspepsia
Functional dyspepsia
First degree relatives of patients with gastric cancer
Chronic active gastritis is completely reversible by H. pylori eradication, and the gastric 
mucosa can be restored to normal (42). However, reversibility is less likely with the 
appearance of gastric atrophy or intestinal metaplasia (43). These premalignant lesions 
particularly occur in patients with corpus-predominant and atrophic gastric, rather 
than in patients with antrum-predominant gastritis. Patients with corpus-predominant 
gastritis therefore are most at risk for developing gastric cancer (18). H. pylori eradication 
can prevent the progression of premalignant lesions to gastric cancer, but the point of 
no return beyond which eradication cannot prevent progression is still unclear (43, 44). 
A meta-analysis presented on this topic found improvement for atrophy of the corpus 
but not for antrum atrophy or gastric intestinal metaplasia (45). Another meta-analysis 
however has reported improvement for both antrum and corpus atrophy (46). Intestinal 
metaplasia is uniformly considered as an irreversible gastric lesion (41). Nevertheless, 
the evidence that eradication prevents the development of gastric cancer is critically 
evaluated in several reviews and meta-analyses, and has been confirmed (46-48). The 
conflicting results regarding the effect of H. pylori eradication on premalignant lesions 
underline the point that H. pylori eradication should as much as possible be performed 
before the appearance of gastric atrophy and in particular intestinal metaplasia (43, 49).
A still controversial reason for H. pylori testing and treatment is uninvestigated 
dyspepsia. It is related to peptic ulcer disease, but in the majority of patients the nature 
is functional (33). Management of patients with uninvestigated dyspepsia is primarily 
depending on the presence of alarm symptoms (33, 41). If present a prompt endoscopy 
is required. In patients younger than 45 years and living in an area with an H. pylori 
population prevalence above 20%, a test and treat approach is recommended (33, 41). In 
populations with lower prevalence, empiric PPI therapy is a valid option (33, 35). 
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2.1.2 Antibiotic resistance
Treatment regimens for H. pylori infection continue to change, particularly owing 
to declining effectiveness of most commonly recommended antibiotic strategies. 
Paradoxically, H. pylori is sensitive to many antibiotics in vitro, but they all fail as 
monotherapy in vivo (18). Several reasons can be mentioned. The niche of H. pylori has a 
low pH and a viscous mucus layer, lowering the effectiveness of the antibiotics. Moreover, 
at any time, a proportion of the bacteria is either not replicating or is replicating very 
slowly, making it difficult for antibiotics to affect them (50). In this way persistence of 
infection usually develops, owing to outgrowth of a small existing population of resistant 
bacteria (51). Several approaches have been introduced to overcome this problem: 
combination of antibiotics, increasing the dose and duration, addition of bismuth to 
reduce bacterial load, and addition of a PPI to increase pH and hence antimicrobial 
efficacy (50). Effectiveness of eradication therapy is also influenced by compliance, which 
is often suboptimal because of the frequent occurrence of antimicrobial-related side 
effects (52). 
Resistance to clarithromycin is the major reason of this reduced effectiveness. Increase of 
clarithromycin dose or duration is not effective, since resistance is associated with failure 
to bind ribosomes (50, 53, 54). This binding is necessary to kill H. pylori. During the past 
10 years clarithromycin resistance is almost doubled from 10% to 18% in Europe (55). 
The highest clarithromycin resistance rates are observed in Southern Europe, Mexico, 
Japan and the Middle East. In Northern Europe resistance rates generally are <10%, 
whereas the other regions have a prevalence >20% (41, 55).
Another important cause of decreasing effectiveness is resistance to metronidazole, 
which also differs geographically. Primary metronidazole resistance was observed in 
27% of patients worldwide, with highest rates in Africa (92%) and lowest in Europe 
(17%) (56). The latter percentage may be an underestimation given the recently found 
resistance rate of 35% in Europe (55). In contrast to other antibiotics, resistance to 
metronidazole can be partially overcome by increase of dose and duration of treatment 
(57). Metronidazole is widely used as substitution of amoxicillin in penicillin-allergic 
individuals. Use of either metronidazole or amoxicillin is supposed to be equivalent with 
respect to effectiveness (41). 
It had been observed that gene polymorphisms of cytochrome P450 2C19 play an 
essential role in PPI metabolism (58). This genetic polymorphism determines fast, 
intermediate, and slow PPI metabolism (resp. 70%, 25-30%, and 2-5% of Caucasian 
population). Triple therapies containing omeprazole achieve lower eradication rates in 
extensive metabolisers (59, 60). Therefore, a tailored therapeutic regimen is suggested 
to improve effectiveness. Prior screening of patients for primary antibiotic resistance 
and CYP2C19 polymorphisms has shown a higher eradication rate, owing to a tailored 
antibiotic treatment and PPI choice (61).
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2.1.3 H. pylori eradication therapy
Initial treatment for H. pylori can consist of triple, quadruple or sequential therapy 
(see Table 4). The usually recommended triple therapy, consisting of a PPI, clarithromycin 
and amoxicillin, is failing in most studies to reach 80% eradication intention-to-treat (50). 
Although antibiotic resistance is increasing to unacceptable levels, this clarithromycin-
containing triple therapy is still recommended by American, European, and Asia-Pacific 
guidelines (41, 62, 63). Choice for this first-line therapy should depend on regional 
clarithromycin resistance. In areas with high clarithromycin resistance guidelines advise 
to abandon the clarithromycin-containing triple therapy (41). Increase of PPI-dose and 
extension of therapy duration to 10-14 days has some effect on eradication rates (64). 
Rationale is that particularly clarithromycin is sensitive for degradation by acid. Increase 
of gastric pH therefore prevents this degradation. In a meta-analysis of single versus 
double dose PPI-therapy, cure rates were significant higher with twice daily PPI-therapy 
(resp. 78% vs. 84% intention-to-treat analysis) (65). Attempts for further improvement 
of eradication are made by extending the duration of therapy. A meta-analysis of 21 
randomized trials showed that treatment for 10 to 14 days had about 5-10% advantage 
over 7-day therapy (66). Nevertheless, 7-day treatment may still be acceptable in regions 
where local studies have shown that a particular treatment is very effective. 
Table 4 Summary of current treatment regimens available for H. pylori eradication
Drug class Drug Triple therapy1 Quadruple 
therapy2
Sequential 
therapy3
Acid suppression Proton pump inhibitor⁴ 20-40 mg bid 20-40 mg bid 20-40 mg bid
Antimicrobials Bismuth compound5 2 tablets bid 2 tablets bid
Amoxicillin 1 g bid 1g bid
Metronidazole 500 mg bid 500mg tid 500 mg bid
Clarithromycin 500 mg bid 500 mg bid
Tetracyclin 500mg qid
Salvage antimicrobials Levofoxacin 300 mg bid 300mg bid
Rifabutin 150 mg bid
Furazolidone 100 mg bid
Doxycycline 100 mg bid
Nitazoxanide 1 g bid
1: Triple therapy consists of a PPI or bismuth compound, together with two of the listed antibiotics, 
given for 7-14 days.
2: Quadruple therapy consists of a PPI plus either the combination of a bismuth compound, 
metronidazole, and tetracycline for 4-10 days, or the combination of levofloxacin, doxycyclin, and 
nitazoxanide for 10 days.
3: Sequential therapy consists of 10 days of PPI treatment, plus amoxicillin for 5 days and a combination 
of clarithromycin and an imidazole (when available, tinidazole; otherwise, metronidazole) during 
days 6-10. 
4. PPI dose equivalent to omeprazole 20 mg bid. 
5. When available (in some countries use is restricted).
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Quadruple therapy consists of a PPI plus either the combination of a bismuth compound, 
metronidazole, and tetracycline, or the combination of levofloxacin, doxycycline, and 
nitazonaxide. A quadruple regimen is recommended both as first- and second-line 
treatment (41, 62). Bismuth salts have a local antimicrobial effect on H. pylori (67). 
Until now, resistance has not been described. Bismuth salts are however not generally 
available due to concerns about toxicity in some countries, particular as a result of 
their potential neurological consequences (68). These however never have been 
described with short-term H. pylori treatment, but only in the past with high-dose 
longer treatments for instance long time ago for syphilis. A meta-analysis identified the 
number of adverse events in patients using bismuth containing H. pylori eradication 
therapy (68). In total 4763 patients were assessed, and no serious adverse events occured 
with bismuth therapy. Non-bismuth quadruple therapy can be an alternative to triple 
therapy in countries where bismuth use is restricted. A recently performed meta-analysis 
of randomized controlled trials compared standard triple therapy with nitroimidazole 
added to triple therapy (69). The latter showed better eradication rates compared with 
standard triple therapy (90% vs. 78% ITT). In areas with high clarithromycin resistance 
quadruple therapy is supposed to be an appropriate alternative (41). Nevertheless, meta-
analyses comparing both regimens yielded conflicting results (70, 71). A meta-analysis 
of 93 studies showed that in populations with either clarithromycin or metronidazole 
resistance, quadruple therapy containing both antibiotics led to higher eradication 
rates compared with clarithromycin-containing triple therapy (70). However, another 
meta-analysis of 9 RCTs showed no significant difference between clarithromycin triple 
therapy and bismuth quadruple therapy (resp. 77% vs 78%) (71). Hence, both regimens 
yielded suboptimal eradication rates of <80%. Based on these results it was suggested to 
base the choice of treatment upon H. pylori susceptibility testing. To date, susceptibility 
testing requires endoscopy and gastric mucosal biopsy, which is invasive and costly. The 
new European guideline recommends susceptibility testing only after failure of second-
line therapy (41). 
A superior alternative to the standard triple therapy can be the so-called sequential 
therapy, firstly introduced in Italy in 2000 (72). This therapeutic approach is based 
on different combinations of the available antibiotics. It starts with a dual therapy 
including a PPI for 10 days plus amoxicillin 1 g twice daily during day 1-5, followed 
by a combination of clarithromycin 500 mg and tinidazole or metronidazole (all twice 
daily) for day 6-10. Initial therapy with amoxicillin during the first 5 days may serve as 
an induction phase that amplifies the effectiveness of the second phase of treatment 
including clarithromycin and tinidazole (73). Moreover, regimens containing amoxicillin 
may prevent the selection of secondary clarithromycin resistance (74). On the other hand, 
the improved eradication rate could also be due to the larger number of antibiotics 
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to which the organism is exposed. Several randomized clinical trials and meta-analyses 
have demonstrated that this sequential therapy is more effective than triple therapy (74-
79). A randomized controlled trial found a significant higher eradication with a 10-day 
sequential therapy containing tinidazole compared with standard triple therapy (89% vs. 
77% ITT) (76). By using pooled data a recently published systematic review demonstrated 
that H. pylori infection was cured in 86% of 2,853 patients treated with sequential 
therapy compared with 75% out of 3,079 patients treated with standard triple therapies 
(80). In patients with clarithromycin resistance, clarithromycin-containing sequential 
therapy has also been shown to be more effective than standard triple therapy (75). 
Moreover, substitution of clarithromycin by levofloxacin further improved results. In an 
area with >15% prevalence of clarithromycin resistance, a levofloxacin-based regimen led 
to eradication rate of 97% (ITT) compared to 81% (ITT) with clarithromycin-containing 
sequential therapy (81). However, use of levofloxacin as first-line treatment prevents to 
apply it as a second-line treatment in cases of eradication failure (82, 83). 
2.1.4 Confirmation of eradication
No treatment regimen is able to achieve a 100% eradication rate. Thus, it is uncertain 
in a given patient whether treatment successfully eradicated H. pylori. In patients with 
for instance non-ulcer dyspepsia, this is acceptable and the effect of eradication is only 
assessed by symptoms. However, in cases with complicated peptic ulcer disease, after local 
treatment for gastric cancer, or with a gastric MALT-lymphoma, the effect of eradication 
treatment needs to be assessed. This can be done by means of upper endoscopy, making 
it possible to perform biopsy-based tests. It is recommended to wait at least 4 weeks 
before testing (41). 
2.2 Pharmacotherapy for chemical gastritis/gastropathy 
2.2.1 NSAID/aspirin induced gastropathy
The best treatment for chemical gastropathy is withdrawal of the causative agent. 
However, since many patients need longer duration treatment with NSAIDs or aspirin, 
primary prevention of gastric injury is important, in particular for high risk patients. 
Risk factors include a history of ulcer disease, dual antiplatelet therapy, age >65 years, 
and concomitant corticosteroid use (84, 85). At the start of NSAID therapy, an accurate 
risk and benefit assessment is essential to prevent harmful gastrointestinal events (86). 
There are several options that reduce the risk for gastric damage; using misoprostol 
or a PPI together with a nonselective NSAID or using a selective COX-2 inhibitor with 
or without a PPI. Misoprostol is a prostaglandin E analog, which decreases the risk for 
NSAID-induced gastric or duodenal ulcer. Misoprostol 200 mcg qd was in comparison 
with placebo associated with an approximate 3-fold risk reduction for serious upper 
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gastrointestinal complications in patients with rheumatoid arthritis treated with NSAIDs 
(87). However, long-term use of misoprostol is often impaired by adverse events, like 
diarrhea, abdominal pain and nausea (88). H2 receptor antagonists used in standard 
dose are also effective for the prevention of NSAID-related duodenal ulcers, but not 
for gastric ulcers (89). Double doses of H2 receptor antagonists were found effective in 
reducing risk for both gastric and duodenal ulcers. 
NSAID-induced mucosal damage is influenced by intragastric acidity (90). Acid 
suppression therapy is thus effective in the prevention and treatment of NSAID-related 
diseases. PPIs therefore are useful for the prevention of NSAID-induced ulcers (91). 
Clinical studies have suggested that PPIs are better tolerated but have slightly lower 
efficacy compared with misoprostol (92). A multicenter trial compared the efficacy of 
lansoprazole with misoprostol in long-term NSAID users (88). Misoprostol was found 
superior to lansoprazole, but due to limited compliance and more frequent adverse 
effects associated with misoprostol, both lansoprazole and misoprostol were clinically 
equivalent. Pooled data of two placebo-controlled trials showed that the estimated 
cumulative risk for development of ulcers over 6 months was 17% with placebo, 5.2% 
with 20 mg esomeprazole and 4.6% with 40mg esomeprazole (93). Furthermore, no 
differences were found in ulcer development between selective COX-2 inhibitors and 
non-selective NSAIDs. In general, success of primary prevention is largely depending 
on adherence to gastro-protective agents like misoprostol and PPIs. Non-adherence is 
significantly associated with higher risk of upper gastrointestinal bleeding (94). 
Secondary prevention of NSAID-related gastric injury is preferentially achieved by the 
withdrawal of NSAIDs. In patient who must continue taking NSAIDs it is recommended 
to prescribe a COX-2 inhibitor with a PPI (95, 96). This combination is associated with 
lower risk of secondary peptic ulcer complications than treatment with a COX-2 inhibitor 
alone. Omeprazole is superior to ranitidine and misoprostol in the prevention of 
recurrent erosions and ulcers (97, 98). 
NSAID use and H. pylori infection are independent risk factors for peptic ulcer disease. 
It has been shown that there is an increased risk when these factors are both present 
(99). Particularly naive NSAID users have clear benefit of H. pylori eradication (100). For 
aspirin, H. pylori eradication can prevent gastropathy and is strongly advised in patients 
with peptic ulcer history (41). 
In summary, the focus with respect to NSAID-related chemical gastropathy should be on 
primary prevention in high risk patients. Proton pump inhibition (at a dose equivalent 
to omeprazole 20 mg once daily) and misoprostol (at a dose of 800 mg/day) can protect 
against gastric ulcers during NSAID use. 
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2.2.2 Bile reflux induced gastritis 
Recurrent reflux of bile into the stomach can lead to chemical gastritis. A general 
approved medical treatment for this bile reflux gastritis is not available. Use of proton 
pomp inhibitors can provide some relief of symptoms (29). However, it is still arbitrary 
whether PPIs are as effective at suppressing duodenogastro reflux as they are at inhibiting 
acid reflux. One study evaluated the combination of rabeprazole and hydrotalcite in 
patients with bile reflux gastritis after cholecystectomy (29). Combination therapy was 
associated with a significant improvement of histological activity score compared with 
mono-therapy of either drug alone or no therapy. However, no differences were found 
in the histological score of chronic inflammation. Moreover, this study had no placebo 
group, so that possible placebo effects on symptoms relief not could be identified. 
Another study compared rabeprazole, sucralfate, and no therapy in patients after 
cholecystectomy (101). After 12 weeks follow-up treatment with both rabeprazole and 
sucralfate equally led to significant improvement of symptoms, as well as endoscopic and 
histological findings. To date, randomized controlled trials confirming these benefits are 
still lacking.
2.3 Treatment of autoimmune gastritis
There is no curative treatment for autoimmune gastritis at this moment. Pernicious 
anemia can be alleviated by vitamin B12 replacement therapy. However, this has no 
impact on the underlying destructive autoimmune disease process (102). The effect of 
immunosuppression by prednisolone was assessed in a mouse model of autoimmune 
gastritis. It led to remission of the gastric inflammation during therapy (103). However, 
withdrawal promptly results in disease recurrence. Patients with pernicious anemia have 
an increased risk of intestinal-type gastric cancer and gastric carcinoid tumors, the latter 
as a result of the associated persistent hypergastrinemia in the presence of achlorhydria 
due to the severe atrophy with pronounced parietal cell loss (104, 105). The benefits of 
surveillance in patients with pernicious anemia have not been established. A guideline of 
the American Society for Gastrointestinal Endoscopy recommends a single endoscopy to 
reveal gastric lesions in patients with pernicious anemia, but there are insufficient data 
to support routine endoscopic surveillance of these patients (106). The new European 
guideline recommends surveillance endoscopy at 2-3 years intervals (41). For carcinoid 
tumors, surveillance is controversial and should be individualized per patient (106). 
2.4 Treatment of special forms of gastritis
Treatment of eosinophilic gastritis or gastroenteritis is usually focused on symptoms 
relief, and medications used are largely based on empiric observation and experience 
(30). Steroids have an effect on the inflammatory process, yet require prolonged 
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treatment (107). This is in particular a disadvantage of systemic therapy, but less of 
topical treatment. Other treatments include proton pump inhibitors, mast cell stabilizers, 
ketotifen, and leukotriene antagonists (30). However, none of these have been stated 
as standard treatment. Owing to the rarity of this condition, no controlled clinical trials 
are performed.
Lymphocytic gastritis can be found in the presence of H. pylori infection, which is probably 
the major etiologic factor. Eradication of H. pylori has shown healing of lymphocytic 
gastritis (108, 109). Hence, testing for H. pylori in case of histological diagnosed 
lymphocytic gastritis is important. 
3. CONCLUSION
In this review we focused on the combination of endoscopic and histologic gastritis. 
Accurate classification is essential for choosing the right therapy. Although upper 
endoscopy is mandatory in the diagnostic process, diagnosis can only be made by 
histology. Treatment for H. pylori-induced gastritis is best studied and several regimens 
are available. However, owing to expanding antibiotic resistance eradication rates are 
declining. In many countries standard triple therapy does no longer achieve acceptable 
eradication rates. Therefore knowledge of local resistance rates and eradication 
effectiveness of specific regimens is indispensable. In addition, it is impossible to provide 
one applicable therapy for H. pylori eradication. Prior susceptibility testing is a promising 
tool for improvement of eradication rates. However, until now costs are too high for 
general implementation. Regarding NSAID/aspirin-induced gastropathy, focus should be 
on primary prevention of gastroduodenal damage by gastro-protective agents, especially 
in high risk patients. NSAID use accompanied with a PPI has shown significant reduction in 
ulcer development. PPIs can be beneficial in patients with bile reflux gastritis, but further 
research by randomized controlled trials is required for confirmation of found benefits. To 
date, curative treatment of autoimmune gastritis is not available and therefore therapy 
targets on treatment of pernicious anemia. Surveillance of this preneoplastic condition 
is still arbitrary. Testing for H. pylori is important in lymphocytic gastritis. Eradication 
has shown healing of former gastritis. Therapy for eosinophilic gastritis is focused on 
symptom relief, since exact etiology is unknown till now. 
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4. EXPERT OPINION
Gastritis is a condition with different definitions used by clinicians, endoscopists, and 
pathologists. The condition is generally based on the combination of endoscopy and 
histology. These reveal that chronic gastritis is a very common condition, in particular 
associated with H. pylori colonization. There is only a weak association between 
dyspeptic symptoms, and endoscopic plus histologic evidence for gastritis. However, the 
clinical importance of gastritis lays in the fact that it predisposes to more pronounced 
damage to the gastric mucosa, in particular peptic ulcer disease, and eventually atrophic 
gastritis, intestinal metaplasia, and gastric malignancy, both adenocarcinoma and MALT 
lymphoma. 
The management of gastritis aims at prevention and cure of ulcer disease, and 
prevention of progression towards gastric malignancy. For this purpose, a range of H. 
pylori eradication regimens have been developed. At this moment, greatest challenge 
in this field is to overcome the problem of growing antibiotic resistance. Eradication 
treatment for H. pylori is close to 20 years old, and hampered by diminishing instead of 
increasing efficacy. Besides induction of antimicrobial resistance by the extensive use of 
antibiotics, this may be influenced by changing treatment indications, deficient therapy 
adherence, and change in bacterial strains. 
It is clear that no current therapy for H. pylori is able to achieve a 100% eradication 
rate, however rates below 80% are in clinical practice unacceptable. Triple therapies 
without prior susceptibility testing should therefore be abandoned in regions with a high 
clarithromycin resistance (>15-20%). Without susceptibility testing, first-line treatment 
in these regions should consist of either quadruple or sequential therapy. Exact content 
of these regimens can be determined per region, according to results of local studies to 
effectiveness of particular regimens. 
Further research should concentrate on new techniques for testing of susceptibility 
to antibiotics rather than the currently ongoing comparisons of different eradication 
therapies, as antimicrobial resistance is likely to increase. A tailored approach to H. pylori 
infection leads to high success rates and prevents development of resistance. For the 
same reason, it is also mandatory to carefully adhere to guidelines in terms of indications 
for treatment. 
Some indications for H. pylori testing and treatment remain to be debated, in particular 
due to conflicting data regarding benefits of eradication. This pertains among others to 
patients with premalignant gastric lesions. Although H. pylori eradication cures gastritis 
and may to some extent lead to regression of premalignant lesions, prospective studies 
have so far not shown that this also reduces the risk of cancer. 
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Primary prevention of NSAID/aspirin-induced gastropathy can be improved by restrictive 
use of these drugs, and by more adequate prescription of gastro-protective agents, and 
increase of therapy adherence. Until now, remarkably high numbers of patients with 
at least one risk factor for gastrointestinal bleeding do not receive concomitant gastro-
protective agents. Therefore clinicians should be better informed about risk factors and 
already existing recommendations. In addition, better adherence can be achieved if 
patients are convinced that non-adherence can have serious effects. We suppose that 
adequate education is the key for more indicated prescriptions and enlargement of 
therapy adherence. 
5. KEY ASPECTS 
- Adequate classification of gastritis is essential for management and choices 
on pharmacotherapy. 
- The main etiologic factor of gastritis is H. pylori. Other common causes 
include autoimmune gastritis and chemical gastritis/gastropathy. 
- Owing to raising clarithromycin resistance in many countries, standard triple 
therapy should be abandoned as first-line treatment in those countries. 
Quadruple and sequential therapies are proved superior for H. pylori 
eradication. 
- Gastro-protective agents are essential in preventing NSAID/aspirin-induced 
gastropathy, which eventually leads to gastroduodenal ulcer disease. 
Misoprostol and PPIs are both effective therapies. 
- PPIs can be beneficial in patients with bile reflux gastritis, but further 
research by randomized controlled trials is required for confirmation of 
found benefits. 
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ABSTRACT 
Declining Helicobacter pylori (H. pylori) prevalence rates have resulted in a decrease of 
peptic ulcer bleeding incidence. Moreover, eradication reduces peptic ulcer recurrence 
rate. Newer studies confirm that H. pylori eradication lowers the risk of recurrent peptic 
ulcer bleeding. Guidelines therefore advocate a test-and-treat strategy for H. pylori-
positive patients with a history of ulcer bleeding and NSAIDs and/or aspirin use. There 
is mounting evidence that H. pylori status has no effect on symptoms and treatment 
efficacy in patients with gastroesophageal reflux disease (GERD). Some studies observed 
an improvement of GERD complaints after H. pylori eradication, which underlines 
that H. pylori treatment is not contra-indicated in GERD patients. The exact role of H. 
pylori in functional dyspepsia (FD) remains controversial. However, there is growing 
consensus that H. pylori-positive FD should be assessed as a separate entity. In these 
patients eradication can be beneficial and appropriate. Finally, several studies suggest 
that H. pylori colonization may also be associated with beneficial effects for the host. 
Epidemiological studies showed an inverse relation between H. pylori colonization and 
asthma and allergy, although data are conflicting and need to be expanded. 
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Peptic Ulcer Disease
The relationship between H. pylori infection and peptic ulcer disease (PUD) and also 
peptic ulcer bleeding (PUB) has been extensively studied. A meta-analysis reported that 
the prevalence of PUD ranged worldwide between 0.1% and 4.7%, with an annual 
incidence ranging from 0.19% to 0.3% (111). The majority of studies have reported a 
decrease in the incidence and/or prevalence of PUD over time, presumably due to a 
decrease in H. pylori–associated PUD. H. pylori was initially responsible for up to 95% 
of all gastroduodenal ulcers, but more recent studies reported that the prevalence of 
H. pylori in patients with PUD ranged between 36% to 73%, depending on ethnicity, 
geographic and socioeconomic factors (112).
A compilation of 71 original studies, including 8496 patients, found a mean 72% 
prevalence of H. pylori infection in PUB (113). The association between H. pylori infection 
and PUB was further studied in a meta-analysis which confirmed that H. pylori infection 
increased the risk of ulcer bleeding (OR 1.79) (99). As a consequence of the introduction 
of potent acid inhibitors and eradication of H. pylori, a rapid decrease in both incidence 
and mortality of PUB was expected. However, although most studies confirm such a 
decrease, the rate of hospitalization because of PUB only slowly decreases (114).
H. pylori resistance rates to antibiotics vary even in different regions of the same country. 
Effective H. pylori eradication reduces the rate of ulcer recurrence. Therefore, it is 
plausible that H. pylori eradication also prevents recurrence of ulcer bleeding. However, 
the efficacy of eradication for the prevention of recurrent bleeding from peptic ulcer has 
not been completely established. A prospective, long-term study included 1000 patients 
with previous PUB, 41% of them had previously used an NSAID and none received a PPI 
or NSAID during follow-up (115). Peptic ulcer rebleeding virtually did not occur after H. 
pylori eradication (0.5%). The authors concluded that maintenance antisecretory therapy 
is not necessary if eradication is achieved. However, NSAID intake or H. pylori reinfection 
may exceptionally cause rebleeding in H. pylori-eradicated patients.
In daily clinical practice, concomitant H. pylori infection and NSAID and/or aspirin use are 
common, in particular in elderly. Both H. pylori infection and NSAID use are independent 
risk factors for the development of PUD and associated bleeding. There is a synergistic 
effect for the development of GI bleeding when these factors are both present (41). 
Although H. pylori is frequently reported as a risk factor for upper GI bleeding in aspirin 
users, the real effect of H. pylori eradication on reducing the risk of bleeding remains 
unclear. The international Maastricht guideline advocates an H. pylori test-and-treat 
strategy in aspirin users with a history of gastroduodenal ulcer because the long-term 
incidence of peptic ulcer bleeding is low in these patients after H. pylori eradication, even 
in the absence of gastroprotective treatment (41). Despite these findings, further studies 
are needed to confirm whether this strategy is a (cost-) effective therapy to reduce ulcer 
bleeding in high-risk aspirin users.
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A prospective 10 years cohort study from Hong Kong assessed whether testing for H. 
pylori in aspirin users with a high ulcer risk would reduce the long-term incidence of 
ulcer bleeding (116). The investigators divided patients into three different cohorts. The 
first included H. pylori–positive aspirin users with a PUB history in whom H. pylori had 
been eradicated (n=249). The second group consisted of H. pylori–negative aspirin users 
with a PUB history (n=118). The third group assigned as average-risk cohort consists of 
aspirin users without a history of ulcers (n=537). The incidence of ulcer bleeding (per 
100 patient-years) in the H. pylori–eradicated cohort (OR 0.97; 95% CI 0.53–1.80) was 
similar to the average-risk cohort (OR 0.66; 95% CI 0.38-0.99). On the other hand, the 
H. pylori negative cohort had a high incidence of recurrent bleeding (OR 5.22; 95% CI 
3.04-8.96). This confirms that the long-term incidence of recurrent ulcer bleeding with 
aspirin use is low after H. pylori eradication despite a history of ulcer bleeding. Aspirin 
users without current or past H. pylori infections who develop ulcer bleeding however 
have a high risk of recurrent bleeding. Tests for H. pylori infection can be used to assign 
high-risk aspirin users to groups that require different gastroprotective strategies, in 
particular patients with a positive test for H. pylori should receive anti–H. pylori therapy 
followed by confirmation of eradication. Their need for long-term gastroprotective 
therapy depends on the success of H. pylori eradication and concomitant use of drugs 
that can cause bleeding. However, H. pylori negative patients should receive adequate 
gastroprotective co-therapy if they have a history of ulcer because they are prone to 
ulcer bleeding with aspirin use.
Gastroesophageal Reflux Disease
Gastroesophageal reflux disease (GERD) is a highly prevalent condition in the general 
population. Although it has previously been suggested that H. pylori eradication may 
cause both reflux symptoms and erosive esophagitis, the existence of such an association 
remains largely unsubstantiated. 
A meta-analysis of 10 trials in which data of patients treated for H. pylori infection were 
compared to those receiving placebo concluded that the post-treatment incidence of 
reflux symptoms (17% vs 22.6%) and erosive esophagitis (5% vs 5.1%) were similar 
between both groups (117). A further sub-analysis revealed a significantly lower 
incidence of  GERD  symptoms in the eradicated versus non-eradicated group (13.8% 
vs 24.9%) (OR 0.55; 95% CI 0.35-0.87, p=0.01). Overall, these data suggest that H. 
pylori eradication is not significantly associated with either reflux symptoms or erosive 
esophagitis onset, with some data actually suggesting an advantage in eradication in 
terms of a negative association with later development of GERD symptoms. One study 
showed a significant improvement in reflux disease-related quality of life scores one year 
after H. pylori eradication therapy (118). In another study from the United States 1611 
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cases of an African-American population with esophagitis and/or gastritis and confirmed 
H. pylori status were included between 2004-2007 and compared with controls (119). 
The frequency of H. pylori positivity in gastritis patients was 40%, in esophagitis patients 
4% and in normal controls 34%. After adjusting for effects of age and sex, odds ratio 
of H. pylori was 0.06 (95% CI 0.01-0.59; p = 0.01) for the esophagitis group versus the 
normal group. They concluded that H. pylori has a significant negative association with 
esophagitis in African-Americans, which may point to a protective role of H. pylori in 
the pathogenesis of esophagitis. In addition, another study on 2442 patients referred 
for upper gastrointestinal endoscopy observed H. pylori colonization in 82% of GERD 
patients. A statistically significant relationship was found between H. pylori positivity 
and the grade of GERD (120). In line with these observations, the updated Maastricht 
consensus on management of H. pylori infection concluded that H. pylori status has no 
effect on symptom severity, symptom recurrence, and treatment efficacy in GERD (41). H. 
pylori eradication does not exacerbate pre-existing GERD nor affect treatment efficacy. 
Therefore, the presence of GERD should not dissuade H. pylori eradication treatment 
when otherwise indicated. Furthermore, long-term efficacy of PPI maintenance treatment 
for GERD is not influenced by H. pylori status (121).
Functional Dyspepsia
Functional dyspepsia (FD) is currently defined as symptoms of epigastric pain, epigastric 
burning, postprandial fullness, or early satiation, in the absence of any organic, systemic, 
or metabolic disease that is more likely to explain the symptoms (122). This chronic, 
relapsing and remitting disorder is commonly seen in individuals from all around 
the world. Data from a large population-based study demonstrated no effect on life 
expectancy and no differences in the numbers of gastrointestinal related deaths between 
subjects with or without dyspepsia (123). 
The exact role of H. pylori in FD is still under debate. Some investigators have argued 
that if H. pylori gastritis is considered an organic disease, H. pylori-associated FD should 
not be considered as a functional disorder (124, 125).
Possible mechanisms by which H. pylori may elicit dyspeptic symptoms include alterations 
of gastric motility, as well as endocrine and acid-secretory abnormalities (126). Hunger 
sensations, acid secretion and gastrointestinal motility are regulated by ghrelin, 
particularly produced by the gastric enteroendocrine cell compartment (126). Gastric 
colonization with H. pylori is associated with decreased ghrelin secretion (127). A study 
from China in fifty children with FD showed a significant increase in plasma ghrelin levels 
and gastric ghrelin mRNA expression after successful H. pylori eradication treatment 
(128). In contrast, no significant differences were found in children who did not achieve 
successful eradication. A small RCT from Japan demonstrated an improvement of upper 
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gastrointestinal symptoms in adult patients treated with rikkunshito (i.e. a traditional 
Japanese medicine) compared to patients treated with domperidone (129). The 
improvement of symptoms correlated with enhanced plasma ghrelin levels. Apart from 
the need for more trials on this topic, these findings may give insights in the underlying 
pathophysiology of FD symptoms. 
Most guidelines recommend a test-and-treat strategy for H. pylori, especially in 
populations with a high H. pylori prevalence (126). However, the efficacy of this approach 
is limited, with a number to treat of 14 to achieve complete symptomatic response in one 
patient (35). It is becoming more clear that the role of H. pylori infection in FD differs 
between Western and Asian populations. H. pylori colonization and related diseases are 
more common in Asia, and therefore considered as the major differential diagnoses of 
FD (130). Moreover, there is a trend of higher symptom response by H. pylori eradication 
treatment in Asian patients. Hence, particular in these patients exclusion of H. pylori 
infection is necessary before diagnosing FD. As in the past, current studies do not always 
give support for this statement. Sodhi et al. found no effect of H. pylori eradication on 
FD symptoms (131). In this trial from India H. pylori positive patients suffering from FD 
(Rome II criteria) were randomly allocated to triple therapy (n=259) or PPI and placebo 
(n=260) for two weeks. After 12 months follow-up no difference in symptom resolution 
was found between the triple therapy and placebo group (44% vs 37%, p=0.13). It should 
be taken into account that despite the low eradication rate of 70% all patients allocated 
to the triple therapy arm were included in the comparison, which may have influenced 
the outcome. 
Asthma and Allergy
H. pylori is suggested to have not only pathogenic properties. Considered as a human 
commensal, H. pylori is thought to influence the development of the host immune 
system (1). Changes in our microbiota affected by altered ecological circumstances 
might explain the increasing prevalence of atopic diseases like asthma and allergy. 
H. pylori is a specific component of the human microbiome. In this context, several 
epidemiological studies showed an inverse relation between H. pylori colonization 
and asthma occurrence (132), but data are conflicting. Last year, two meta-analyses 
both found a weak inverse association between asthma and H. pylori colonization 
(133, 134). One study included cross-sectional, case-control, and cohort studies (133). 
Meta-analyses of pooled data from separate study types revealed a significant inverse 
association between H. pylori colonization and asthma for cross-sectional studies only 
(OR 0.84; 95% CI 0.74-96). Discrepancies among pooled outcome of the study groups 
might be explained by differences in heterogeneity of study design, participants, and 
study quality. Stratification by age did not show a difference in trend between children 
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and adults. No conclusions for children below age of 10 could be demonstrated, due 
to their low number in the analysis. The second meta-analysis was based on 14 studies, 
either with cross-sectional or case-control study design (134). Overall, a significant lower 
H. pylori colonization rate was found in asthmatic participants (OR 0.84; 95% CI 0.73-
0.96). Stratification to geographical region revealed that data from the United States 
determined this outcome, since studies from Asia and Europe did not show a significant 
inverse association. The prevalence of CagA-positive strains was similar in asthmatics and 
non-asthmatics. In both children and adults an inverse but non-significant association 
between asthma and H. pylori was found.
Both meta-analyses in particular included adults rather than children. Therefore, more 
studies in children are needed for validation of the hypothesis that asthma is inversely 
associated with H. pylori colonization.
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This thesis focuses on the epidemiology of H. pylori and its relationship with gastric 
and extra-gastric diseases. The two main aims of this thesis are: 1) getting insight in the 
current epidemiology of H. pylori colonization in a multi-ethnic Western population, and 
2) assessment of the prior suggested involvement of H. pylori in extra-gastric diseases in 
children and their mothers participating in a large prospective cohort study. 
Part I provides two review articles in which the main topics of this thesis are discussed. 
In Part II, we focus on the epidemiology of H. pylori colonization in mothers and their 
children participating in the Generation R study. Besides antibodies against H. pylori, 
we also measure antibodies against an important virulence factor, called cytotoxin-
associated gene A (CagA). H. pylori strains that express CagA are more pathogenic, 
causing more severe gastritis, which is associated with an increased risk for ulceration 
and gastric cancer. Chapter 2 defines H. pylori prevalence as well as risk groups for 
H. pylori in a cohort of young women living in Rotterdam, a city with a multi-ethnic 
population. The focus in Chapter 3 is first on the prevalence and risk factors for H. pylori 
colonization in their children, and secondly we look at transmission from mother-to-child 
and intergenerational differences between these two multi-ethnic cohorts. 
Part III comprises the chapters on H. pylori and associated extra-gastric diseases, and 
the follow-up of patients known with premalignant gastric lesions. H. pylori infection 
has been implicated in the aetiology of nausea and vomiting during pregnancy (NVP). 
Adverse birth outcomes are more common after severe NVP. In chapter 4, we investigated 
the association of H. pylori with vomiting severity and its effect on birth outcome. Apart 
from NVP, H. pylori colonization may be associated with pregnancy complications like 
pre-eclampsia (PE), small for gestational age (SGA), and spontaneous preterm birth 
(PTB). In chapter 5, we address the question whether H. pylori is indeed associated with 
these pregnancy complications. H. pylori colonization may also have beneficial effects, in 
line with the “disappearing microbiota” hypothesis. One of the supposed effects is that 
carriage of H. pylori has a protective effect on the development of asthma and allergy 
during childhood. We aim to examine the association between H. pylori colonization in 
children and risk of asthma and related conditions at school age (Chapter 6). We secondly 
examine additional effects of maternal H. pylori status by pairing with children’s status. 
Epidemiological studies indicated that colonization with H. pylori may affect body mass 
index (BMI), but with inconsistent results. In chapter 7, we examine the relationship 
between H. pylori colonization and BMI/obesity in a large population-based cohort 
setting using a Mendelian Randomization approach. H. pylori is a well-defined risk factor 
for intestinal type gastric cancer. Identification and endoscopic surveillance of precursor 
lesions may prevent subjects from invasive gastric carcinoma. Chapter 8 shows the results 
of a prospective follow-up study including patients with premalignant gastric lesions. 
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In this study we aim to assess the incidence of neoplastic progression in patients from a 
low-risk area and to assess discriminative tests for identifying those patients who are at 
risk. 
In part IV, we summarize and discuss the main results of this thesis (chapter 9). 
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PART II
Epidemiology of H. pylori in a 
multi-ethnic population

CHAPTER 2
Ethnicity is a strong predictor for Helicobacter 
pylori infection in young women in a multi-
ethnic European city
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ABSTRACT
Background and aim: At the same time that H. pylori prevalence is declining in Western 
countries, immigrants from developing countries with high H. pylori prevalence have 
settled in Western urban areas. Actual epidemiologic data on H. pylori in a migrant 
community may help in realizing a more selective approach to assess H. pylori-related 
diseases. We aimed to define H. pylori prevalence as well as risk groups for H. pylori in a 
cohort of young women living in a multi-ethnic European city.
Methods: We measured IgG anti-H. pylori and CagA-antibodies in serum of pregnant 
women included in a population-based prospective cohort study. Information on 
demographics, and socio-economic status was collected by questionnaires. Chi-square 
and logistic regression were used.
Results: In total, 3146 (46%) of the 6837 tested women (mean age 29.7 ± 5.3) were H. 
pylori-positive and 1110 (35%) of them were CagA-positive. The H. pylori prevalence in 
Dutch women was 24%, which was significantly lower than in non-Dutch women (64%; 
p<0.001). In particular, H. pylori positivity was found in 92% of Moroccan (OR 19.2; 95% 
CI 11.8-32.0), 80% of Cape Verdean (7.6; 5.0-11.5), 81% of Turkish (9.0; 6.7-12.1), 60% of 
Dutch Antillean (3.3; 2.3-4.7), and 58% of Surinamese women (3.0; 2.3-3.8). Among H. 
pylori-positive Dutch subjects, 19% were CagA-positive compared with 40% of the non-
Dutch subjects (p<0.001).
Conclusions: Despite a general trend of declining prevalence in Western countries, H. 
pylori remains highly prevalent in migrant communities, which may constitute target 
groups for screening and eradication to prevent H. pylori-related diseases.
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INTRODUCTION
Isolation and identification of Helicobacter pylori in 1982 led to better understanding 
of gastric pathophysiology. This Gram-negative bacterium is an important risk factor for 
peptic ulcer disease, gastric adenocarcinoma and MALT-lymphoma (1). The prevalence of 
H. pylori widely varies geographically, and is highest in developing countries. In Western 
countries, however, prevalences have declined over recent decades to below 40%, in 
part as a result of improved hygiene and sanitation as well as the active elimination by 
antibiotics (1). In parallel to the declining H. pylori prevalence, incidences of certain H. 
pylori-related diseases are decreasing as well (2, 3).
These trends in Western populations call for risk group identification, as test-and-treat 
strategies for H. pylori both on population as well as individual level are unlikely to be 
cost-effective in low prevalence countries (4). Knowledge about specific risk groups may 
permit assessment of disease risk, and will offer opportunities for targeted interventions. 
The H. pylori colonization rate is associated with factors such as age, socioeconomic 
status, childhood crowding, and non-western ethnicity (5). During past decades, many 
immigrants from developing countries with high H. pylori prevalence have settled in 
Western urban areas. In Rotterdam, a large Western city, more than 50% of the urban 
population is originating from outside The Netherlands. The largest non-Dutch ethnic 
groups consist of people from Morocco, Turkey, Suriname, Dutch Antilles, and Cape 
Verde. Previous studies indicated that H. pylori colonization rates in immigrants are higher 
compared to native western populations (6-8). Some of these migrant communities have 
a high risk of gastric cancer (9, 10), in which H. pylori is involved as the major causative 
agent. Especially CagA-positive H. pylori strains are known to be more interactive with 
higher risk of peptic ulcer disease, atrophic gastritis, and gastric cancer (11, 12), and 
lower risk of gastro esophageal reflux disease, Barrett’s esophagus, adenocarcinoma of 
the gastric-esophageal junction, and childhood-onset asthma (13, 14).
In this study, we aimed to obtain actual epidemiologic data on H. pylori prevalence in 
different ethnic groups living in a Western urban area. Moreover, we also measured 
anti-CagA-antibodies. As mothers are considered to be a source for transmission to their 
children, this study was performed in a cohort of pregnant women living in Rotterdam, 
a multi-ethnic European city. 
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METHODS
Setting and participants
This study was embedded in the Generation R Study, a population-based cohort study 
from fetal life until young adulthood in Rotterdam, with a multiethnic community, and 
the second largest city in the Netherlands. The background, design and aims of this study 
have been reported in detail (15).
Briefly, 8880 pregnant women were enrolled in the study between April 2002 and January 
2006. Medical data were collected by physical examination, and by questionnaires, and 
information on age, ethnicity, educational level, life style, and household income was 
obtained by questionnaires (15).
The Generation R Study was approved by the Medical Ethical Committee of the Erasmus 
University Medical Center. All participants gave written informed consent. 
Socio-demographic determinants
The cohort comprises various ethnic groups, reflecting the urban population of 
Rotterdam. The largest ethnic groups consist of Dutch, Surinamese, Turkish, Moroccan, 
Dutch-Antilles and Cape Verdean mothers. Ethnicity was determined by country of 
birth of the pregnant mother and her parents. A participating mother was considered 
of non-Dutch ethnic origin if one of her parents was born abroad (according to the 
definition of Statistics Netherlands) (16). If both parents were born in different countries 
other than the Netherlands, the country of the mother prevailed. Subjects of non-Dutch 
origin and born abroad were defined as first-generation immigrants. A participant 
of non-Dutch origin but born in the Netherlands was defined as a second-generation 
immigrant. People of Dutch origin were considered as the native population. According 
to the definitions of Statistics Netherlands(16) participants with other ethnic background 
as mentioned above were grouped as ‘other western’ for European (n=493), North 
American (n=24), Oceanean (n=9), Japanese (n=7) and Indonesian (n=194), and as ‘other 
non-western’ for African (n=123), Asia (n=189) and South- and Central American (n=91). 
The division into ‘western’ and ‘non-western’ is based on differences in socioeconomic 
and cultural situation. Participants from Indonesian were classified as ‘western’, since 
they are originating from former Dutch-East Indies. Educational level was classified into 
four educational levels on the basis of the highest completed education: high (university 
or higher vocational training), high-secondary (general secondary school or intermediate 
vocational training), low-secondary (intermediate general school or lower vocational 
training), and low (primary school or no education). Educational level served as proxy 
for the socio-economic status. Household income, defined by the total net monthly 
income of the family, was categorized as < € 1200, € 1200-2000, and > € 2000. Data on 
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possible confounders like age, smoking habits, and alcohol use were obtained from the 
questionnaires.
Serologic determinants
Mid-pregnancy serum samples of 7185 mothers were available for analysis (Figure 1). 
Mothers included more than once (due to more than one pregnancy within inclusion 
period) were excluded (n=348), which left a total study population of 6837 pregnant 
women. Procedures for collection and storage of the sera samples have been described 
in detail previously (17). Samples were examined for H. pylori IgG antibody levels by 
enzyme-linked immunosorbent assay (ELISA), using whole cell antigens (18). A separate 
ELISA was performed to determine serum IgG antibodies against a specific recombinant 
truncated CagA protein, as described (19). All samples were measured in duplicate. 
For each sample, the optical density ratio (ODR) was calculated by dividing the optical 
density (OD) by the mean OD of the positive controls. H. pylori positivity was defined as 
either an ODR ≥ 1 or CagA positivity. The cut-off for CagA positivity was an ODR value ≥ 
0.35. Both ELISAs were validated locally. 
Statistical analysis
Chi-square tests (categorical variables) and t-tests (continuous variables) were used 
to compare different variables in relation to H. pylori status. Univariate analysis was 
performed to assess determinants associated with the presence of H. pylori. To study the 
individual effect of each potential determinant, each was separately tested, followed 
by a multivariate analysis corrected for all other determinants. In addition, a stratified 
analysis according to ethnicity was performed. Subjects with missing data on any of 
above-mentioned covariates were excluded from the multivariate analysis; this left a 
total of 4605 evaluable subjects. 
A two sided p-value <0.05 was considered to be statistically significant. All analyses were 
performed using PASW Statistics 20.0 (SPSS, IBM, New York, United States). 
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Figure 1. Study design 
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Figure 1. Study design.
RESULTS
Presence of H. pylori 
In total, the serum samples of 6837 women were analyzed. Their mean age was 29.7 (± 
5.3) years. Subjects of Dutch origin were older (mean age 31.4 years) than non-Dutch 
participants (mean age 28.4 years) (p<0.001). Table 1 shows the general characteristics 
and H. pylori status: 3146 (46%) subjects were H. pylori-positive and 3691 (54%) subjects 
H. pylori-negative. 
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Table 1. Baseline characteristics of study population, distribution by H. pylori status, and univariate 
analysis 
Study population 
(n)
H. pylori -
(n=3691)
H. pylori +
(n=3146)
OR
Univariate
95% CI
Age, mean (SD)
Dutch population (%)
Non-Dutch
6837 (100)
3166 (46)
3223 (47)
30.7 (4.9)
31.5 (4.4)
29.2 (5.5)
28.7 (5.4)
31.0 (4.9)
27.9 (5.4)
0.93
0.98
0.96
0.92-0.94
0.96-1.0
0.94-0.97
Parity (%)
Nulli parity
Multi parity
Missing
3746 (55)
3025 (45)
66 (1)
2173 (58)
1496 (50)
1573 (42)
1529 (51)
1.0
1.4 1.3-1.6
Ethnicity (%)
Dutch 3166 (50) 2415 (76) 751 (24) 1.0
Other western 726 (11) 467 (64) 259 (36) 1.8 1.5-2.1
Turkish 597 (9) 116 (19) 481 (81) 13.3 10.7-16.6
Surinamese 577 (9) 244 (42) 333 (58) 4.3 3.7-5.3
Moroccan 408 (6) 32 (8) 376 (92) 37.8 26.0-54.7
Cape Verdean 275 (4) 54 (20) 221 (80) 13.2 9.7-17.9
Dutch Antilles 237 (4) 94 (40) 143 (60) 4.9 3.7-6.4
Other non-western 403 (6) 154 (38) 249 (62) 5.2 4.2-6.5
Missing 448 (7)
Dutch + Western 3892 (61) 2882 (74) 1010 (26) 1.0
Non Western 2497 (39) 694 (28) 1803 (72) 7.4 6.6-8.3
Immigrant generation (%)
Native
1st generation
3115 (49)
2225 (35)
2376 (76)
688 (31)
739 (24)
1537 (69)
1.0
7.2 6.4-8.1
   2nd generation 1046 (16) 510 (49) 536 (51) 3.4 2.9-3.9
Missing 451 (7)
Education (%)
Low 719 (11) 199 (28) 520 (72) 6.6 5.5-8.0
Low secondary 980 (16) 451 (46) 529 (54) 3.0 2.6-3.5
High secondary 1971 (31) 1026 (52) 945 (48) 2.3 2.1-2.6
High 2613 (42) 1873 (72) 740 (28) 1.0
Missing 554 (8)
Household income (%)
<1200 Euro 1101 (21) 354 (32) 747 (68) 5.2 4.5-6.0
1200-2000 Euro 992 (19) 489 (49) 503 (51) 2.5 2.2-2.9
>2000 3182 (60) 2264 (71) 918 (29) 1.0
Missing 1562 (23)
Alcohol (%)
Yes 3005 (51) 2027 (68) 978 (32) 0.4 0.3-0.4
No 2948 (49) 1296 (44) 1652 (56) 1.0
Missing 884 (13)
Smoking (%)
Yes 1688 (28) 930 (55) 758 (45) 1.0 0.9-1.2
No 4348 (72) 2430 (56) 1918 (44) 1.0
Missing 801 (12)
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Data on ethnicity were available for 6389 women: 3166 (50%) subjects were of Dutch 
ethnicity, 597 (9%) of Turkish, 577 (9%) of Surinamese, 408 (6%) of Moroccan, 275 (4%) 
of Cape Verdean, 237 (4%) of Dutch Antilles, 726 (11%) of other western and 403 (6%) 
of other non-western origin. The H. pylori positivity rate was highest among Moroccan 
women (92%), followed by Cape Verdian (80%), Turkish (81%), Dutch Antillean (60%), 
and Surinamese subjects (58%) (Figure 2). In contrast, the prevalence in women of Dutch 
origin was 24% (p<0.001). 
The overall CagA-prevalence rate was 16.2%. Among H. pylori-positives, 1110 women 
(35.2%) were colonized with a CagA-positive strain, which however varied widely 
between ethnicities (Figure 2). Only 64 subjects were CagA-positive but H. pylori-negative 
(6%). Colonization with a CagA-positive H. pylori strain was most common in Surinamese 
(56%) mothers, followed by subjects of other non-western (46%), Dutch Antillean (46%), 
Turkish (39%), Cape Verdean (34%), Moroccan (34%), other western (29%), and Dutch 
(19%) origin (p<0.001). 
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Figure 2. Proportion of CagA-positive and H. pylori-positive subjects. 
 
 
 
Figure 2. Proportion of CagA-positive and H. pylori-positive subjects.
Determinants of H. pylori colonization
Univariate logistic regression revealed that non-Dutch ethnicity was an independent 
risk factor for H. pylori positivity (Table 1). Furthermore, lower educational level, first 
generation immigrant, and lower household income were significantly associated with 
H. pylori infection. However, alcohol use was inversely associated with H. pylori presence. 
The following variables were entered into the multivariate logistic regression model: 
age, ethnicity, education level, household income, smoking, and alcohol use. This analysis 
continued to reveal ethnicity as the most important independent risk factor for H. pylori 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
H. pylori colonization in a multi-ethnic Western city
61
2
(Figure 3). Compared to Dutch ethnicity, highest risk was found for Moroccan women 
(odds ratio 19.4; 95% confidence interval 11.8-32.0), followed by Turkish (9.0; 6.7-12.1), 
Cape Verdean (7.6; 5.0-11.5), other non-western (3.4; 2.6-4.5), Dutch Antillean (3.3; 
2.3-4.7), Surinamese (3.0; 2.3-3.8), and other western (1.7; 1.4-2.0) subjects. In addition 
to ethnicity, the following independent risk factors were found: low education level 
compared with high education level (1.9; 1.4-2.5), and low income compared with high 
income (1.5; 1.2-1.9). 
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Figure 3. Multivariate analysis of determinants associated with H. pylori colonization in one 
model. Odds ratios (ORs) and 95% confidence intervals are adjusted for age.  
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Odds ratios (ORs) and 95% confidence intervals are adjusted for age. 
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After stratification by ethnicity, multivariate analysis showed within all non-Dutch 
ethnicities that subjects born abroad (first generation immigrants) had a significantly 
higher risk to be colonized with H. pylori compared with second-generation immigrants 
(p<0.05 for Turkish, Surinamese, Moroccan, Cape Verdean, and Dutch Antillean subjects) 
(Table 2). Within the different ethnicities, age, smoking, and alcohol use were not 
associated with H. pylori colonization. Except for the Turkish and Cape Verdean subjects, 
low socio-economic status was an independent risk factor for H. pylori colonization. 
Dividing the whole population into either western or non-western showed in both 
groups first generation immigrants, subjects with low education level, and low household 
income to be more at risk for H. pylori colonization (Table 3). 
Table 3. Multivariate analysis stratified to ethnicity (western vs non-western)
All Western
n=3119
All non-Western
n=1484
Age 1.0 (1.0-1.0) 1.0 (1.0-1.0)
Education 
Low 2.0 (1.3-3.2) 2.1(1.4-3.2)
Low secondary 1.4 (1.1-1.9) 2.0 (1.4-3.0)
   High secondary 1.2 (1.0-1.5) 1.4 (1.0-1.9)
High 1.0 1.0
Generation 
Native 1.0 N.A.
1st generation 1.8 (1.4-2.3) 2.0 (1.5-2.6)
2nd generation 1.4 (1.1-1.8) 1.0
Household income
<1200 Euro 1.7 (1.2-2.4) 1.4 (1.1-2.0)
1200-2000 Euro 1.1 (0.9-1.4) 1.4 (1.0-1.9)
>2000 1.0 1.0
Alcohol 
Yes 0.9 (0.7-1.0) 0.6 (0.5-0.8)
No 1.0 1.0
Smoking 
Yes 1.0 (0.8-1.3) 0.8 (0.6-1.1)
No 1.0 1.0
Numbers are displayed as Odds Ratio (95% Confidence Interval). Reference categories are put as 1.0.
All listed variables were entered into the multivariate analysis.
N.A. = Not applicable
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DISCUSSION
This population-based study demonstrates that H. pylori colonization is still common in 
a Western society, in particular in migrant communities. Among women of non-Dutch 
ethnicity, first generation immigrants were more at risk for H. pylori colonization then 
second-generation immigrants. Although others have focused on risk group identification 
as well, both the cohort size and design of this study are unique, and results reflect the 
actual epidemiologic data on H. pylori colonization in a Western urban area. 
The relatively high prevalence of H. pylori and CagA-positive strains found in ethnic 
minority groups indicates that the health risks imposed by H. pylori remain a significant 
concern. Studies comparing first and second-generation immigrants with the native 
population have demonstrated a higher risk for non-cardia gastric cancer in first-
generation immigrants (20, 21). Childhood colonization with H. pylori could be a possible 
cause (22, 23). Our results support this explanation, since H. pylori colonization among 
second-generation immigrants was significantly lower compared to first-generation 
immigrants, but still higher than in the native population. 
Based on estimates of the incidence of gastric cancer in different regions all around the 
world, study participants originating from Surinam, Caribbean, and Turkey are expected 
to have a higher gastric cancer risk compared with subjects from Western Europe (24). 
Indeed, studies from Sweden have indicated a higher gastric cancer incidence ratio in 
immigrants born in high risk countries and living in Sweden (20). Hence, those migrant 
communities could be an appropriate focus for considering the health advantages of H. 
pylori eradication. The latter is found effective for gastric cancer prevention in patients 
without precancerous lesions (25, 26). 
We tested for H. pylori antibodies in pregnant women, about to give birth. Close family 
members like mothers and siblings are considered to be the major transmission sources 
for H. pylori acquisition during the first years of life (1). Hence, a high prevalence in 
mothers may be considered predictive for a high colonization rate in their children. 
Moreover, via day care attendance these children may also be a source for transmission 
to other children (27, 28). Our finding indicates that H. pylori will remain to be prevalent 
for the coming decades, even in Western societies. 
The observed H. pylori colonization rate in the Dutch study subjects was consistent with a 
previous study in subjects of the same age (29). Studies evaluating H. pylori colonization 
in immigrant groups all showed higher infection prevalence than in native populations 
(8, 29-33). A previous study of 288 adults in Rotterdam showed nearly similar positivity 
rates among different immigrant groups, however higher prevalence in subjects of Dutch 
origin (46%) than we observed (8). This may have been due to both the relative higher 
age and the small number of Dutch patients in that study.
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The geographical variance of H. pylori strains was confirmed by this study. H. pylori strains 
colonizing Western subjects were least often CagA-positive (34). In a Finnish population, 
CagA-positive H. pylori strains declined faster than CagA-negative H. pylori strains, 
especially among subjects less than 45 years old (35). The low CagA prevalence among 
Dutch and other Western subjects is consistent with those observations. Nevertheless, 
overall prevalence of CagA-positive strains was lower than expected, especially in 
subjects born abroad.
This study is limited by the inclusion of young women in a limited age range which 
restricted the possibility of extrapolating our finding to older age cohorts. Owing to 
the well described birth cohort effect for H. pylori (27), we expect H. pylori to be more 
prevalent in older age cohorts. However, whether this is true for all various ethnic groups 
remain unclear. Second, the population in our study may not have been reflective of the 
general population of Rotterdam owing to overrepresentation of more highly educated 
women in this cohort (36). 
In conclusion, in a multi-ethnic population, ethnicity is the strongest predictor of H. 
pylori colonization in young women. In particular, migrant communities constitute 
target groups for screening of H. pylori to minimize H. pylori-related diseases. Additional 
knowledge of H. pylori biological costs, and details on implementation require further 
research. 
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Intergenerational reduction in Helicobacter 
pylori prevalence is similar between different 
ethnic groups living in a Western city
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ABSTRACT
Objective: Helicobacter pylori (H. pylori) colonization rates in childhood have declined in 
Western populations, but it is unknown whether this trend is similar in children of non-
Western ethnic backgrounds, born in a Western country. We aimed to identify H. pylori 
status in children, and determine both mother-to-child transmission and risk factors for 
colonization. 
Design: Antibodies against H. pylori and cytotoxin-associated gene A (CagA) were 
measured in children participating in a population-based prospective cohort study in 
Rotterdam, the Netherlands. Information on demographics and characteristics was 
collected using questionnaires. 
Results: We analysed the serum of 4,467 children (mean age 6.2 years ±0.5 SD) and 
compared the results with the H. pylori status of their mothers (available for 3,185 
children). Overall, 438 (10%) children were H. pylori-positive, of whom 142 (32%) 
were CagA-positive. Independent risk factors for colonization were: maternal H. pylori 
positivity (OR 2.12; 95%CI 1.62-2.77), non-Dutch ethnicity (OR 2.05; 95%CI 1.54-2.73), 
female gender (OR 1.47; 95%CI 1.20-1.80), and lower maternal education level (OR 1.38; 
95%CI 1.06-1.79). Comparing mothers and children, we found an intergenerational 
decrease of 76% and 77% for Hp+CagA- and Hp+CagA+-strains, respectively, consistent 
across all nine ethnic groups studied. Male gender, higher maternal educational level, 
and no older siblings, were independently associated with absence of H. pylori.
Conclusions: Although the highest H. pylori and CagA prevalence was found in children 
of non-Dutch ethnicities, the decreased colonization rates were uniform across all ethnic 
groups, implying the importance of environmental factors in H. pylori transmission in 
modern cities, independent of ethnicity.
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SUMMARY BOX
1. What is already known about this subject?
•	 H. pylori prevalence of children living in Western countries is low. 
•	 Maternal H. pylori status is an important transmission source for H. 
pylori colonization in their children. 
•	 Migrant communities in Western populations constitute risk groups for 
H. pylori colonization. 
2. What are the new findings? 
•	 A high intergenerational reduction in H. pylori prevalence was found, 
comparing mothers with their children, with nearly identical rates (76% 
and 77%) for Hp+CagA- and Hp+CagA+-strains, respectively.
•	 The intergenerational drop in H. pylori prevalence was uniform in nine 
separate ethnicities. 
•	 Risk factors for H. pylori positivity are mostly the same among diverse 
ethnic groups.
•	 Our data suggest a continuing acquisition of H. pylori at least to age 7.
3. How might it impact on clinical practice in the foreseeable future?
•	 The maternal-child linkage is to some degree predictive of H. pylori 
positivity in a child, which affects risk of subsequent diseases. 
INTRODUCTION
The gastric bacterium Helicobacter pylori (H. pylori) colonizes more than half of the 
human population. It usually induces the influx of inflammatory cells in the stomach wall, 
which is a major risk factor for peptic ulcer disease and gastric cancer (1, 2), and may also 
be associated with diminished risk of oesophageal reflux and childhood-onset asthma 
(3-5), and possibly more resistance to infectious diseases (6, 7). H. pylori colonization is 
usually acquired during early childhood, and in most cases persists unless eliminated by 
antibiotic treatment (8). A recent study reported that the risk of H. pylori colonization 
was influenced by host genetics (9).
The prevalence of colonization differs between children and adults (10). Several cross-
sectional surveys in Western countries have shown that H. pylori prevalence increases with 
age (11, 12). Since acquisition during adulthood is rare (13, 14), the higher prevalence in 
the elderly rather reflects a birth cohort effect with higher rates of childhood exposure 
to the organism in the past (1). The current lower levels of exposure to H. pylori and 
consequent lower prevalence in children are believed to be due to improved hygiene, 
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and active elimination by antibiotics, together contributing to declining transmission 
risk (1, 15). 
However, a recent study in Dutch children reported similarity in the H. pylori prevalence 
in two subsequent birth cohorts (16), possibly indicating that determinants previously 
responsible for declining colonization in the past now have stabilized. One factor 
contributing to this trend is the altered composition of western populations; during 
recent decades, the populations of western cities have become multi-ethnic as a result 
of immigration, often from countries where H. pylori remains endemic. Recently, we 
reported large differences in colonization rates among pregnant women of different 
ethnic origins living in Rotterdam, the Netherlands (17), but whether these differences 
are reflected in their offspring was not determined. Analysis of H. pylori transmission and 
risk factors would allow better prediction of the future incidence of H. pylori-associated 
illnesses. 
In this population-based prospective cohort study, we aimed to measure H. pylori status, 
as well as risk factors for colonization and transmission, in children living in a multi-
ethnic Western urban population, and in relation to colonization of their mothers. 
Unexpectedly, we found a relatively uniform intergenerational decrease in H. pylori 
prevalence in all nine ethnic groups studied. We explore the factors associated with this 
broad change.
METHODS
Design and setting
This study was embedded in the Generation R Study, a population-based prospective 
cohort study from fetal life onwards. All participants live in the multi-ethnic Rotterdam, 
the second largest city in the Netherlands. The children were born in Rotterdam between 
April 2002 and January 2006. The background, design, and aims of the Generation R study 
have been reported in detail (18). In total, 8,305 children and their parents participated 
in the postnatal phase of the study (from birth onwards) (Figure 1). From this initial 
population, 6,690 children visited the research centre at the age of 6 years. During these 
visits, blood samples were collected from 4,593 (69%) children (see Table S1 comparing 
the children, with and without H. pylori data). Data on age, ethnicity, breastfeeding, 
day-care attendance, antibiotic use, and socioeconomic status of the mother were 
collected using questionnaires. The Generation R Study was approved by the Medical 
Ethical Committee of the Erasmus University Medical Centre, and parents of the children 
gave written informed consent.
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Covariates
The Generation R cohort comprises a wide range of ethnic groups, reflecting Rotterdam’s 
urban population as a typical Western city; the largest ethnic groups are of Dutch, 
Surinamese, Turkish, Moroccan, Dutch-Antilles, and Cape Verdean descent. Ethnicity is 
determined by country of birth of the parents. According to the definition of Statistics 
Netherlands, a child was considered of non-Dutch ethnic origin if one of its parents 
was born abroad (19). If both parents were born in two different countries outside the 
Netherlands, the country of the mother prevailed. Children of Dutch origin are considered 
as the native population. Participants with an ethnic background other than mentioned 
above are grouped together as European, Asian, African, or ‘rest of the world’, which 
included Central and South America (n = 95), Indonesia (n = 32), North America (n = 21), 
Asia, western (i.e. western ethnicity but parents had lived in Asia, n = 21), and Oceania 
(n = 9). Data on type of delivery was obtained by review of midwife and hospital registries. 
Exclusiveness of breastfeeding was categorized into three breastfeeding groups: never, 
non-exclusive breastfeeding until 4 months, or exclusive breastfeeding until 4 months. 
Data on day-care attendance was based on each child’s first year of life. Maternal parity 
served as a proxy for the presence of older siblings in the family, which was categorized as 
either none or at least one older sibling. Use of antibiotics was assessed by questionnaire 
at the ages of 12, 24, 36, 48, and 72 months. Parents were asked whether their child had 
received antibiotics (for example, penicillin) during the past year. Data on antibiotic use 
were not validated by physician prescriptions or pharmacy records. The socioeconomic 
status of the children was defined according to the educational level of their mother 
on the basis of her highest level of completed education. The highest educational level 
was defined as completion of university or higher vocational training. Mothers were 
categorized as having a middle/low level of education if they had completed intermediate 
vocational training, or had completed education below that level. 
Serological determinants
Serum samples from 4,467 children, obtained at the mean age of 6.2 (±0.4) years (range 
4-8 years), were available for analysis (Figure 1). The main reasons for missing blood 
samples were non-consent of the parents and technical or logistic failure. Procedures 
for the collection and storage of serum samples have been described (20). Samples were 
examined for H. pylori IgG antibody levels by enzyme-linked immunosorbent assay 
(ELISA), using whole cell and water-extracted antigens (21). These preparations were 
previously tested and only cross-reactivity in children or adults infected with C. jejuni 
was observed with flagellin, which is a minor antigen in these preparations. A separate 
ELISA was performed to determine serum IgG antibodies against a specific recombinant 
truncated cytotoxin-associated gene A (CagA) protein, as described (22). Both ELISAs 
have been previously tested against many different ethnic groups, and in all cases the 
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tests have been validated and had similar sensitivity and specificity (23-26). Furthermore, 
the antigenic diversity of H. pylori strains around the world was studied; the antigens 
reacted in a similar way against specific antisera (27). Both ELISAs have been validated 
in children (28), and have been previously used in Dutch children (16). All samples 
were examined in duplicate; for each, the optical density ratio (ODR) was calculated 
by dividing the optical density (OD) by the mean OD of the positive controls. H. pylori-
positive samples were those having either an ODR ≥ 1 or a CagA-positive test result. The 
cut-off value for CagA positivity was ODR value ≥ 0.35 (22). Only 13 children were found 
to be CagA-positive but H. pylori-negative (0.3% of H. pylori-negative children). Based 
on prior studies, these subjects were considered as truly H. pylori positive (29). Data on 
the maternal H. pylori status was available for 3,185 children (71%). The tests on the 
mothers were done 1 year earlier, using the same assays as for children; however, with 
specific calibration for adults. H. pylori antibody distributions for both children and their 
mothers are shown in Figure S1. Details regarding H. pylori colonization in the total 
cohort of mothers have been described (17). 
Statistical analysis
Chi-square tests (categorical variables) and t-tests (continuous variables) were used to 
compare different variables with H. pylori status. Univariate analyses were performed 
to assess determinants associated with H. pylori presence. To study the individual effect 
of each potential determinant, each was tested separately, followed by a multivariate 
analysis corrected for all others. For all covariates, the percent of missing values 
within the population for analysis was lower than 10%, except for caesarean section, 
breastfeeding, day-care attendance, and antibiotic use. Missing data in the covariates 
(except maternal H. pylori status) were imputed with multiple imputations using chained 
equations, by which the most likely value for a missing response is selected (30). Ten 
new datasets were created by imputation based on all covariates and outcomes in the 
model. Data from each separate imputation was analysed, after which results were 
combined. Except for breastfeeding and antibiotic exposure, no major differences in the 
direction or magnitude of the effect estimates were observed between analyses with 
imputed missing data and complete cases only. Only the results based on the pooled 
imputed datasets are presented in this manuscript. To identify the potential modifying 
effect of determinants included in the multivariate analyses, we evaluated statistical 
interaction by adding to the multivariate model the product term of an independent 
variable and subgroup (independent variable x subgroup) as covariate. The interaction 
was tested between ethnicity and day-care, ethnicity and gender, and ethnicity and 
maternal education level. We calculated the population attributable fraction (PAF) for 
H. pylori disappearance in children with an H. pylori-positive mother, using adjusted 
odds ratios estimated from logistic regression models (31). All measures of associations 
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are presented as Odds Ratios (OR) with their 95% Confidence Intervals (CI). Statistical 
analyses were performed using IBM SPSS Statistics 21.0 for Windows (SPSS IBM, Armonk, 
New York, USA). 
RESULTS
H. pylori prevalence
The serum of 4,467 children was analysed (Figure 1). Table 1 summarizes both the 
observed population characteristics as well as the imputed data, stratified by H. pylori 
status. Overall, 438 (10%; 95% CI 8.9-10.7%) children were H. pylori-positive, of whom 
142 (32%; 95% CI 28.0-36.8%) also were CagA-positive. In all children of non-Dutch 
ethnicity, the colonization rate was significantly higher than that in children of Dutch 
ethnicity (Figure 2A). 
8,305 children participated in the 
follow-up at the age of 6 years
6,690 visited research centre at the 
age of 6 years
Sera obtained in 4,593 children
(69%)
Not available for analysis due to
logistic of technical reasons
(n=85) or duplicate samples of 
twins (n=41)
H pylori status identified
N = 4,467
H pylori-positive
n= 438 (10%)
H pylori-negative
n= 4,029 (90%)
CagA-positive
n= 142 (32%)
CagA-negative
n= 296 (68%)
Maternal H pylori status available for
n= 3,185 children (71%)
H pylori-negative
n= 1,857 (58%)
H pylori-positive
n= 1,328 (42%)
Figure 1. Definition of the study population.
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Table 1. Characteristics of the 4,467 children and their mothers, categorized according to H. pylori 
status.
Child characteristics Observed Imputed H. pylori- 
n = 4,029
H. pylori+ 
n = 438
Univariate OR 
(95% CI)
Female sex (%) 2,164 (48.4) 2,164 (48.4) 1,916 (47.6) 248 (56.6) 1.44 (1.18-1.76)*
Mean age sera taken, years (SD) 6.2 (0.4) 6.2 (0.4) 6.2 (0.01) 6.4 (0.03) 1.66 (1.39-1.98)*
Ethnicity (%)
Dutch 2,505 (56.1) 2,516 (56.3) 2,374 (58.9) 142 (32.4) 1.0
Surinamese 317 (7.1) 318 (7.1) 285 (7.1) 33 (7.5) 1.95 (1.29-2.94)*
Turkish 311 (7.0) 324 (7.3) 279 (6.9) 45 (10.3) 2.64 (1.71-4.07)*
Moroccan 256 (5.7) 261 (5.8) 192 (4.8) 69 (15.8) 6.01 (4.27-8.44)*
Dutch Antilles 141 (3.2) 142 (3.2) 120 (3.0) 21 (4.8) 2.96 (1.78-4.92)*
Cape Verdean 129 (2.9) 151 (3.4) 115 (2.9) 36 (8.2) 5.20 (3.31-8.16)*
Other:
European 331 (7.4) 332 (7.4) 298 (7.4) 34 (7.8) 1.92 (1.28-2.89)*
Asian 111 (2.5) 112 (2.5) 95 (2.4) 17 (3.9) 3.01 (1.73-5.23)*
African 100 (2.2) 106 (2.4) 91 (2.3) 15 (3.4) 2.63 (1.31-5.30)*
Rest of the worlda 148 (3.3) 206 (4.6) 180 (4.5) 26 (5.9) 2.11 (0.74-6.00)
Data missing 118 (2.6)
Caesarean Section (%)
No 3,358 (75.2) 3,878 (86.8) 3,483 (86.4) 395 (90.2) 1.0
Yes 496 (11.1) 589 (13.2) 546 (13.6) 43 (9.8) 0.70 (0.47-1.02)
Data missing 613 (13.7)
Breastfeedingb (%)
Never 264 (5.9) 388 (8.7) 356 (8.8) 32 (7.3) 1.0
Partial 1,857 (41.6) 2,925 (65.5) 2,623 (65.1) 302 (68.9) 1.34 (0.73-2.43)
Exclusive 723 (16.2) 1,154 (25.8) 1,050 (26.1) 104 (23.7) 1.14 (0.64-2.03)
Data missing 1,623 (36.3)
Day-care attendancec (%)
No 1,019 (22.8) 2,110 (47.2) 1,849 (45.9) 261 (59.6) 1.0
Yes 1,548 (34.7) 2,357 (52.8) 2,180 (54.1) 177 (40.4) 0.57 (0.44-0.75)*
Data missing 1,900 (42.5)
Number of older siblings (%)
0 2,370 (53.1) 2,425 (54.3) 2,219 (55.1) 206 (47.0) 1.0
≥1 1,936 (43.3) 2,042 (45.7) 1,810 (44.9) 232 (53.0) 1.38 (1.13-1.69)*
Data missing 161 (3.6)
Cumulative antibiotic use
Never 529 (11.8) 940 (21.0) 861 (21.4) 78 (17.8) 1.0
1-2 courses 1,162 (26.0) 1,715 (38.4) 1,564 (38.8) 151 (34.5) 1.07 (0.73-1.56)
≥3 courses 828 (18.5) 1,813 (40.6) 1,604 (39.8) 209 (47.7) 1.44 (1.01-2.06)*
Data missing 1,948 (43.6)
Maternal characteristics
Maternal education level (%)
Primary, or secondary 2101 (47.0) 2,438 (54.6) 2,127 (52.8) 311 (71.0) 2.20 (1.76-2.75)*
Higher 1955 (43.8) 2,029 (45.4) 1,902 (47.2) 127 (29.0) 1.0
Data missing 411 (9.2)
Mean age sera taken, years (SD) 30.5 (5.0) 30.5 (5.0) 31.3 (4.6) 29.4 (5.4) 0.92 (0.91-0.94)*
Values are means (and standard deviation), absolute numbers (and percentages) or odds ratio (and 
95% confidence interval). Missing data on maternal H. pylori and CagA status were not imputed.
aIncludes subjects from Central and South America (n = 95), Indonesia (n = 32), North America (n = 
21), Asia, western (n = 21), and Oceania (n = 9). 
bData until 4 months of life
cData completed from the first year of life. * p < 0.05
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Higher H. pylori colonization rates were observed in children of either Dutch or non-
Dutch ethnicity of older age (Figure S2). The proportion of CagA-positivity amongst H. 
pylori-positive children varied widely between ethnic groups (Figure 2B). The lowest 
proportions were found in children with Dutch or other European ethnicities (16% and 
14%, respectively).
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Figure 2. Prevalence of H. pylori and CagA-positivity in 4,467 children according to ethnic group. 
Panel A: H. pylori prevalence, by ethnic group. Panel B: Proportion of CagA-positive strains amongst 
the H. pylori-positive children, by ethnic group. 
Numbers are either percent (above bars) or absolute numbers (Tables). 
P-values reflect differences between children of Dutch ethnicity (reference group) and any other 
group, using Chi-square test. Children classified as ‘rest of the world’ are not shown in this figure. 
Their H. pylori-positivity rate is 12.6% (26 of 206), and proportion of CagA-positive strains is 42% 
(11 of 26). 
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Risk factors for H. pylori colonization
In univariate analyses, a child’s H. pylori positivity was associated with an H. pylori-positive 
mother (OR 3.22; 95% CI 2.52-4.12), and non-Dutch ethnicity (OR 2.99; 95% CI 2.32-3.86). 
Female gender, age, breastfeeding, presence of older siblings, antibiotic exposure (see 
also Table S3), and lower maternal educational level also were positively associated with 
H. pylori status, whereas day-care attendance was negatively associated (Table 1).
Using multivariate analysis (Figure 3), we identified the following independent risk 
factors for H. pylori positivity in a child: maternal H. pylori positivity [(CagA-positive 
mother OR 2.25; 95% CI 1.61-3.16) (CagA-negative mother OR 2.05; 95% CI 1.53-2.74)], 
non-Dutch ethnicity (OR 2.04; 95% CI 1.53-2.72), female gender (OR 1.47; 95% CI 1.20-
1.81), and lower maternal education level (OR 1.37; 95% CI 1.06-1.78). A separate 
multivariate analysis to examine risk for CagA-positivity amongst all H. pylori-positive 
children revealed independent associations with lower educational level of mother (OR 
2.65; 95% CI 1.33-5.28), and non-Dutch ethnicity (OR 2.48; 95% CI 1.27-4.85) (Table S4). 
Compared with males, we found female gender independently associated with never 
having had exposure to antibiotics (OR 1.30; 95% CI 1.07-1.60) and lower educational 
level of the mother (OR 1.17; 95% CI 1.01-1.35) (Table S5). Caesarian section was not 
significantly associated with H. pylori colonization. Comparison of C-section with vaginal 
birth revealed independent associations with no breastfeeding (OR 1.98; 95% CI 1.31-
2.98), nulliparity (OR 1.81; 95% CI 1.48-2.20), and day-care attendance (OR 1.34; 95% CI 
1.01-1.77) (Table S6). 
A stratified analysis by ethnicity was performed (Dutch vs. non-Dutch), based on the 
significantly lower H. pylori colonization rate in children of Dutch ethnicity compared to 
all other subjects (Figure 3, and Table S7 for comparison of European vs. non-European). 
Differences in the odds ratios for H. pylori colonization were observed for gender, 
educational level of mother, and day-care attendance. There was no evidence for effect 
modification by ethnicity for the associations of gender, educational level of mother, and 
day-care attendance with H. pylori colonization (p-value for interactions >0.05). 
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Figure 3. Multivariate analyses of determinants associated with H. pylori colonization in the total 
population, and comparing Dutch and non-Dutch origins. All listed variables are entered into the 
logistic regression model. Odds ratios (ORs) and 95% confidence intervals (CIs) are adjusted for age 
and express the association with H. pylori positivity. The ORs for the total population are in bold. 
Reference groups: aH. pylori-negative mother, bDutch ethnicity, cmale gender, dno breastfeeding, 
ehigher educational level, fno older siblings, gno day-care attendance, hvaginal birth, inever exposed 
to antibiotics. 
* p < 0.05.
Comparison of H. pylori colonization in mothers and their children
Data on the H. pylori status of mother was available for 3,185 (71%) children (Table 2). 
The H. pylori positivity rate in mothers (mean age of 30.5 ±5.0 years) was 42%. An H. 
pylori-positive mother was associated with an H. pylori-positive child (OR 3.22; 95% CI 
2.52-4.12). Of the 1,328 children with an H. pylori-positive mother, 211 (15.9%) were H. 
pylori-positive, compared to 103 (5.5%) of the 1,857 children with an H. pylori-negative 
mother. As a result, 33% (n=103) of all H. pylori-positive children had a mother who tested 
H. pylori-negative. The median antibody titer in these children was significantly lower 
(1.43; 2.5-97.5th percentile 0.74-6.68) than in children with an H. pylori-positive mother 
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(2.11; 2.5-97.5th percentile 0.56-15.68). In children of non-Dutch ethnicity, the proportion 
H. pylori-positive children with an H. pylori-negative mother was 22% compared to 
55% of children with Dutch ethnicity (p<0.001). Table 2 shows the associations between 
mother and child’s H. pylori colonization rates by strain type. Children born from H. 
pylori-negative mothers were significantly less likely to be colonized at age 6 with either 
a CagA-negative or CagA-positive H. pylori strain than children born from H. pylori-
positive mothers. Conversely, children born from H. pylori+CagA- mothers were more 
likely to be colonized with the same strain type, and for children with H. pylori+CagA+ 
mothers, the OR for carrying the same strain type was 6.74 (95% CI 4.52-10.05).
Table 2. H. pylori colonization by strain type in 3,185 mother-child pairsa.
Child’s H. pylori status
Hp-
(n= 2,871) 
Hp+
(n= 314)
Hp+CagA-
(n=210)
Hp+CagA+ 
(n=104)
M
o
th
er
’s
 H
. p
yl
o
ri
 s
ta
tu
s
Hp- [n= 1,857 (%)]
OR (95% CI)
1,754 (94.5)
Reference
103 (5.5)
0.31 (0.24-0.40)*
86 (4.6)
0.44 (0.33-0.59)*
17 (0.9)
0.12 (0.07-0.21)*
Hp+ [n= 1,328 (%)]
OR (95% CI)
1,117 (84.1)
Reference
211 (15.9)
3.22 (2.52-4.12)*
-- --
Hp+CagA- [n= 873 (%)]
OR (95% CI)
746 (85.5)
Reference --
92 (10.5)
2.22 (1.67-2.95)*
35 (4.0)
1.45 (0.95-2.19)
Hp+CagA+ [n= 455 (%)]
OR (95% CI)
371 (81.5)
Reference --
32 (7.0)
1.21 (0.82-1.79)
52 (11.5)
6.74 (4.52-10.05)*
aValues shown are absolute numbers and their percentages in relation to maternal H. pylori status. 
The odds ratios and 95% confidence intervals represent the association between the reference 
group (children without H. pylori) and the other groups. * p <0.05
Overall, the H. pylori prevalence decreased 76% comparing mothers and their children. 
A significant reduction in H. pylori prevalence was observed across all nine ethnic 
groups studied (Figure 4). This reduction was consistent for both H. pylori+CagA- and H. 
pylori+CagA+-strains (Figure 4A and 4B). The overall reduction rate for males (-80%) was 
slightly higher than for females (-72%), which was consistent across all ethnic groups. 
Multivariate analysis of the absence of H. pylori in children with an H. pylori-positive 
mother (n = 1,328) revealed male gender (OR 1.64; 95% CI 1.21-2.23), higher maternal 
education level (OR 1.78; 95% CI 1.15-2.76), and no older siblings (OR 1.37; 95% CI 1.01-
1.88) independently associated with an H. pylori-negative child (Table S8). The proportion 
of the H. pylori reduction attributable to male gender (21%), having no older siblings 
(14%), and higher maternal education level (14%), were all significant (Figure 5). 
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Figure 4. Prevalence and differential rates of H. pylori -strains in 3,185 mothers and their children 
by ethnic group. A: CagA- strains B: CagA+ strains. Numbers are either percentages (above or below 
bars) or absolute numbers (Tables). Light grey bars reflect the percent differences between mothers 
and their children. The p-values reflect differences between the positivity rates in mothers (dark 
grey bars) compared to their children (black bars). Subjects categorized in ‘rest of the world’-group 
are not shown as a separate group, but included in ‘All’ category. 
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14.0 (0.5-24.3)
20.8 (9.3-29.5)
PAF (%)
Figure 5. Population-attributable fraction (PAF) for decline in H. pylori colonization in 1,328 
children with an H. pylori-positive mother. PAF was calculated from adjusted ORs (aOR) derived 
from multivariable logistic regression model comparing H. pylori-negative children (n = 1,117) with 
H. pylori-positive children (n = 211), additionally adjusted for caesarean section, breastfeeding, 
day-care attendance and cumulative antibiotic exposures. PAF, population-attributable fraction; CI, 
confidence interval.
DISCUSSION
In this multi-ethnic population-based cohort, we found highly variable H. pylori 
colonization rates in six-year old children, with both the prevalence of H. pylori and the 
proportion of CagA-positive strains higher in children of non-Dutch ethnicity. Independent 
of ethnic background, maternal H. pylori colonization was the strongest risk factor for H. 
pylori-positivity in their offspring. Our study design made it possible to compare H. pylori 
colonization in children directly with that of their mothers, showing essentially identical 
intergenerational reductions for both H. pylori+CagA- and H. pylori+CagA+-strains. 
The overall colonization rate of 10% differs from that found in a previous study 
performed in the Netherlands (16). This recent study of 545 Dutch children between 
7 and 9 years old, which used the same ELISA as did we, found an H. pylori positivity 
rate of 9% (95% CI 6.6-11.4%) (16), a prevalence slightly higher than that measured in 
children of Dutch ethnicity in our study (6%). This difference may reflect a continuing 
decline in colonization, or may be due to the different study designs, or the younger 
age of children in our study. The latter may contribute, as our data suggest continuing 
acquisition of H. pylori at least until the age of 7, consistent in children of Dutch and 
non-Dutch ethnicities. The higher H. pylori prevalence in children of non-Dutch ethnicity 
confirms findings of other studies (32, 33). The CagA-prevalence is lower than expected 
(1). However, recent studies from The Netherlands have found similar CagA prevalence 
to our results (34). In addition, there is evidence from Finland that CagA+-strains are 
disappearing faster than CagA--strains (35).  
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The intergenerational reduction was of the same magnitude among all different ethnic 
groups, resulting in the same birth cohort effect in all groups. A recent study from Japan 
independently confirms the decline in two generations (36). We calculated the reduction 
in H. pylori colonization rate across generations: comparing the H. pylori prevalence 
in grandmothers and mothers showed a reduction of 37%, while the prevalence in 
mothers and their children showed a reduction of 72%. The latter is essentially the same 
reduction as we observed. The decline in children with an H. pylori-positive mother can be 
partially attributed to male gender, lack of older siblings, and higher educational level of 
mother. The lack of older siblings may reduce horizontal transmission of H. pylori within 
a family. Others found the number of siblings within a family rather than birth order 
independently associated with H. pylori colonization (37). Nevertheless, our findings 
imply that environmental factors and living conditions of the country in which a child 
is raised have a major impact on transmission, irrespective of ethnicity. The consistent 
reduction across all ethnic groups support the hypothesis that in contemporary Dutch 
society, and probably elsewhere as well, there are highly prevalent factors that interfere 
with the early life acquisition and/or maintenance of H. pylori. Besides the involvement 
of socio-economic status, family size, and other living conditions, possible candidates 
include the widespread use of antibiotics, particularly in young children. The effect 
of antibiotic monotherapy on H. pylori status is limited (38), but repeated antibiotic 
exposure may eventually result in eradication. Another possibility could be the run-off 
of antibiotics from farms where antibiotic-intensive husbandry is being practiced, which 
may contaminate surface and drinking water (39). In contrast to the use of antibiotics in 
humans, the Dutch consumption of antibiotics per animal exceeds the consumption of all 
European countries, and despite the prohibition of antibiotics as growth promoters, the 
use remained stable (40). However, there is no strong evidence of contaminated drinking 
water (40). Regardless of its cause, the clinical consequences of this rapid disappearance 
may have opposite effects: a fall in prevalence of the later life expression of gastric and 
duodenal ulcer disease, and gastric carcinoma (41, 42), but a rise in earlier life-expressed 
atopy, asthma, and reflux-related disorders (11), since epidemiological studies have 
shown inverse associations of these disorders with H. pylori colonization (3, 5). 
The association of specific H. pylori types in mother and child provides further evidence 
supporting a role for maternal inheritance in early life transmission, shown in molecular 
typing studies (43). A recent German study that included the H. pylori status of parents 
and siblings in a multivariate model, showed that only maternal infection was associated 
with H. pylori positivity in the children (33). Despite this important maternal role, 
we found that one third of all positive children had an apparently H. pylori-negative 
mother. This proportion was even higher (>50%) in children of Dutch ethnicity, implying 
the involvement of other transmission sources, such as fathers and siblings (43), or 
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grandmothers (36). There also is evidence for transmission from outside the nuclear family, 
including environmental reservoirs or other children in the community (44, 45), although 
these seem more likely in developing than in developed countries (46). An alternative 
hypothesis is that some maternal H. pylori colonisations were missed, due to lack of 
complete sensitivity of the assay, or post-natal acquisition of the organism. Especially in 
a multi-ethnic population, children may become colonized with H. pylori by acquiring 
the bacterium from persons of ethnicities with higher H. pylori prevalence, e.g., in day-
care facilities. However, a recently published meta-analysis found no significant effect 
of day-care attendance on H. pylori colonization (summary OR 1.12; 95% CI 0.82-1.52) 
(47). Nevertheless, a Portuguese study of 1,047 children reported increasing H. pylori 
prevalence with cumulative attendance in day-care centres (48). Our stratified analysis 
of ethnicity revealed opposite trends for the relation between H. pylori colonization 
and day-care attendance. Such observations suggest that child-to-child transmission in 
a day-care setting may be more likely for children of Dutch ethnicity where children of 
non-Dutch ethnicity could serve as transmission sources. 
Remarkably, female gender was found to be associated with H. pylori colonization. 
Although most prior studies found a decreased risk for infection, pooled data from 
studies in children found no difference (49). Specific multivariate analysis of determinants 
associated with female gender (Table S5) showed that both lower socioeconomic status 
and lack of antibiotic use were associated with female gender. Our findings are consistent 
with prior studies from The Netherlands, which observed that males from 0 to 4 years of 
age received more antibiotics than females of the same age (50, 51), while for older ages, 
the trends were opposite. In most prior studies, breastfeeding is associated with lower 
H. pylori colonization rates: a meta-analysis of pooled data found an OR of 0.78 (95% 
CI 0.61-0.99) for H. pylori infection (52). However, 6 of 14 included studies observed an 
increased risk for H. pylori infection, which is in line with our trend. We speculate that 
breastfed children had been in closer contact with mother, and were more likely to be 
born vaginally, which may have increased the risk of transmission. Nevertheless, we did 
not observe a significant association between breastfeeding and H. pylori status, and 
therefore firm conclusions are not possible. The positive associations of Caesarian section 
with nulliparity, and no breastfeeding, confirm prior observations (53), but that mothers 
who underwent Caesarian section were more likely to use day-care suggests that mode 
of delivery correlates with other lifestyle aspects. 
An important strength of this study is that we had a large multi-ethnic study population 
drawn from the general population of Rotterdam; since immigration is common in many 
western countries, our findings may be more broadly applicable. An additional strength 
is the use of maternal data on H. pylori colonization, which provides insight into mother-
to-child transmission. 
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This study has some limitations, including missing data for several characteristics and 
potential risk factors for colonization, which may have biased the outcome. However, we 
performed the final analyses after a multiple imputation procedure, considered useful to 
deal with missing data, as it requires the fewest assumptions and reduces potential bias 
when missing data are not random (30). A second limitation was lack of data on H. pylori 
colonization in fathers and siblings, precluding examination of their potential roles in 
transmission. A third limitation is that data on antibiotic exposures were not validated by 
pharmacy records, nor was information available on specific types. Strong conclusions on 
the effect of antibiotic exposure for the H. pylori colonization are not possible. Our data 
may overestimate prescribed antibiotic courses: a Dutch longitudinal observational study 
found that 25% of the studied children between 0-4 years of age received at least one 
oral antibiotic prescription per year (51). Taking these limitations into consideration, we 
believe that the questionnaire-based antibiotic data are at least worthwhile to report, 
since prior studies had considered such exposure as a potential confounder for the H. 
pylori colonization rates. A fourth limitation is that since we do not exactly know the 
maternal H. pylori status at age 6, the true intergenerational reduction may be over- or 
under-estimated. Since we have no indication that the likelihood of new infections or loss 
of infection after age 6 would be different across the ethnic groups, it should not affect 
our main finding of uniform rates of reduction across all ethnic groups. Finally, although 
both ELISAs have been validated in adults and children, including Dutch adults, and 
have been used in previous studies in Dutch children (16), they have not been separately 
validated in Dutch children. 
In conclusion, we found relatively high H. pylori colonization rates in children of non-
Dutch ethnicity who were born and raised in a western city. Regardless of ethnicity, 
maternal H. pylori type was an important predictor for a child’s H. pylori type. The 
high and consistent intergenerational reduction in H. pylori prevalence irrespective of 
ethnicity and sex points toward very common exposures fuelling this phenomenon.
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Figure S1. H. pylori antibody distribution in mothers and children. Distribution of levels (ODR) 
of mothers (A) and children (B). The numbers above the bars reflect the percent within the total 
population. 
Figure S2. Continuing acquisition of H. pylori by age. H. pylori positivity rates (%) in 2,516 children 
of Dutch  and 1,951 children non-Dutch ethnicity at ages 5, 6, and 7. The p-value for trend is <0.05 
in both groups. 
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3Figure S3. Comparison of H. pylori and CagA status in 3,185 mothers and their children. The 3,185 
children are grouped by H. pylori and CagA status. Each figure shows the percent (%) of children 
with an H. pylori-negative (Hp-), CagA- (Hp+CagA-), or CagA+ (Hp+CagA+) mother. *p < 0.05 by Chi-
square test. The p-values reflect the difference between the corresponding H. pylori status of 
mother and child, and the two other groups. 
Table S1. Comparison of the maternal and child characteristics between those included and those 
not included in the study among the 8,305 eligible subjects.
Population without H. 
pylori data
N=3,338 (40.2)
Population with H. 
pylori data
N=4,467 (59.8)
p-value
Child characteristics
Age 6.1 (0.5) 6.2 (0.6) <0.01
Female sex 1,948 (50.8) 2,164 (48.4) 0.04
Gestational age at birth 39.7 (1.9) 39.8 (1.8) 0.06
Birth weight 3,383 (586) 3,413 (569) 0.26
Ethnicity
       Dutch 1,999 (55.2) 2,505 (57.6) 0.02
        Surinamese 287 (7.9) 317 (7.3)
        Turkish 309 (8.5) 311 (7.2)
        Moroccan 241 (6.7) 256 (5.9)
        Dutch Antilles 118 (3.3) 141 (3.2)
        Cape Verdean 99 (2.7) 129 (3.0)
        Other 630 (17.4) 690 (15.9)
Caesarean section 441 (13.1) 496 (12.9) 0.74
Breastfeeding 2,448 (90.9) 3,248 (92.5) 0.03
Day-care attendance 1st year 1,043 (57.2) 1,548 (60.3) 0.04
Maternal characteristics
Parity
       Nulliparous 2,077 (55.9) 2,370 (55.0) 0.45
       Multipara 1,640 (44.1) 1,936 (45.0)
Maternal education
       Low/medium 1,989 (58.3) 2,101 (51.8) <0.01
       High 1,420 (41.7) 1,955 (48.2)
Values shown are absolute numbers (and percentages) for categorical variables, except that age, 
gestational age at birth, and birth weight are reported as the mean (and standard deviation).
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Table S2. Missing data analyses in 4,467 children.
Population with 
incomplete
data on covariates*
N= 3,039 (68.0)
Population with 
complete
data on covariates
N= 1,428 (32.0)
P-value Missing 
(%)a
Child characteristics
Age (SD) 6.36 (0.54) 6.03 (0.35) <0.001 0
Female sex (%) 1,469 (48.3) 695 (48.7) 0.84 0
Gestational age at birth (SD) 39.6 (1.9) 40.0 (1.7) <0.001 0.7
Birth weight (SD) 0.2
Ethnicity (%) <0.001 2.6
        Dutch 1,509 (51.7) 996 (69.7)
        Surinamese 247 (8.5) 70 (4.9)
        Turkish 250 (8.6) 61 (4.3)
        Moroccan 222 (7.6) 34 (2.4)
        Dutch Antilles 118 (4.0) 23 (1.6)
        Cape Verdean 108 (3.7) 21 (1.5)
        Other 467 (16.0) 223 (15.6)
Caesarean section (%) 299 (12.3) 197 (13.8) 0.19 13.7
Breastfeeding (%) 1,917 (92.0) 1,331 (93.2) 0.18 21.4
Day-care attendance 1st year (%) 637 (55.9) 911 (63.8) <0.001 42.5
Maternal characteristics
Parity (%) <0.001 3.6
       Nulliparous 889 (51.2) 866 (60.6)
       Multiparous 846 (48.8) 562 (39.4)
Maternal education (%) <0.001 9.2
       Low/medium 1,562 (59.4) 539 (37.7)
       High 1,066 (40.6) 889 (62.3)
*Data on ≥ 1 covariate is missing. aPercentage of missings per category. 
Values shown are absolute numbers (and percentages) for categorical variables. Gestational age at 
birth and birth weight are reported as the mean (and standard deviation).
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Table S3. Antibiotic exposure during the first 6 years of life. 
Observed Imputed H. pylori-
n = 4,029
H. pylori+
n = 438
Univariate OR
(95% CI)
Antibiotic exposure (%)
6-11 months
No 1,800 (40.3) 2,728 (61.1) 2,467 (61.2) 261 (59.6) 1.0
1-2 courses 879 (19.7) 1,390 (31.1) 1,263 (31.3) 127 (29.0) 0.95 (0.68-1.32)
≥3 courses 105 (2.4) 350 (7.8) 300 (7.4) 50 (11.4) 1.51 (0.82-2.77)
Data missing 1,683 (37.7)
12-23 months
No 1,638 (36.7) 2,337 (52.3) 2,114 (52.5) 223 (50.9) 1.0
1-2 courses 1,111 (24.9) 1,702 (38.1) 1,541 (38.2) 161 (36.8) 0.99 (0.74-1.32)
≥3 courses 195 (4.4) 428 (9.6) 374 (9.3) 54 (12.3) 1.35 (0.86-2.11)
Data missing 1,523 (34.1)
24-35 months
No 1,817 (40.7) 2,642 (59.1) 2,404 (59.7) 238 (54.3) 1.0
1-2 courses 886 (19.8) 1,521 (34.0) 1,364 (33.9) 156 (35.6) 1.16 (0.87-1.56)
≥3 courses 105 (2.4) 305 (6.8) 260 (6.5) 44 (10.0) 1.71 (0.99-2.95)
Data missing 1,659 (37.1)
36-47 months
No 1,977 (44.3) 2,820 (63.1) 2,566 (63.7) 254 (58.0) 1.0
1-2 courses 763 (17.1) 1,253 (28.1) 1,131 (28.1) 122 (27.9) 1.09 (0.79-1.50)
≥3 courses 75 (1.7) 395 (8.8) 333 (8.3) 62 (14.2) 1.80 (0.91-3.57)
Data missing 1,652 (37.0)
60-71 months
No 2,956 (66.2) 3,303 (73.9) 2,999 (74.4) 304 (69.4) 1.0
1-2 courses 760 (17.0) 921 (20.6) 829 (20.6) 93 (21.2) 1.10 (0.83-1.46)
≥3 courses 73 (1.6) 243 (5.4) 202 (5.0) 41 (9.4) 1.95 (1.03-3.67)*
Data missing 678 (15.2)
Values are absolute numbers (and percentages) or odds ratio (and 95% confidence interval). 
* p < 0.05
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Table S4. Multivariate analysis of determinants for CagA-positivity in 438 H. pylori-positive childrena. 
Ageb 0.93 (0.51-1.71)
Gender
Female
Male
0.87 (0.56-1.35)
Reference
Ethnicity
Dutch
Non-Dutch
Reference
2.48 (1.27-4.85)*
Breastfeedingc
Never
Partial
Exclusive
Reference
0.84 (0.31-2.25)
0.60 (0.20-1.87)
Educational level
Primary/secondary
Higher
2.65 (1.33-5.28)*
Reference
Number of older siblings
0
≥1
Reference
1.02 (0.66-1.60)
Day-care attendanced
No
Yes
Reference
0.62 (0.35-1.12)
Caesarian section
No
Yes
Reference
1.66 (0.72-3.81)
Cumulative antibiotics exposuree
0 courses
1-2 courses
≥3 courses
Reference
0.76 (0.34-1.73)
0.76 (0.35-1.67)
aMultivariate logistic regression analysis comparing 142 CagA+ with 296 CagA--chlildren. Numbers 
are displayed as odds ratio (95% confidence interval) and represent the association with CagA+-
children. All listed variables were entered into the multivariate analysis. 
bfor each additional year
cData pertain to the first 4 months of life
dData pertain to the first year of life
eCumulative antibiotic exposure data combined until the age of 72 months. 
* p < 0.05 
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Table S5. Multivariate analysis of determinants associated with female gendera.
Ageb 0.94 (0.82-1.07)
Ethnicity 
Dutch
Non-Dutch
Reference
1.04 (0.91-1.18)
Breastfeedingc
Never
Partial
Exclusive
Reference
1.00 (0.75-1.34)
1.03 (0.78-1.35)
Educational level
Primary/secondary
Higher
1.17 (1.01-1.35)*
Reference
Number of older siblings
0
≥1
Reference
0.90 (0.79-1.01)
Day-care attendanced
No
Yes
Reference
1.09 (0.92-1.29)
Caesarian section
No
Yes
Reference
0.89 (0.73-1.08)
Cumulative antibiotic exposuree 
0
1-2 courses
1.30 (1.07-1.60)*
1.06 (0.89-1.25)
≥3 courses Reference
aMultivariate logistic regression analysis comparing 2,164 females with 2,303 males. Numbers are 
displayed as odds ratio (and 95% confidence interval) and represent the association with female 
gender. All listed variables were entered into the multivariate analysis. 
bfor each additional year
cData pertain to the first 4 months of life
dData pertain to the first year of life
eCumulative antibiotic exposure data combined until the age of 72 months. 
* p < 0.05 
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Table S6. Multivariate analysis of determinants associated with Ceasarian sectiona.
Ageb 1.01 (0.81-1.27)
Ethnicity (%)
Dutch
Non-Dutch
Reference
0.98 (0.79-1.21)
Breastfeedingc
Never
Partial
Exclusive
1.98 (1.31-2.98)*
1.30 (0.95-1.78)
Reference
Educational level
Primary/secondary
Higher
0.98 (0.69-1.30)
Reference
Number of older siblings
0
≥1
1.81 (1.48-2.20)*
Reference
Day-care attendanced
No
Yes
Reference
1.34 (1.01-1.77)*
Cumulative antibiotic exposuree
0
1-2 courses
≥3 courses
Reference
0.95 (0.69-1.30)
1.00 (0.76-1.31)
aMultivariate logistic regression analysis comparing Ceasarian section (n=589) with vaginal births 
(n=3,878). Numbers are displayed as odds ratio (95% confidence interval) and represent association 
with Ceasarian section. All listed variables were entered into the multivariate analysis. 
bfor each additional year
cData pertain to the first 4 months of life
dData pertain to the first year of life
eCumulative antibiotic exposure data combined until the age of 72 months. 
* p < 0.05 
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Table S7. Multivariate analysis of H. pylori status by ethnicity (European vs. non-European)a.
European Non-European
Ageb 1.55 (1.07-2.24)* 1.09 (0.82-1.44)
Gender
Female
Male
1.50 (1.10-2.06)*
Reference
1.46 (1.12-1.92)*
Reference
Breastfeedingc
Never
Partial
Exclusive
Reference
1.10 (0.58-2.12)
1.08 (0.51-2.27)
Reference
1.33 (0.57-3.11)
1.45 (0.64-3.29)
Educational level
Primary/secondary
Higher
1.10 (0.76-1.60)
Reference
1.74 (1.13-2.69)*
Reference
Number of older siblings
0
≥1
Reference
1.13 (0.81-1.56)
Reference 
1.16 (0.87-1.54)
Day-care attendanced
No
Yes
Reference
1.22 (0.71-2.08)
Reference 
0.77 (0.52-1.14)
Caesarean section
No
Yes
Reference
0.90 (0.53-1.53)
Reference
0.69 (0.39-1.22)
Cumulative antibiotic usee
0
1-2 courses
≥3 courses
Reference
1.24 (0.77-1.99)
1.20 (0.74-1.93)
Reference
0.92 (0.56-1.50)
0.91 (0.56-1.48)
Maternal H. pylori status
Hp-
Hp+CagA-
Hp+CagA+
Reference
2.16 (1.42-3.27)*
3.75 (2.14-6.59)*
Reference
1.99 (1.31-3.04)*
1.95 (1.24-3.07)*
Multivariate logistic regression analysis comparing 2,848 subjects of European with 1,619 subjects 
of non-European ethnic background. Numbers are displayed as odds ratio (and 95% confidence 
interval) and represent association with H. pylori positivity. All listed variables were entered into 
the multivariate analysis. 
bfor each additional year
cData pertain to the first 4 months of life
dData pertain to the first year of life
eCumulative antibiotic exposure data combined until the age of 72 months. 
* p < 0.05 
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Table S8. Multivariate analysis of risk factors for H. pylori loss in 1,328 children with an H. pylori-
positive mothera.
Gender
Female
Male
Reference
1.64 (1.21-2.23)*
Breastfeedingb
Never
Partial
Exclusive
1.38 (0.55-3.48)
1.10 (0.65-1.84)
Reference
Educational level
Primary/secondary
Higher
Reference
1.78 (1.15-2.76)*
Number of older siblings
0
≥1
1.37 (1.01-1.88)*
Reference
Day-care attendancec
No
Yes
Reference
1.30 (0.81-2.09)
Caesarian section
No
Yes
Reference
1.58 (0.74-3.39)
Cumulative antibiotic exposuresd
0 
1-2 courses
≥3 courses
Reference
1.08 (0.56-2.06)
1.03 (0.58-1.83)
aMultivariate logistic regression analysis comparing 1,117 H. pylori-negative children with 211 H. 
pylori-positive children. Numbers are displayed as odds ratio (and 95% confidence interval) and 
represent association with H. pylori-negative children (loss of H. pylori). All listed variables were 
entered into the multivariate analysis. 
bData pertain to the first 4 months of life
cData pertain to the first year of life
dCumulative antibiotic exposure data combined until the age of 72 months. 
* p < 0.05 
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Helicobacter pylori infection: a predictor 
of vomiting severity in pregnancy and 
adverse birth outcome
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ABSTRACT
Background and aim: Nausea and occasional vomiting in early pregnancy (NVP) is common. 
It is unknown why some women experience severe NVP. Causes are multifactorial and only 
symptomatic treatment options are available, while adverse birth outcomes have been 
described. Helicobacter pylori (H. pylori) infection has been implicated in the etiology 
of NVP. We aimed to investigate the association of H. pylori with vomiting severity in 
pregnancy and its effect on birth outcome.
Methods: Population-based prospective cohort of pregnant women in the Netherlands. 
Enrolment took place between 2002 and 2006. H. pylori serology was determined in 
mid gestation. Women reported vomiting symptoms and had their weight measured in 
early, mid and late gestation. Birth outcomes were obtained from medical records. Main 
outcome measures were vomiting frequency (no-occasional-daily) and duration (early-
mid-late gestation), maternal weight gain, birthweight, small for gestational age (SGA) 
and prematurity. Data were analyzed using multivariate regression.
Results: 5,549 Women were included, of whom 1,932 (34,8%) reported occasional 
vomiting and 601 (10.8%) reported daily vomiting. H. pylori-positive women (n=2,363) 
were more likely to report daily vomiting (adjusted odds ratio (OR) 1.44, 95%CI 
1.16−1.78). H. pylori-positivity was associated with a reduction of total weight gain in 
women with daily vomiting (adjusted difference -2.1 kg, 95%CI -2.7−-1.5) and infants 
born to women with H. pylori and daily vomiting had an increased risk of being small for 
gestational age (SGA; adjusted OR 1.49, 95%CI 1.04−2.14). H. pylori and daily vomiting 
did not significantly affect birth weight or prematurity rate.
Conclusion: This study suggests that H. pylori is an independent risk factor for vomiting in 
pregnancy. In women with daily vomiting, H. pylori is also associated with low maternal 
weight gain and SGA. Since effective treatments for severe NVP are currently lacking, the 
effect of H. pylori eradication therapy on NVP symptom severity should be the target of 
future studies.
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INTRODUCTION
Nausea and occasional vomiting in early pregnancy (NVP) affects 50-90% of pregnant 
women in the first half of gestation,(1) and can greatly impact maternal wellbeing and 
quality of life.(2) When vomiting is severe or protracted, or is accompanied by weight loss, 
dehydration, electrolyte disturbances or hospitalization, it is referred to as hyperemesis 
gravidarum (HG).(3) In the absence of an internationally recognized definition, HG and 
severe NVP are likely to overlap in studies.(4) In the Western world, severe NVP more 
often affects socially disadvantaged women and those of non-Western ethnicity.(5) To 
date, there is no clear explanation for the risk differences between Western and non-
Western ethnic groups. In a recent meta-analysis, colonization with the gastric bacterium 
Helicobacter pylori (H. pylori) was positively associated with severe NVP (odds ratio (OR) 
3.34, 95% CI 2.92−4.81).(6) Interestingly, the H. pylori prevalence in pregnant women 
of Western ethnicity is much lower than in women of non-Western ethnicity.(7) The 
association between H. pylori and severe NVP has been replicated in several studies, but 
mainly in non-Western populations in which the prevalence of H. pylori is high.(8-10) 
Three small studies on this topic have been conducted in a Western setting but reported 
conflicting findings.(11-13) Furthermore, some have suggested that more pathogenic 
variants of H. pylori, such as cytotoxin associated gene A (CagA)-positive strains are more 
often found among women with severe NVP.(14) Several small studies have suggested 
that H. pylori infection is not only associated with the presence of severe NVP, but also 
positively associated with symptom severity(8) and persistence.(10) 
Severe NVP has repeatedly been associated with adverse birth outcome. This includes low 
birth weight, small for gestational age (SGA) and prematurity,(15) but the mechanism by 
which severe NVP may lead to adverse birth outcomes is not well understood. Weight 
loss or insufficient weight gain during pregnancy has been suggested to play a role,(16, 
17) although other factors such as the presence of H. pylori on birth outcome has not 
been investigated.
In the present study, we investigate the hypothesis that H. pylori is associated with 
vomiting severity in pregnancy, and contributes to adverse birth outcomes in women 
with severe NVP. Furthermore, we investigate whether H. pylori explains the marked 
ethnic differences in maternal daily vomiting incidence. The study was performed in a 
large prospective multi-ethnic cohort study in the Netherlands, the Generation R study.
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METHODS
Study population
This study was embedded in the Generation R study, a population-based, prospective 
cohort study from early pregnancy until young adulthood. Approval of the Generation R 
Study was obtained from the Central Committee on Research involving Human Subjects 
in the Netherlands (CCMO) via the Medical Ethics Committee of the Erasmus Medical 
Center, Rotterdam (198.782/2001/31). All participants provided written informed consent. 
The study is still ongoing and conducted in Rotterdam, the second largest city of the 
Netherlands with a multi-ethnic community. Study design and aims have been described 
in detail elsewhere.(18) In brief, 8,879 pregnant women were enrolled between 2002 and 
2006. Women underwent physical examinations (measurement of height and weight) 
and filled out questionnaires, in early, mid and late gestation (<18 weeks, 18-25 weeks, 
>25 weeks respectively). These questionnaires contained information on medical history, 
socioeconomic background, lifestyle and current pregnancy. The number of physical 
examinations and questionnaires received was dependent on the gestational age at 
enrolment. Serum samples were obtained during mid gestation.(19)
In this study, 5,549 women with complete data on H. pylori serology and vomiting status 
at enrolment were included. Women were excluded if they participated multiple times in 
subsequent pregnancies or delivered before 23 weeks gestation. Because the diagnosis 
of severe NVP is unlikely when symptoms first appear after 22 weeks gestation, women 
enrolled from 23 weeks gestation onwards were also excluded. See figure 1. 
Definition of daily vomiting
There is no internationally recognized definition for severe NVP or HG. We used self-
reported daily vomiting during the past three months, present at study enrolment. 
Answers ranged from never through daily on a one to five scale (never - less than once 
a week - once a week - few times a week - daily). When vomiting occurred less than 
once a week, once a week or few times a week, this was defined as occasional vomiting. 
Since occasional vomiting in pregnancy is considered ‘physiological’, women with no or 
occasional vomiting are considered the reference group.
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Figure 1. Flow diagram of participant selection
Symptom severity
Symptom severity was explored according to vomiting frequency (no - occasional - daily 
vomiting) and vomiting duration. When daily vomiting during the past three months 
was reported in both the first and second questionnaire, women were considered to 
have daily vomiting persisting into mid gestation. Similarly, when daily vomiting was 
reported in all three questionnaires, women were considered to have daily vomiting 
persisting into late gestation. Because inadequate weight gain is often part of severe 
NVP, the association of H. pylori and daily vomiting with total maternal weight gain 
(kg) was also investigated. Weight gain was based on self-reported pre-pregnancy 
weight and measured weight in late gestation (adjusted for gestational age difference 
at measurement). 
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H. pylori serology
Mid pregnancy (18-25 weeks) serum samples were used to determine H. pylori serology. 
H. pylori immunoglobulin G (IgG) antibody levels were examined by enzyme-linked 
immunosorbent assay (ELISA), using whole cell antigens.(20) A separate ELISA was 
performed to determine serum IgG antibodies against cytotoxin-associated gene A 
(CagA) protein.(21) Both ELISA’s were validated locally, by adapting the ELISA properties 
based on positive and negative controls.
Pregnancy outcomes
Gestational age at birth, birth weight and neonatal sex were obtained from medical 
records.(18) Prematurity was defined as birth <37 weeks gestation, small for gestational 
age (SGA) was defined as gestational age-adjusted birth weight below the 10th percentile 
in this study’s population, based on the reference standard by Niklasson et al.(22) 
Covariates
General characteristics
Maternal age (y) was assessed at enrolment. Pre-pregnancy BMI (kg/m2) was calculated 
using self-reported pre-pregnancy weight and height measured at enrolment. All socio-
demographic characteristics were self-reported. Ethnicity was determined according to 
the definition of Statistics Netherlands(23) by country of birth of the pregnant woman 
and her parents. Based on the urban population of Rotterdam, the following ethnic 
groups were identified: Dutch, ‘other Western’ (women originating from Europe, 
North America, Oceania, Japan or Indonesia), Surinamese, Turkish, Cape Verdean/Dutch 
Antilles, Moroccan and ‘other non-Western’ (women originating from Africa, Asia, 
South or Central America). Dutch and ‘other Western’ ethnic groups were classified as 
Western, all other ethnic groups described were classified as non-Western. Educational 
level served as a proxy for socioeconomic status and was based on the highest completed 
education (none or primary school; secondary school; higher education). Smoking during 
pregnancy was also self-reported.
Pregnancy characteristics
All major pregnancy characteristics and outcomes were obtained from medical records.
(18) These included parity, twin pregnancy and information on hypertensive disorders in 
pregnancy (pregnancy induced hypertension; preeclampsia; HELLP-syndrome: hemolysis, 
elevated liver enzymes, low platelets).
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Data analysis
Logistic regression analysis was performed to study associations between H. pylori and 
vomiting frequency and vomiting persistence. We adjusted for maternal age, parity, 
ethnicity (ethnic groups), education level and smoking (model 2). Effects of H. pylori and 
daily vomiting on maternal weight gain and birth outcomes were explored using linear 
regression analysis. These analyses were adjusted for neonatal sex, gestational age at 
birth, twin pregnancy, maternal age, parity, hypertensive disorders, ethnicity, education 
level, pre-pregnancy BMI and smoking. We examined potential interactions for these 
outcomes between H. pylori and daily vomiting, ethnicity and education level. Sensitivity 
analyses were performed by including maternal weight gain based on measured weight 
in early and late gestation, and excluding twin pregnancies. We also investigated whether 
H. pylori explained ethnic differences in daily vomiting. Using logistic regression analysis 
we first explored the association of ethnicity and daily vomiting, followed by adjustment 
for H. pylori (model 2). We then further adjusted for maternal age, parity, education 
level and smoking (model 3). Possible strain specific effects on vomiting frequency were 
assessed among H. pylori-positive (CagA-positive and CagA-negative) women. Due to 
small numbers, analyses on birth outcomes were not repeated in this subgroup. Lastly, 
sensitivity analyses were performed to examine whether the associations between H. 
pylori, vomiting severity and birth outcomes were similar for Dutch women only (largest 
ethnic group). Possible confounders were identified using Directed Acyclic Graphs,(24) 
based on known risk factors for HG. Missing data of covariates were imputed using 
multiple imputation (five datasets). The percentages of missing values within the 
population for analysis were below 2%, except for pre-pregnancy weight (10.8%), total 
weight gain (14.1%), vomiting in mid pregnancy (14.7%) and vomiting in late pregnancy 
(18.8%). All analyses were performed using IBM SPSS Statistics for Windows 21.0 (SPSS, 
IBM, Armonk, NY, USA).
RESULTS
Baseline characteristics of women with and without daily vomiting
The study population consisted of 5,549 pregnant women, of which 601 women 
experienced daily vomiting at enrolment (10.8%). Table 1 describes socio-demographic 
and clinical characteristics of women and infants according to vomiting frequency. 
Compared to women with no or occasional vomiting, women with daily vomiting were 
younger, more often of non-Western ethnicity and less highly educated. Women with 
daily vomiting were more often H. pylori positive (64.4%), compared to women with no 
vomiting (36.5%) and occasional vomiting (45.2%, p<0.001).
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 4
108
Table 1 Demographics and clinical characteristics of women and infants according to daily vomiting
Characteristics Total 
population
No 
vomiting
Occasional 
vomiting
Daily 
vomiting
p Value
n= 5,549 3,016 1,932 601
Demographics
Age (y) 29.7±5.2 30.6±5.0 28.9±5.1 27.6±5.0 <0.001
Pre-pregnancy BMI 
(kg/m2)
22.6 
(20.8-25.5)
22.4 
(20.7-25.1)
22.7 
(20.7-25.5)
23.7 
(21.1-27.6)
<0.001
Ethnicity <0.001
Western 62.7 71.6 58.5 31.8
Non-Western 37.3 28.4 41.5 68.2
Ethnic groups <0.001
Dutch 50.8 58.9 46.7 23.5
Other Western 11.9 12.8 11.7 8.3
Moroccan 6.0 3.9 6.8 13.7
Turkish 8.6 6.5 9.0 18.1
Surinamese 9.2 7.4 10.5 14.6
Cape Verdean/Dutch 
Antilles
7.6 5.7 9.0 12.4
Other non-Western 5.9 5.0 6.3 9.5
Education level <0.001
Primary 10.6 8.2 11.2 20.0
Secondary 47.3 42.5 50.7 59.9
Higher 42.1 49.2 38.1 20.1
Smoking 18.1 17.7 18.3 19.3 0.62
IgG anti-H. pylori positive* 42.6 36.5 45.2 64.4 <0.001
CagA + 34.4 11.9 15.4 41.1 <0.001
Pregnancy characteristics
Nulliparous 61.8 63.1 62.0 54.9 <0.05
Twin pregnancy 1.1 0.9 1.4 1.0 0.23
Gestational age at intake 
(wk)
13.8 
(12.4-16.2)
13.6 
(12.2-16.1)
13.8 
(12.5-16.4)
14.2 
(12.5-16.6)
<0.05
Duration of daily vomiting 
Early gestation 7.2 - - 66.6
Mid gestation 2.4 - - 22.1
Late gestation 1.2 - - 11.3
Total weight gain (kg)** 10.5±5.1 10.9±4.9 10.6±5.2 8.5±5.9 <0.001
Infant characteristics
Gestational age at birth (d) 281 (273-287) 281 (274-287) 281 (274-287) 280 (273-286) 0.18
Prematurity (<37 wk) 5.6 5.3 5.7 6.5 0.51
Birth weight (g) 3,402±569 3,422±563 3,387±572 3,360±577 <0.05
SGA (<p10) 10.1 9.5 10.2 11.9 0.19
Data represent mean±SD, median (IQR) or %. Differences in subject characteristics between groups 
were evaluated using Chi-square tests for proportions and One-way ANOVA or Kruskal Wallis 
for continuous variables. Abbreviations: BMI: body mass index; IgG: immune globuline G; CagA: 
Cytotoxin-associated gene A protein; SGA: small for gestational age. * CagA-negative or positive 
**Total weight gain based on pre-pregnancy weight and measured weight in late gestation
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Does H. pylori underlie symptom severity? 
After adjustment for confounders including ethnicity and education level, the association 
between H. pylori and daily vomiting was still present (table 2). H. pylori was also 
positively associated with symptom duration. 39.9% of women with no or occasional 
vomiting were H. pylori positive, compared to 62.4% of women with daily vomiting in 
early pregnancy, 66.4% of women with daily vomiting persistent into mid pregnancy, and 
72.1% of women with daily vomiting persistent into late pregnancy (p<0.001). Logistic 
regression for the association of H. pylori and daily vomiting duration is shown in figure 
2. After adjustment for confounders, the association was reduced but a similar trend was 
seen. Furthermore, women with daily vomiting had reduced weight gain in pregnancy 
(table 3). The presence of H. pylori further reduced weight gain in these women (p-value 
for interaction 0.07). 
Figure 2. Logistic regression for H. pylori and daily vomiting according to symptom duration
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Table 2 Logistic regression for H. pylori and vomiting frequency
No vomiting Occasional vomiting Daily vomiting
OR 95% CI OR 95% CI OR 95% CI
Crude 
H. pylori 1.0 1.44** 1.28; 1.61 3.14** 2.62; 3.77
Adjusted
H. pylori 1.0 1.10 0.96; 1.26 1.44* 1.16; 1.78
‘No vomiting’ is reference group. Adjusted for maternal age, parity, ethnicity, education level, 
smoking. OR: odds ratio; CI: confidence interval. * p<0.05, ** p<0.001
Does H. pylori underlie the association between daily vomiting and poor pregnancy 
outcome?
In table 3, we also examined the effects of H. pylori and daily vomiting on birth outcomes. 
After adjustment for confounders, there was no significant association between H. pylori 
or daily vomiting and birth weight, SGA or prematurity. However, infants born to women 
with both H. pylori and daily vomiting, had an increased risk for SGA. Interaction of H. 
pylori and daily vomiting for SGA was borderline significant (p=0.07), but not for birth 
weight or prematurity. There was no significant interaction for H. pylori and ethnicity or 
education level. Maternal weight gain was significantly associated with birth weight (for 
every kg maternal weight gain adjusted birth weight difference (β) 18g, 95%CI 15−21, 
p<0.001). 
Table 3 Associations of H. pylori and daily vomiting with maternal weight gain and birth outcomes
H. pylori Daily vomiting H. pylori + daily vomiting
β/OR 95% CI β/OR 95% CI β/OR 95% CI
Maternal outcome
Total weight gain (kg) -0.1  -0.4; 0.2 -1.1*  -1.9; -0.4 -2.1**  -2.7;-1.5
Neonatal outcome
Birthweight (g) -24  -57; -9 19  -57; 95 -58 -119; 2
SGA (<p10) 1.08 0.87; 1.34 0.77 0.45; 1.30 1.49* 1.04; 2.14
Prematurity (<37 wk) 1.13 0.85; 1.49 1.21 0.67; 2.18 1.36 0.83; 2.22
‘No/occasional vomiting and no H. pylori’ is reference group. Adjusted for neonatal sex, gestational 
age at birth, twin pregnancy, maternal age, parity, hypertensive disorders, ethnicity, education level, 
pre-pregnancy BMI, smoking, H.pylori*daily vomiting. β: difference; OR: odds ratio; CI: confidence 
interval; SGA: small for gestational age. * p<0.05, ** p<0.001
Does H. pylori underlie ethnic differences in daily vomiting? 
Daily vomiting occurred more often in women of non-Western ethnicity (crude OR 
4.25, 95%CI 3.55−5.10). After adjustment for H. pylori, the OR diminished only slightly 
(model 2, adjusted OR 3.47, 95%CI 2.84−4.24). Across all ethnicities, the OR for daily 
vomiting according to the presence of H. pylori was similar. After further adjustment for 
major confounders, non-Western ethnicity remained significantly associated with daily 
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vomiting (model 3, adjusted OR 2.49, 95% CI 1.99−3.10). In fact, this was true for all non-
Dutch ethnicities (supplement table S1). 
Are there H. pylori strain specific effects?
Sub-analysis among H. pylori-positive women (n=2,363) showed that CagA-positive 
women were more likely to suffer from daily vomiting compared to women that were 
H. pylori-positive but CagA-negative (crude OR 1.36, 95%CI 1.09−1.70). After adjustment 
for ethnicity this difference was rendered non-significant (adjusted OR 1.17, 95% CI 
0.93−1.48).
DISCUSSION
This study confirms the association between H. pylori and daily vomiting and adds to 
the existing evidence that the presence of H. pylori is associated with reduced maternal 
weight gain. More importantly, we found evidence that H. pylori contributes to SGA. 
This makes H. pylori eradication in pregnancy in women with severe NVP an attractive 
target for future intervention studies.
Previous studies have established that H. pylori infection is associated with severe 
NVP, although the strength and size of these associations varied between different 
populations and countries.(6, 11, 25, 26) Our findings confirm this association. Similarly, 
the prevalence of H. pylori infection among Dutch (24%) and non-Dutch women (64%) 
in this cohort(7) is in line with the existing literature. We found that H. pylori remained 
a risk factor for daily vomiting after adjustment for ethnicity and socioeconomic status, 
lending further support to the hypothesis that H. pylori is causally implicated in the 
pathophysiology of severe NVP. 
Several studies evaluating birth outcome in pregnancies complicated by severe NVP 
have demonstrated modest negative effects on birth weight, SGA and prematurity 
rates.(15) Both H. pylori and severe NVP have been implicated in placental dysfunction 
disorders.(27, 28) Interestingly, we observed an increased risk for SGA in H. pylori-
positive women with daily vomiting, but not in H. pylori-negative women with daily 
vomiting. This might explain why not all studies found adverse birth outcomes following 
pregnancies complicated by severe NVP. SGA may be a result of poor placentation, 
including failed remodeling of the spiral arteries.(29) Causes of impaired remodeling 
might include an excessive or atypical maternal immune response to trophoblasts.(30) 
Franceschi et al. have shown that anti-CagA antibodies in vitro were able to recognize 
β-actin on the surface of trophoblast cells in a dose-dependent binding activity.(31) 
This binding resulted in impaired cytotrophoblast invasiveness, which is crucial for the 
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development of the placental syndrome. This study may provide a biological explanation 
for the epidemiological association between H. pylori and the placental syndrome. 
Taken together, it is possible that H. pylori has a local gastrointestinal effect leading to 
NVP symptoms, and a systemic placental effect resulting in an increased risk for SGA. 
Furthermore, interaction of H. pylori and NVP might result in reduced maternal weight 
gain, which in turn negatively affects birth outcome. 
Most likely H. pylori is acquired at a young age leading to lifelong colonization unless 
specifically treated.(32) More pathogenic variants of H. pylori, in particular CagA-positive 
strains, are associated with increased gastric inflammation.(21, 33, 34) Like Xia et al,(14) 
we found that CagA-positive women were more likely to suffer from daily vomiting 
compared to women that were H. pylori-positive but CagA-negative, which might be 
partly explained by differences in geographic distribution of CagA-strains. 
This study was embedded in a large prospective cohort study and data collection was 
performed by trained research assistants. Questionnaires enquiring the presence of 
vomiting were collected prospectively, making the risk of recall bias low. If misclassification 
of vomiting frequency had occurred, the presented effects could be underestimated. 
Furthermore, we were unable to confirm HG diagnosis based on hospital admission 
or other more common used criteria(35) and numbers for persistent vomiting in late 
pregnancy were small. Due to the observational design, residual confounding might 
still be an issue. Despite these limitations, characteristics of women suffering from 
daily vomiting largely resembled previous reported data on severe NVP patients.(5, 36) 
Additionally, we were informed about maternal weight gain and symptom persistence 
and able to adjust for all previously described major confounders known to be associated 
with H. pylori and severe NVP,(12) with detailed information on ethnic background. 
Sensitivity analyses on the studied associations including only Dutch women resulted in 
similar findings (data not shown). We were underpowered to show that the presence of 
H. pylori was associated with daily vomiting persistence, and to study potential effects of 
H. pylori strains on vomiting severity and birth outcome. 
There is debate on the accuracy of various diagnostic strategies to establish H. pylori 
infection. Many studies(6) including this study, have investigated the presence of H. 
pylori IgG antibodies in serum using ELISA. Other tests with greater accuracy have 
replaced serology in clinical practice, but due to low costs, acceptability to patients and 
practicability, serology is still indicated for epidemiological studies.(37) The declining 
H. pylori prevalence in the Netherlands might affect the positive predictive value of 
serology(38) but it is unlikely this has influenced our findings. Unlike most infectious 
diseases, H. pylori infection does not result in acquired immunity. Therefore, IgG anti-H. 
pylori and anti-CagA antibodies are indicative of active disease, unless eradication 
therapy has been prescribed in the previous months.(39) This would have been rare 
among pregnant women.
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To date, no effective treatment options are available for severe NVP, nor do we know 
how to identify patients at risk for persistent symptoms during the course of pregnancy. 
Several case studies have reported that H. pylori eradication effectively relieved symptoms 
in women with persistent vomiting, unresponsive to conventional treatment.(40-43) H. 
pylori eradication therapy in the Netherlands normally consists of triple therapy, including 
a proton pump inhibitor (PPI), amoxicillin and clarithromycin or metronidazole.(38) A 
meta-analysis performed by Gill et al. showed no teratogenic effects of PPI use in early 
pregnancy.(44) No teratogenic effects were described for amoxicillin, clarithromycin 
and metronidazole.(45-47) Clarithromycin, but not amoxicillin and PPI, was associated 
with miscarriage when administered in first trimester.(47) These studies indicate that 
triple therapy consisting of PPI, amoxicillin and metronidazole might be safely used in 
pregnancy. Further evidence to confirm the effectiveness of H. pylori eradication on NVP 
symptom reduction and adverse birth outcome is needed from a randomised controlled 
trial.
In conclusion, our study suggests that H. pylori is an independent risk factor for vomiting 
in pregnancy, leading to low maternal weight gain and increased risk of SGA. Since 
treatment options for severe NVP are currently lacking, the effect of H. pylori eradication 
therapy on NVP severity should be target of future studies.
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ABSTRACT
Background and aim: Preeclampsia (PE), small for gestational age (SGA), and spontaneous 
preterm birth (PTB) each may be complications of impaired placental function in 
pregnancy. Although their exact pathogenesis is still unknown, certain infectious agents 
seem to play a role. Helicobacter pylori (H. pylori) colonization has been associated with 
increased risk for PE. Our aim was to assess the association between H. pylori colonization 
and PE, SGA, and PTB. 
Methods: We measured IgG anti-H. pylori and CagA-antibodies in serum of pregnant 
women (median 20.5 weeks, range 16.5-29.4) who participated in a population-based 
prospective cohort study. Delivery and medical records were assessed. Information on 
demographics, education, and maternal risk factors was collected by questionnaire. We 
used multivariate logistic regression analyses to assess associations between H. pylori 
colonization and PE, SGA, and PTB. 
Results: In total, 6348 pregnant women were assessed. H. pylori-positivity was found 
in 2915 (46%) women, of whom 1023 (35%) also were CagA-positive. Pregnancy was 
complicated by PE, SGA or PTB in 927 (15%) women. H. pylori colonization was associated 
with PE (aOR 1.51; 95%CI 1.03-2.25). Differentiation according to CagA-status revealed 
the same risk. H. pylori was positively related with SGA, mainly explained by CagA-
positive strains (aOR 1.34; 1.04-1.71). No association was observed between H. pylori and 
PTB. 
Conclusions: Our data suggest that H. pylori colonization may be a risk factor for PE and 
SGA. If these associations are confirmed by future studies and shown to be causal, H. 
pylori eradication may reduce related perinatal morbidity and mortality.
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INTRODUCTION
The involvement of systemic inflammatory responses in pregnancies complicated by pre-
eclampsia (PE), small for gestational age (SGA), and spontaneous preterm birth (PTB) 
has led to the hypothesis that maternal infections may play a role in the etiology and 
pathogenesis of these pregnancy complications (1, 2). Although the exact causes of these 
complications are still unknown, one hypothesis for their origin is that they each are 
related to suboptimal placentation in early pregnancy (3-5). In this respect, colonization 
with Helicobacter pylori (H. pylori) may be of interest as it might be involved in the 
pathogenesis of impaired remodeling of the spiral arteries (6). 
H. pylori is a Gram-negative bacterium that colonizes the stomach of about half of the 
world’s population. After its re-discovery in 1982, extensive research demonstrated that 
H. pylori is an important risk factor for peptic ulcer disease, gastric adenocarcinoma, and 
mucosa associated lymphoid tissue (MALT)-lymphoma (7). An important host-interaction 
factor of H. pylori is the cytotoxin-associated gene A (cagA). The CagA protein is directly 
injected by H. pylori into the cytoplasm of gastric epithelial cells and subsequently affects 
cell morphology, proliferation and apoptosis (8). Colonization with CagA-positive strains 
is associated with higher levels of inflammatory cells and mediators compared to CagA-
negative strains, both locally and systemically (9).
As such, recent studies have focused on extra-gastric manifestations of H. pylori 
colonization, including cardiovascular, hematologic, respiratory, and pregnancy-related 
diseases, including PE, SGA, and PTB (10). However, only few studies, each with a small 
number of cases, assessed the associations between H. pylori colonization and PE (11-
14), and SGA (12, 15). These studies yielded conflicting results. Therefore, we examined 
the association between H. pylori colonization and each of these pregnancy-related 
complications in pregnant women participating in a large population-based prospective 
cohort study. As colonization with a CagA-positive strain is associated with higher levels 
of inflammatory mediators (16), we also assessed the effects of CagA-positive H. pylori 
strains on the risk of having these illnesses.
MATERIALS AND METHODS
Design and setting
This study was embedded in The Generation R Study, a population-based prospective 
cohort study among women and their children in Rotterdam, The Netherlands. In 
total 8879 pregnant women were included between April 2002 and January 2006. 
Assessments consisted of physical examinations, fetal ultrasounds, biological samples, 
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and questionnaires (17, 18). Approval was obtained from the Medical Ethics Committee 
of the Erasmus Medical Center. All participants provided written informed consent. H. 
pylori status could be measured in 6837 women. For the present study, women with 
maternal comorbidity known to be associated with an increased risk for the occurrence 
of these three illnesses (i.e. chronic hypertension, heart disease, diabetes, high 
cholesterol, thyroid disease and systemic lupus erythematosus) were excluded (n=179). 
Twin pregnancies, and women without data on PE, SGA, and PTB were also excluded. 
This left a study population of 6348 pregnant women with available information on 
both H. pylori status and pregnancy complications (Figure 1). 
Figure 1. Study design 
 
 
Prenatally included mothers 
N = 8879 
Exclusion of twin 
pregnancies (n=75) and loss 
to follow-up (n=1) 
 
Mothers with a live born singleton pregnancy 
N = 6761 
No serum taken at mid 
pregnancy (n=1694) or multiple 
participations (n=348) 
Known H. pylori status 
N = 6837 
 
Preeclampsia 
N = 129 
  
Spontaneous pre-term birth 
N = 219 
Total included in study 
N = 6348 
 
Population for analysis: 
PE    n = 5500 
SGA  n = 6059 
PTB  n = 5640 
No data on placental syndrome 
(n=234) 
Pre-existing high blood 
pressure or superimposed 
preeclampsia (n=107) 
Comorbidity for placental 
syndrome (n=72)  
Small for gestational age 
N = 638 
Figure 1. Study design
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H. pylori colonization during pregnancy
Mid-pregnancy serum samples (median 20.5 weeks, range 16.5-29.4) were examined 
for IgG antibodies against H. pylori and the cytotoxin-associated gene A (CagA) protein 
using two separate enzyme-linked immunosorbent assays (ELISA), as described (19, 20). 
All samples were measured at least in duplicate. For each sample, the optical density 
ratio (ODR) was calculated by dividing the optical density (OD) by the mean OD of the 
positive controls. H. pylori positivity was defined as either an ODR≥1 or CagA positivity. 
The cut-off for CagA positivity was an ODR value ≥0.35. Details regarding H. pylori 
colonization in this cohort of pregnant women have been described (21). Both ELISAs 
were validated locally. 
Pregnancy complications: PE, SGA, and PTB
Information on the pregnancy complications PE, SGA and PTB was obtained from medical 
records. For women who had suspected PE, the records were cross-checked with the 
original hospital charts (22). PE was defined as the development of systolic blood pressure 
≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg after 20 weeks of gestation in 
previously normotensive women, with concurrent proteinuria (≥0.3 g in a 24-hour urine 
specimen or ≥2+ (1 g/L] from a voided specimen, or ≥1+ [0.3 g/L] from a catheterized 
specimen) (23). Pregnancies complicated by hemolysis, elevated liver enzymes, and 
low platelet (HELLP) syndrome (n=22) were defined as cases of preeclampsia. PTB was 
defined as spontaneous onset of birth <37 weeks of gestation. We defined SGA as birth 
weight under the 10th percentile based on reference curves from our own cohort (24). 
Birth weight was adjusted for gestational age and transformed resulting in a normal 
distribution, which allowed use of means and standard deviations (SD) (25).
Covariates
Data on maternal age, ethnicity, educational level, parity, smoking during pregnancy, and 
maternal comorbidity (chronic hypertension, heart disease, diabetes, high cholesterol, 
thyroid disease and systemic lupus erythematosus) were obtained from questionnaires 
repeatedly applied during pregnancy. Height and weight were measured at enrolment 
and body mass index (BMI, kg/m2) was calculated. In Rotterdam, the largest ethnic 
groups are of Dutch, Surinamese, Turkish, Moroccan, Dutch-Antilles, and Cape Verdean 
descent. Women with another ethnic background were categorized into ‘other Western’ 
(European, North American, Oceanean) or ‘other non-Western’ (African, Asian, South- 
and Central American). The highest educational level of the mother was defined as 
completion of university or higher vocational training. Mothers were categorized as 
having a middle/low level of education if they had completed intermediate vocational 
training, or had completed education below that level. 
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Statistical analysis
Firstly, with respect to missing data on BMI (0.6%), ethnicity (6.5%), educational 
level (8.1%), parity (0.8%) and smoking (11.9%), values were imputed using multiple 
imputation (26). In the present study, five draws for each missing value were performed 
providing five substituted data points, which in turn created five completed data 
sets. Analyses were performed separately on each completed dataset and thereafter 
combined into one global result (26). Supplementary table 1 provides the percentages 
of missing values per covariate. Secondly, the frequency distributions between risk 
factors for pregnancy complications and H. pylori colonization were examined using the 
Independent Students’ t-test (normally distributed continuous data) and the Chi-square 
test (categorical data). Then, univariate and multivariate logistic regression analyses 
were applied to assess the associations between H. pylori colonization and each separate 
pregnancy outcome (i.e. PE, PTB, and SGA). A number of cases was diagnosed with more 
than one of these pregnancy complications. The inclusion of potential confounders was 
based on earlier literature and/or if they changed the effect estimates with ≥10%. We 
used three regression models to explore the effect of potential confounders on the 
association between H. pylori and PE, PTB, and SGA. In model 1, we adjusted for maternal 
age, ethnicity and parity. Model 2 was additionally adjusted for body mass index and 
smoking during pregnancy. The third model was also adjusted for maternal education 
level as a proxy for socio-economic status. Lastly, to examine effect modification we 
evaluated statistical interaction by multiplying the H. pylori colonization status with 
the covariates maternal educational level, parity, smoking, body mass index, and fetal 
gender. The latter may be involved with sex specific associations regarding placentation 
(27). If the p-value for interaction was <0.05, a stratified analysis according to the specific 
covariate was performed. All measures of associations are presented as Odds Ratios (OR) 
with their 95% Confidence Intervals (CI). Statistical analyses were performed using IBM 
SPSS Statistics 21.0 for Windows (SPSS IBM, Armonk, New York, USA).
RESULTS
Population characteristics 
In total, 6348 women were included in the study. Their baseline characteristics are shown 
in Table 1. Mean age at enrolment was 29.7 years (SD 5.3), and 51.0% were of non-Dutch 
ethnic background. Overall, the H. pylori colonization rate was 45.9%, of whom 35.1% 
carried CagA-positive strains. Nine-hundred and twenty-seven (14.6%) developed either 
PE, SGA or PTB. Compared to women without one of the indicator conditions, women 
with a complicated pregnancy were younger, had attained a lower level of education, 
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were more often of non-Dutch ethnicity, and were more often pregnant with their 
first child. (Table 1, p<0.001 for univariate comparisons; see supplementary table 1 for 
observed and imputed data). In total, 129 (2.0%) women were diagnosed with PE, 638 
(10.1%) with SGA, and 219 (3.4%) with PTB (Figure 1). Fifty-eight women (0.9%) had 
more than one of these complications, and contribute to both complication groups. 
Table 1 Characteristics of mothers (n = 6348)
Imputed
Complicated pregnancy1 p-value
No (n=5421) Yes (n=927)
Age, years (SD) 29.7 (5.3) 29.9 (5.2) 28.9 (5.6) <0.001
Body mass index, kg/m2 (range) 23.7 (15.2-51.2) 23.8 (15.2-51.2) 23.3 (15.8-50.2) <0.001
Ethnicity (%) <0.001
Dutch 3031 (47.7) 2656 (49.0) 375 (40.1)
Turkish 654 (10.3) 546 (10.1) 88 (9.5)
Surinamese 569 (9.0) 433 (8.0) 143 (15.4)
Moroccan 458 (7.2) 421 (7.8) 45 (4.9)
Cape Verdean 302 (4.8) 235 (4.3) 68 (7.3)
Dutch Antillean 246 (3.9) 190 (3.5) 59 (6.4)
Other Western 689 (10.9) 605 (11.2) 86 (9.3)
Other non-Western 399 (6.3) 335 (6.2) 63 (6.8)
Education level (%) <0.001
Low/Middle 3807 (60.0) 3178 (58.6) 628 (67.7)
High 2541 (40.0) 2243 (41.4) 299 (32.3)
Parity (%) <0.001
Nulli parity 3503 (55.2) 2865 (52.9) 638 (68.8)
Multi parity 2845 (44.8) 2556 (47.1) 289 (31.2)
Smoking during pregnancy (%) <0.001
No 5136 (80.9) 4462 (82.3) 675 (72.8)
Yes 1211 (19.1) 959 (17.7) 252 (27.2)
Children’s gender 0.65
Female 3209 (50.5) 2733 (50.4) 475 (51.2)
Male 3139 (49.5) 2687 (49.6) 452 (48.8)
H. pylori and CagA
H. pylori-negative 3433 (54.1) 2979 (55.0) 454 (49.0) <0.001
H. pylori-positive 2915 (45.9) 2442 (45.0) 473 (51.0)
CagA-negative 1892 (64.9) 1604 (65.7) 288 (60.9) <0.001
CagA-positive 1023 (35.1) 838 (34.3) 185 (39.1)
Values are means (SD), medians (range) or absolute numbers (percentages). 
1Pregnancy complicated by PE, SGA, or PTB
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 5
124
H. pylori colonization and PE, SGA, and PTB
Women with one of these pregnancy complications were more often H. pylori positive 
(51.0%) than women with an uncomplicated pregnancy (45.0%) (p<0.001). Among those 
women with H. pylori, the CagA-positivity rate was higher in those with a complicated 
pregnancy (39.1% vs. 34.3%, p<0.001) (Table 1).
Supplementary table 2 shows the prevalence of PE, SGA, and PTB according to H. pylori 
and CagA-status. Univariate logistic regression analyses showed an increased risk of PE 
and SGA in H. pylori-positive mothers (OR 1.49; 95% CI 1.05-2.12 and OR 1.32; 1.12-
1.56, respectively) (Supplementary table 3). Parallel results for H. pylori and SGA were 
observed when using an ethnic-specific 10th percentile definition for SGA. Differentiation 
into CagA-negative and CagA-positive strains revealed a positive association between 
Hp+CagA+ mothers and SGA (OR 1.59; 95% CI 1.28-1.97). No association was observed 
between H. pylori and PTB. Multivariate analyses revealed an association with PE (final 
OR 1.51; 95%CI 1.03-2.25), but not with SGA or PTB (Table 2). Differentiation into CagA-
negative or CagA-positive strains showed an association between CagA-positive strains 
and SGA (final OR 1.34; 95% CI 1.04-1.71). Increased risk of PE was observed in mothers 
with a CagA-negative strain (Model 2, OR 1.58; 95% CI 1.03-2.40). The association 
attenuated slightly after additional adjustment for educational level. We did not observe 
an interaction between H. pylori status and fetal gender, maternal educational level, 
parity, smoking, and body mass index. 
When excluding cases with more than one pregnancy complication from each group, 
multivariate analyses showed only CagA-positivity independently associated with SGA 
(OR 1.33; 95% CI 1.03-1.72) (Supplementary table 4). 
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DISCUSSION
This large population-based prospective cohort study showed that H. pylori colonization 
is associated with an increased risk on PE and that carriage of a CagA+ H. pylori strain 
is a risk factor for SGA. These findings may be helpful for a better understanding 
of the pathogenesis of these pregnancy complications and support the link with 
chronic inflammatory conditions. The potential association between H. pylori and 
these gestational disorders has been studied before. Previous studies however were 
considerably smaller, thereby limiting power. Furthermore, not all studies included 
separate analyses of CagA data. 
The observed association between H. pylori and PE is consistent with prior epidemiological 
studies (11-14). In a small Italian study of 47 PE cases and 47 controls, Ponzetto et al. 
found a higher H. pylori seropositivity in mothers with PE (51.1%) compared to women 
with an uncomplicated pregnancy (31.9%) (OR 2.67; 95% CI 1.08-6.57) (11). In contrast to 
our observation, they observed greater differences between those having CagA-positive 
and CagA-negative strains (80.9% vs. 14.9%). Another study from the same group 
investigated the association of several H. pylori virulence factors with SGA (SGA, n = 
13), PE (n = 17), and both (PE and SGA, n = 32) compared with controls (n = 49) (12). In 
PE women with or without SGA, the H. pylori-positivity rate was higher while there was 
no difference in prevalence between SGA-only and controls. They observed that CagA-
strains were more prevalent in PE pregnant women compared to controls, while there 
was no difference between SGA cases and controls. An Australian study determined the 
association between H. pylori colonization and SGA in 448 pregnant women (15), of 
whom 34 (7.5%) had SGA. Multivariate analysis revealed that H. pylori seropositivity 
was associated with SGA (OR 2.59; 95% CI 1.12-5.95; p = 0.025). A similar trend was 
observed in our study, but only for those with CagA-positive strains. CagA status data 
were not available in the prior study. We found no association between H. pylori and 
PTB, regardless of CagA-status. One other study, assessing this relation in 416 pregnant 
women, did not observe a significant association between H. pylori colonization and PTB 
(28). 
The overall H. pylori prevalence in this cohort may be higher than for other populations 
in a Western country. This difference is mainly explained by the high colonization rates 
in women with a non-European ethnic background. Studies evaluating the H. pylori 
colonization in multi-ethnic populations all showed higher prevalence among immigrant 
groups, compared to the original population (29, 30). Although PE, SGA, and PTB are 
different clinical entities, all three may be caused by suboptimal deep placentation in 
early pregnancy (5) (31, 32) (33, 34). Large numbers of non-transformed spiral arteries 
are frequently observed in PE patients with or without SGA (5), in patients with SGA 
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without gestational hypertension (31, 32), and in patients with preterm labor with or 
without preterm pre-labor rupture of membranes (PROM) (33, 34). Impaired remodeling 
of the spiral arteries may lead to insufficient uteroplacental arterial flow and episodes 
of irregular placental perfusion (3). Such impaired remodeling might be due to failure 
of appropriate uterine preconditioning (35), and excessive or atypical maternal immune 
responses to trophoblasts (36). Franceschi et al. have shown that anti-CagA antibodies 
were able to recognize β-actin on the surface of trophoblast cells in a dose-dependent 
binding assay in vitro (6). This binding resulted in impaired cytotrophoblast invasiveness, 
which is characteristic for the development of the placental syndrome; however, we 
observed no association between CagA-positive strains and PE. The association between 
H. pylori and PE disappeared when excluding women with more than one of the studied 
pregnancy complications (i.e. with both PE and SGA), which suggests that the significant 
result was based on those cases. PTB is a syndrome caused by multiple pathologic processes 
with placental involvement as one of the possibilities (37). In our study, although all 
spontaneous in onset, we were not able to distinguish between different causes of PTB.
Our data add further evidence to the associations between H. pylori and PE and 
SGA. Although association does not imply causation, epidemiological findings should 
stimulate biological studies. If the association between H. pylori and these illnesses is 
causal, eradication of H. pylori may be part of an effective intervention for reducing 
related perinatal morbidity and mortality. As the overall H. pylori prevalence in Western 
countries is declining, screening for H. pylori may be most efficient in pregnant women 
with increased H. pylori prevalence, like a low socioeconomic status, or a non-Western 
ethnic background (21). 
The strengths of this study include the large number of subjects participating in a 
population-based cohort, with detailed prospectively collected data on socioeconomic, 
and sociodemographic characteristics, together with other potential confounding factors. 
However, it cannot be excluded that the findings may partly result from unmeasured 
confounding. Our study may be limited by the fact that we measured IgG antibodies 
against H. pylori and CagA, indicating present or recent colonization. However, it is not 
clear whether any effect of H. pylori is dependent on active colonization or the presence 
of circulating anti-H. pylori and CagA antibodies. The use of one general definition for 
SGA in all ethnic groups may limit our results, as a prior study has shown differences 
in birth weights between ethnic populations of this cohort (38). However, additional 
analyses, using the ethnic-specific 10th percentile revealed parallel results for H. pylori 
and SGA. Since validated ethnic-specific growth curves are lacking, we continued to use 
the population-specific 10th percentile. Although this study is population-based, selective 
participation occurred since participating women were generally higher educated, 
and were more often from Dutch ethnic background (17). Missing data for several 
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characteristics and potential confounders may have biased the outcome. Therefore, we 
performed the final analyses after a multiple imputation procedure. This is considered 
useful to deal with missing data, since it requires the fewest assumptions and reduces 
potential bias when missing data are not random (26). 
In summary, H. pylori colonization is positively associated with PE. In addition, we 
confirmed the important role of CagA-positive strains in SGA, as the association was 
determined by colonization with these strains. 
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Table S1. Characteristics of mothers – observed and imputed (n = 6348)
Observed Imputed
Age, years (SD) 29.7 (5.3) 29.7 (5.3)
Body mass index, kg/m2 (range) 23.7 (15.2-51.2) 23.7 (15.2-51.2)
Data missing 41 (0.6)
Ethnicity (%)
Dutch 2947 (49.6) 3031 (47.7)
Turkish 558 (9.4) 654 (10.3)
Surinamese 531 (8.9) 569 (9.0)
Moroccan 389 (6.6) 458 (7.2)
Cape Verdean 260 (4.4) 302 (4.8)
Dutch Antillean 212 (3.6) 246 (3.9)
Other Western 669 (11.3) 689 (10.9)
Other non-Western 370 (6.2) 399 (6.3)
Data Missing 412 (6.5)
Education level (%)
Low/Middle 3392 (58.1) 3807 (60.0)
High 2444 (41.9) 2541 (40.0)
Data missing 512 (8.1)
Parity (%)
Nulli parity 3488 (55.4) 3503 (55.2)
Multi parity 2808 (44.6) 2845 (44.8)
Data missing 52 (0.8)
Smoking during pregnancy (%)
No 4525 (80.9) 5136 (80.9)
Yes 1066 (19.1) 1211 (19.1)
Data missing 757 (11.9)
Children’s gender
Female 3208 (50.5) 3209 (50.5)
Male 3139 (49.5) 3139 (49.5)
Data missing 1 (0.0)
H. pylori and CagA
H. pylori-negative 3433 (54.1) 3433 (54.1)
H. pylori-positive 2915 (45.9) 2915 (45.9)
CagA-negative 1892 (64.9) 1892 (64.9)
CagA-positive 1023 (35.1) 1023 (35.1)
Values are means (SD), medians (range) or absolute numbers (percentages). 
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Table S2. Prevalences of PE, SGA, and PTB according to H. pylori and corresponding CagA status 
p = 0.08 PE (n= 5550)
No
(n=5421)
Yes
(n=129)
Hp negative (%)
(n=3037)
98.1 (2979) 1.9 (58)
Hp positive
CagA negative
(n=1650)
97.2 (1604) 2.8 (46)
CagA positive
(n=863)
97.1 (838) 2.9 (25)
p<0.001 SGA (n= 6059)
No
(n=5421)
Yes
(n=638)
Hp negative (%)
(n=3285)
90.7 (2979) 9.3 (306)
Hp positive
CagA negative
(n=1799)
89.2 (1604) 10.8 (195)
CagA positive
(n=975)
85.9 (838) 14.1 (137)
P=0.62 PTB (n= 5640)
No
(n=5421)
Yes
(n=219)
Hp negative (%)
(n=3092) 96.3 (2979) 3.7 (113)
Hp positive
CagA negative
(n=1674)
95.8 (1604) 4.2 (70)
CagA positive
(n=874) 95.9 (838) 4.1 (36)
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Table S3. Univariate analyses of H. pylori and CagA status with PE, SGA, and PTB. 
Preeclampsia 
(n = 5550)
Small for gestational age
(n = 6059)
Spontaneous preterm birth 
(n = 5640)
Hp- Reference
n = 58 / 3037
Reference
n = 306 / 3285
Reference
n = 113 / 3092
Hp+ 1.49
(1.05, 2.12)*
n = 71 / 2513
1.32
(1.12, 1.56)**
n = 332 / 2774
1.14
(0.87, 1.50)
n = 106 / 2548
Hp+CagA- 1.47
(1.00, 2.18)
n = 46 / 1650
1.18
(0.98, 1.43)
n = 195 / 1799
1.15
(0.85, 1.56)
n = 70 / 1674
Hp+CagA+ 1.53
(0.95, 2.46)
n = 25 / 863
1.59
(1.28, 1.97)**
n = 137 / 975
1.13
(0.77, 1.66)
n = 36 / 874
Values are odds ratios for PE, SGA, and PTB (95% confidence interval) from logistic regression 
models. n = number of cases per total group. 
*p<0.05 **p<0.01
Table S4. Associations of H. pylori and CagA status with PE, SGA, and PTB
PE SGA PTB
Odds Ratio 
(95% CI) 
Odds Ratio 
(95% CI) 
Odds Ratio 
(95% CI)
n = 5508 n = 6005 n = 5619
Hp- Reference
n = 42 / 3021
Reference
n = 284 / 3263
Reference
n = 105 / 3084
Hp+ 
1.35
(0.84, 2.17)
n = 45 / 2487
1.14
(0.93, 1.38)
n = 300 / 2742
1.10
(0.79, 1.53)
n = 93 / 2535
Hp+CagA-
1.33
(0.80, 2.23)
n = 29 / 1633
1.05
(0.84, 1.30)
n = 175 / 1779
1.13
(0.79, 1.60)
n = 62 / 1666
Hp+CagA+
1.38
(0.73, 2.63)
n = 16 / 854
1.33
(1.03, 1.72)*
n = 125 / 963
1.03
(0.65, 1.63)
n = 31 / 869
Values are odds ratios for pre-eclampsia (PE), small for gestational age (SGA), or preterm birth (PTB) 
(95% confidence interval) from logistic regression models. 
Cases diagnosed with more than one pregnancy outcome were excluded. 
n = number of cases per total group. 
Adjusted for maternal age, parity, ethnicity, body mass index, smoking, and educational level. 
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ABSTRACT
Background: Helicobacter pylori (H. pylori) prevalence in Western countries has been 
declining simultaneously with increases in childhood asthma and allergic diseases; prior 
studies have linked these phenomena. 
Aims: We aimed to examine the association between H. pylori colonization in children 
and risk of asthma and related conditions at school age. We secondly examined additional 
effects of maternal H. pylori status by pairing with children’s status. 
Methods: This study was embedded in a multi-ethnic population-based cohort in 
Rotterdam, The Netherlands. We measured anti-H. pylori and anti-CagA antibodies in 
serum of children obtained at age 6 years, and of their mothers obtained during mid-
pregnancy. Asthma or related conditions were reported for children at age 6 years. We 
used multivariate logistic regression analyses among 3,797 subjects. 
Results: In children, the H. pylori positivity rate was 8.7%, and 29.2% of these were 
CagA-positive. A child’s colonization with a CagA-negative-H. pylori strain was associated 
with an increased risk of asthma (Odds ratio 2.11; 95% CI 1.23-3.60, but this differed for 
European (3.64; 1.97-6.73) and non-European (0.52; 0.14-1.89) children. When taking 
into account maternal H. pylori status, only H. pylori positive children with an H. pylori 
negative mother had increased risk of asthma (2.42; 1.11-5.27), accounting for 3.4% of 
the asthma risk. 
Conclusions: Colonization of a European child with a CagA-negative-H. pylori strain 
at age 6 was associated with an increased prevalence of asthma, but there was no 
association for non-European children. The underlying mechanisms for the observed risk 
differences require further research. 
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INTRODUCTION
Reduced exposure to exogenous microbes and their products have been suggested to 
be involved in the pathogenesis of asthma and related conditions, such as eczema and 
allergies (1). An alternate hypothesis is that the epidemic rise in asthma and related 
conditions may be partially explained by altered composition of our indigenous 
microbiota due to changes in human ecology (2). The gastric bacterium Helicobacter 
pylori (H. pylori) has been used as a proxy for this modern phenomenon (2). Studies 
in mice have demonstrated that experimental infection with H. pylori prevents allergic 
asthma through the induction of regulatory T cells (Tregs) (3). Direct contact between H. 
pylori and dendritic cells (DCs) was found to be essential for the induction of tolerogenic 
DCs. These DCs produce IL-18, important for the conversion of naïve T-cells into Tregs (3). 
Eventually, these Tregs may suppress asthmatic immune responses in the airways (4). This 
interaction between H. pylori and the immune system may be affected by its genotype: 
expression of the cagA gene (cytotoxin-associated gene A) has been associated with a 
more marked cellular and humoral immune response, with persists throughout human 
life (5). 
During recent decades the prevalence of H. pylori colonization has dropped dramatically 
in Western countries (6). Currently, fewer than 10% of children born in Western 
countries are H. pylori positive (7) (8). Several epidemiologic studies examined the 
relation between H. pylori colonization and asthma and asthma-related conditions in 
childhood (9-14). However, results from these studies appear contradictory. This may 
have been due to differences in study design (9, 10, 14), low number of participants 
(9, 10, 13), differing methods and timing of H. pylori status identification (11, 14), and 
insufficient accounting for potential confounders (12, 14). It also is unclear whether 
maternal H. pylori colonization during pregnancy affects the child’s risk for asthma and 
related conditions. Maternal H. pylori colonization during pregnancy may be a risk factor 
for foetal growth retardation (15, 16), which subsequently might lead to increased risk 
for asthma (17). Children of an H. pylori-positive mother may be more likely to acquire 
colonization at younger age, but it is not known whether this also may affect risk of 
asthma and related conditions. 
Therefore, we first examined the associations of asthma and related conditions with H. 
pylori colonization in children, and secondly we focused on the effect of paired maternal 
and child’s H. pylori status on these outcomes. These analyses were facilitated by a large 
multi-ethnic population-based prospective cohort study in Rotterdam, The Netherlands. 
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METHODS
Design and setting
This study was embedded in the Generation R Study, a population-based prospective 
cohort study of pregnant women and their children in Rotterdam, The Netherlands 
(18). All children were born between April 2002 and January 2006. The Medical Ethics 
Committee of the Erasmus University Medical Centre approved the study protocol and 
parents gave written informed consent for themselves and their children. For the current 
study, data from 3,797 children with information on H. pylori colonization and any 
asthma or related conditions were available (Figure 1). Figure 1 Study design and number of participants  
Missing data on asthma or 
related outcomes at age 6 
years (n = 670) 
3,797 with data on child’s H. pylori 
status and asthma or related 
outcomes at age 6 years 
 
 
Wheezing n = 3,135 
Asthma  n = 3,062 
Eczema  n = 3,082 
Inhalant allergy n = 3,584 
 
8,305 children participated in the 
follow-up at the age of 6 years 
  
2,910 with known maternal 
H. pylori status and asthma 
or related outcomes at age 
6 years 
 
Wheezing n = 2,410 
Asthma  n = 2,353 
Eczema  n = 2,373 
Inhalant allergy n = 2,749 
 
6,690 visited research centre at the 
age of 6 years   
 
Sera obtained in 4,593 children 
(69%)   
 Not available for analysis due to logistic or technical reasons 
(n=85) or duplicate samples of 
twin (n=41) H. pylori status identified in 4,467 
children   
 
Figure 1. Study design and number of participants
H. pylori colonization in children and their mothers
H. pylori colonization of children was defined by measuring IgG antibody levels in serum 
using an enzyme-linked immunosorbent assay (ELISA) (19). Sera samples were obtained 
at age 6 years. A separate ELISA was performed to determine serum IgG antibodies 
against a specific recombinant truncated cytotoxin-associated gene A (CagA) protein 
(20). Both ELISAs were validated locally, by adapting the ELISA properties based on 
positive and negative controls. H. pylori and CagA colonization in mothers was measured 
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from serum samples obtained during mid-pregnancy (gestational age 18-25 weeks) (21). 
Similar ELISAs were used for mothers and children, with specific properties known from 
use in previous birth cohorts (19, 22). 
Asthma and related conditions at school age
Wheezing in the prior 12 months (no, yes), physician-diagnosed asthma ever (no, yes) and 
physician-diagnosed eczema in the last 12 months (no, yes) were assessed using questions 
adapted from the International Study on Asthma and Allergy in Childhood (ISAAC) core 
questionnaires at age 6 years (23). Inhalant allergy was assessed by questionnaire at age 
6 years; a positive history was defined as inhalant allergy to pollens, mites, or pets in the 
prior 12 months (no, yes), diagnosed by a physician. 
Covariates
Information on birth weight, gestational age, and sex of the children were obtained 
from midwife and hospital registries at birth. Postnatal questionnaires at ages of 6 and 
12 months supplied information on breastfeeding, and at age of 6 years about lower 
respiratory tract infections during the prior 12 months. Use of antibiotics in the prior 12 
months was assessed by questionnaires yearly at the ages of 1 to 6 years. Information 
on maternal age, anthropometrics, ethnicity, socio-economic status, history of asthma 
or atopy, parity, and pet keeping were obtained by questionnaire, completed by the 
mother at enrolment. Socio-economic status was assessed using the educational level 
of mother on the basis of her highest level of completed education. Smoking during 
pregnancy was reported at enrolment. Maternal psychological distress in the second 
trimester of pregnancy was defined using a global severity index (GSI) (24). 
 
Statistical analyses
The prevalence of asthma and related conditions in relation to child’s H. pylori and CagA 
status were examined using Chi-square tests. We used multivariate logistic regression 
analysis to examine the association of child’s H. pylori and CagA status with asthma 
and related conditions, taking potential confounders into account. Missing data in the 
covariates were imputed with multiple imputations using chained equations (25). 
If available, a child’s H. pylori status was paired with maternal H. pylori status, resulting 
in four different groups: mother and child both H. pylori negative, mother H. pylori 
negative and child positive, mother H. pylori positive and child negative, both mother 
and child H. pylori positive. We used multivariate logistic regression analysis to examine 
the association of combined H, pylori status of mother and child, with asthma and related 
conditions. Potential confounders were taken into account. Due to the small numbers of 
cases we were not able to differentiate with respect to CagA-status. We calculated the 
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population attributable fraction of H. pylori colonization for asthma, using adjusted ORs 
estimated from logistic regression models (26).
All measures of associations are presented as Odds Ratios (OR) with their 95% Confidence 
Intervals (CI). Statistical analyses were performed using SPSS version 23.0 for Windows 
(SPSS Inc., Chicago, IL, USA). An extensive description of the methods is provided in the 
Supplementary material.
RESULTS
Population characteristics. Characteristics of included children and their mothers are 
provided in Table 1 and Table S1 shows the comparison of the included (n = 3,797) with 
the excluded (n = 4,508) subjects. At a mean age of 6.1 years (SD 0.5), 8.7% of the children 
were H. pylori-positive. H. pylori status was determined in their mothers at a mean age 
of 31.1 years (SD 4.9), and 38.0% tested positive. The proportion of CagA-positive strains 
among H. pylori-positive mothers and children was 33.0% and 29.2%, respectively. As 
expected, the colonization rate of children with an H. pylori-positive mother was higher 
than in children with an H. pylori-negative mother (14.3% vs. 5.4%, p<0.05). 
Table 1 Characteristics of the study population 
Population for analysis 
(n = 3,797)
Observed Imputed
Sex (%)
   Female 48.1 (1,828) 48.1 (1,828)
     Male 51.9 (1,969) 51.9 (1,969)
Gestational age at birth (weeks) 40.1 (35.7-42.3) 40.1 (35.7-42.3)
     Missing 0.8 (29) -
Birth weight (grams) 3,446 (550) 3,445 (551)
     Missing 0.1 (4) -
Ethnicity1 (%) 
     European 65.8 (2,492) 65.6 (2,492)
     Non-European 34.2 (1,294) 34.4 (1,305)
     Missing 0.3 (11) -
Breastfeeding (%)
     Never 9.0 (230) 12.9 (491)
     Ever 91.0 (2,331) 87.1 (3,306)
     Missing 32.6 (1,236) -
Pet keeping (%) 
     No 66.3 (1,977) 64.8 (2,460)
     Yes 33.7 (1,007) 35.2 (1,337)
     Missing 21.4 (813) -
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
H. pylori in children with asthmatic conditions
141
6
Lower respiratory tract infections at 6 years (%)
     No 95.5 (3,458) 95.2 (3,616)
     Yes 4.5 (162) 4.8 (181)
     Missing 4.7 (177) -
Antibiotic use (%)
     Never 17.6 (508) 17.3 (657)
     For 1-2 time periods 55.5 (1,599) 36.3 (1,378)
     For 3 or more time periods 26.8 (772) 46.4 (1,762)
     Missing 24.2 (918)
Maternal education level (%)
     Primary, or secondary 48.8 (1,723) 50.6 (1,922)
     Higher 51.2 (1,811) 49.4 (1,875)
     Missing 6.9 (263) -
Maternal age2 (years) 31.1 (4.9) 31.1 (4.9)
Maternal body mass index2 (kg/m2) 23.7 (18.9-35.5) 23.8 (18.7-35.2)
     Missing 10.5 (398) -
Maternal history of asthma or atopy (%)
     No 61.7 (1,904) 61.8 (2,346)
     Yes 38.3 (1,183) 38.2 (1,451)
     Missing 18.7 (710) -
Parity2 (%) 
     0 56.2 (2,057) 55.3 (2,100)
     ≥1 43.8 (1,601) 44.7 (1,697)
     Missing 3.7 (139) -
Smoking during pregnancy (%) 
     No 85.4 (2,859) 85.1 (3,235)
     Yes 14.6 (490) 14.9 (562)
     Missing 11.8 (448) -
Psychological distress during pregnancy (%)
     No 92.4 (2,646) 91.0 (3,455)
     Yes 7.6 (218) 9.0 (342)
     Missing 24.6 (933) -
Children’s H. pylori colonization rate (%)
     Hp-  91.3 (3,465) -
     Hp+CagA- 6.2 (235) 
     Hp+CagA+ 2.6 (97)
Maternal H. pylori colonization rate3 (%)
     Hp-  62.0 (1,804) -
     Hp+CagA- 25.5 (741) 
     Hp+CagA+ 12.5 (365)  
     Missing 23.4 (887)
Paired maternal and child’s H. pylori status (%)
     mHp-cHp- 58.6 (1,706) -
     mHp+cHp- 32.6 (948)
     mHp-cHp+ 3.4 (98)
     mHp+cHp+ 5.4 (158)
     Missing 23.4 (887)
Values are means (SD), medians (2.5-97.5th percentile) or percentages (absolute numbers). 
1Ethnic background is based on data of mother
2Data measured at moment of enrolment of pregnant mother
3Data on H. pylori colonization is not imputed
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Child’s H. pylori colonization and asthma and related conditions
We observed a higher prevalence of recent asthma, but not of wheezing, eczema, or 
inhalant allergy, in H. pylori-positive compared with H. pylori-negative children (asthma 
prevalence 9.5% vs. 5.2% respectively, p=0.045) (Figure 2, Supplementary Table 2). 
Multivariate analyses showed an association between H. pylori and increased risk of 
asthma (OR 1.75; 95% CI 1.07-2.87) (Table 2). Compared with H. pylori-negative children, 
those colonized with a CagA-negative strain had an increased risk of asthma (OR 2.11; 
95% CI 1.23-3.60), but those colonized with a CagA-positive strains were not (OR 0.94; 
95% CI 0.32-2.79). The size of the effect estimates did not change after additional 
adjustment for maternal H. pylori status. Carriage of an Hp+CagA+ strain tended to be 
inversely related to wheezing and inhalant allergy, but effects were not significant (OR 
0.24; 95% CI 0.05-1.05 for wheezing, OR 0.26; 95%CI 0.06-1.07 for inhalant allergy). 
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Fig re 2 Prevalence of wheezing, asthma, eczema, and inhalant allergy in 6-year old children, 
according to H. pylori and corresponding CagA status of children.
The y-axis reflects the proportion of children with asthma or related outcome at age 6 ye rs. H. 
pylori status is shown on the x-axis, divided by CagA- and CagA+ strains. The reference group 
consists of H. pylori-negative children.
Values are percentages. Mean proportions are compared using Chi-square tests (ns = non-significant). 
* p<0.05
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Table 2. Associations of children’s H. pylori and corresponding CagA status with asthma and asthma-
related outcomes at age 6 years.
Wheezing Asthma Eczema Inhalant allergy
Odds Ratio 
(95% CI) 
Odds Ratio 
(95% CI)
Odds Ratio 
(95% CI)
Odds Ratio 
(95% CI)
n = 3,135 n = 3,062 n = 3,082 n = 3,584
Hp- Reference
n = 251 / 2,886
Reference
n = 175 / 2,820
Reference
n = 551 / 2,834
Reference
n = 206 / 3,282
Hp+ 0.73 
(0.43, 1.27)
n = 18 / 249
1.75
(1.07, 2.87)*
n = 23 / 242
1.04
(0.75, 1.43)
n = 59 / 248
0.69 
(0.39, 1.20)
n = 15 / 302
Hp+CagA- 0.98
(0.55, 1.75)
n = 16 / 181
2.11
(1.23, 3.60)**
n = 19 / 173
1.12
(0.77, 1.61)
n = 42 / 180
0.91
(0.50, 1.66)
n = 13 / 216 
Hp+CagA+ 0.24
(0.05, 1.05)
n = 2 / 68
0.94
(0.32, 2.79)
n = 4 / 69
0.87
(0.48, 1.55)
n = 17 / 68
0.26
(0.06, 1.07)
n = 2 / 86
Values are odds ratios for wheezing, asthma, eczema, and inhalant allergy (95% confidence interval) 
from logistic regression models. 
Models were adjusted for maternal age, ethnicity, pre-pregnancy body mass index, educational 
level, history of asthma or atopy, parity, pet keeping, smoking during pregnancy, psychological 
stress during pregnancy, and child’s birth weight, gestational age at birth, sex, breastfeeding, lower 
respiratory tract infections, and antibiotic use.
1n = number of cases (i.e. children with asthma or related conditions) per total group (i.e. according 
to H. pylori/CagA status)
*p < 0.05, **p<0.01. 
Stratification for ethnicity showed that the association of H. pylori colonization with 
asthma was only present in children of European background (OR 3.11; 95% CI 1.70-
5.72), and not in those of non-European background (OR 0.72; 95% CI 0.29-1.74), with a 
p-value for interaction of 0.009 (Table 3, Supplementary Table 4). Consistent trends were 
observed for wheezing, eczema, and inhalant allergy, however, the interaction terms 
were non-significant (Supplementary Table 4). Other tests for interactions were non-
significant (p-values >0.05). 
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Table 3. Associations of child’s H. pylori status with asthma stratified by ethnicity.
Asthma
Odds Ratio (95% CI)
Asthma
Odds Ratio (95% CI)
European n = 2,140 Non-European n = 922
Hp- Reference
n = 111 / 2,0261
Hp- Reference
n = 65 / 794
Hp+ 3.11
(1.70, 5.72)*
n = 16 / 114
Hp+ 0.72
(0.29, 1.74) 
n = 7 / 128
   Hp+CagA- 3.64
(1.97, 6.73)* 
n = 16 / 100
   Hp+CagA- 0.52
(0.14, 1.89)
n = 3 / 73
   Hp+CagA+ NA
n = 0 / 14
   Hp+CagA+ 0.98
(0.31, 3.11)
n = 4 / 55
Values are odds ratios for asthma (95% confidence interval) from logistic regression models. 
Models were adjusted for maternal age, pre-pregnancy body mass index, educational level, history 
of asthma or atopy, parity, psychological stress during pregnancy, and child’s sex, gestational age 
at birth, birth weight, breastfeeding, pet keeping, lower respiratory tract infections, and antibiotic 
use. 
Overall PInteraction ethnicity
 * H. pylori: <0.05. 
1n = number of cases (i.e. children with asthma) per total group (i.e. according to H. pylori/CagA 
status
*p < 0.01, NA = not applicable.
Paired mother-child H. pylori status and asthma and related conditions in children
In 2,910 (77%) of the children, the H. pylori status of their mother was known. We 
observed no differences in prevalence of wheezing, asthma, eczema and inhalant 
allergy of the children according to the combined H. pylori status of mother and 
child Supplemental table S5) (p-values>0.05). Multivariate analysis revealed a positive 
association with asthma in children who were H. pylori positive, but with a negative 
mother (OR 2.42; 95% CI 1.11- 5.27) (Table 4). The proportion of asthma attributable to 
H. pylori-positivity in children with an H. pylori-negative mother was 3.4% (95% CI 0.6-
4.7) Stratification for ethnicity showed that the association with asthma was only present 
in children of European background, both for H. pylori positive children with a H. pylori 
negative or positive mother (OR 3.25; 95% CI 1.41-7.54 for mHp-cHp+, and OR 4.07; 95% 
CI 1.47-11.31 for mHp+cHp+) (Supplementary Table 6). Interactions of paired H. pylori 
status with maternal asthma or atopy, and child’s sex, gestational age or weight at birth, 
or antibiotic use were not associated with asthma or related conditions (p-values for 
interaction >0.05).
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Table 4. Associations of combined maternal and children’s H. pylori status with asthma and related 
outcomes at the child’s age of 6 years.
Wheezing Asthma Eczema Inhalant allergy
Odds Ratio 
(95% CI) 
Odds Ratio 
(95% CI)
Odds Ratio 
(95% CI)
Odds Ratio 
(95% CI)
n = 2,410 n = 2,353 n = 2,373 n = 2,749
mHp-cHp- Reference
n = 122 / 1,4761
Reference
n = 85 / 1,441
Reference
n = 268 / 1,451
Reference
n = 97 / 1,626
mHp+cHp- 0.99
(0.68, 1.43)
n = 68 / 740
1.11
(0.73, 1.68)
n = 50 / 726
0.85
(0.66, 1.09)
n = 163 / 731
0.86
(0.59, 1.24)
n = 65 / 888 
mHp-cHp+ 0.55
(0.18, 1.63)
n = 4 / 82
2.42
(1.11, 5.27)*
n = 9 / 79
1.04
(0.59, 1.84)
n = 17 / 82
0.55
(0.17, 1.79)
n = 3 / 94
mHp+cHp+ 0.91
(0.43, 1.93)
n = 11 / 112
1.76
(0.81, 3.79)
n = 10 / 107
0.89
(0.55, 1.45)
n = 28 / 109
0.62
(0.28, 1.38)
n = 8 / 141
Values are odds ratios for wheezing, asthma, eczema, and inhalant allergy (95% confidence interval) 
from logistic regression models. Models were adjusted for maternal age, ethnicity, pre-pregnancy 
body mass index, educational level, history of asthma or atopy, parity, pet keeping, smoking during 
pregnancy, psychological stress during pregnancy, and child’s birth weight, gestational age at birth, 
sex, breastfeeding, lower respiratory tract infections, and antibiotic use. 
1n = number of cases (i.e. children with asthma or related conditions) per total group (i.e. according 
to H. pylori status). *p < 0.05
DISCUSSION
In this large population-based prospective cohort, we observed that H. pylori 
colonization in children was associated with an increased risk of asthma at the age of 6 
years. Differentiation of H. pylori-positivity into CagA-negative or CagA-positive strains 
showed that the effects were explained by CagA-negative-H. pylori strains only. This 
association of CagA-negative H. pylori colonization with asthma was present in children 
of European ethnic background, and not in those of non-European ethnic background. 
In non-stratified analysis, maternal H. pylori colonization seems to have a protective 
effect on asthma in their children, as an increased risk of asthma was only found in H. 
pylori-positive children with an H. pylori-negative mother. Although the relative risk was 
higher, the attributable risk for this association only explained 3.4% of the asthma in this 
population. 
Comparison with previous studies
The positive association between H. pylori and physician-diagnosed asthma is in contrast 
with most prior studies in adults and children (9-14, 27, 28). A meta-analysis of pooled 
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data (n= 34,018 subjects) from these studies showed an inverse association between H. 
pylori and asthma in children (OR 0.81; 95% CI 0.72-0.91) (29). However, the pooled OR 
of included (birth) cohort studies was non-significant (10, 11, 13) (OR 0.82; 95% CI 0.53-
1.27) (29). Two of these studies had comparable study designs, but smaller sample size; 
the Dutch study included 575 children between 7 years and 9 years old, and showed an 
OR of 0.87 (95% CI 0.37-2.08) for the relation between H. pylori and physician-diagnosed 
asthma (13). The second study, from Ethiopia, assessed the association with current H. 
pylori colonization at age 3 years and allergic disease in a birth cohort of 878 children 
(11). Due to low asthma prevalence, calculations could not be performed associating 
H. pylori and asthma; however, for H. pylori and wheezing, the outcome was a trend 
towards an inverse association, which is consistent with our study. A second evaluation 
within the cohort from Ethiopia, revealed an inverse association between H. pylori and 
eczema in children at the age of 5 years, but not for wheezing and rhinitis (30). The 
contrast with other studies implies that so far no universal conclusion can be made on 
the relation between H. pylori and asthma. 
In contrast to asthma outcome, the observed tendency of inverse associations of H. 
pylori status with wheezing and inhalant allergy were consistent with prior studies, and 
also consistent with the hypothesis that the endemic rise in asthma and allergy may be 
causally related to compositional changes in our indigenous microbiota (31), probably as 
a result of a modern lifestyle (2). Since H. pylori colonization persists for life, it may be 
considered as a model to examine the effects of once-common microorganisms on the 
development of asthma and related disease. 
Interpretation of results
Considering this paradigm and the data from prior studies, our finding of CagA-
negative H. pylori colonization in 6-year old children of European origin as a risk factor 
for asthma is notable, and requires further explanation. First, the positive association 
between H. pylori and asthma was explained by CagA-negative-strains in children with 
a European ethnic background only. In this group, none of the asthmatic children were 
colonized with a CagA-positive strain. This suggests that the asthma risk may be lower 
in CagA-positive children compared with H. pylori-negatives. The low number of cases 
in this group reflects the overall low H. pylori-prevalence in children of European ethnic 
background, and therefore limits our conclusions based on these findings. Due to lack of 
CagA-positives in asthmatic children in this subgroup, the overall detected effect of H. 
pylori-positivity might be skewed to an increased risk for asthma. It has been shown that 
CagA-positive strains have a stronger interaction with their hosts, leading to pronounced 
immune responses (5). Prior studies have observed more pronounced effects of CagA-
positivity in lowering the risk on asthma and wheezing (32). Accordingly, we found 
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larger effects towards an inverse trend for CagA-positive strains than for CagA-negative 
strains in relation to all outcomes examined. Second, although an association between 
H. pylori and asthma was only present in children of European ethnic background, 
consistent trends were observed for wheezing, eczema, and inhalant allergy, either for 
CagA-negative or CagA-positive strains. Such differences may reflect variation of the 
gut microbiome by ethnicity, in both richness and composition. Children (33) and adults 
living in developing countries have significantly greater faecal diversity than those in 
developed countries (34). Among subjects differing in ethnic background, but migrating 
to the same country, gut microbiome composition also varies (35). In animal models, there 
is growing evidence that H. pylori colonization not only affects the gastric microbiome 
(36), but also the composition of the lower gastro-intestinal tract (37). In addition, the 
composition of the gut microbiome itself also may modulate the development of H. 
pylori-associated disease (38). Within this context, we speculate that the effects of H. 
pylori on asthma or related disease may depend on both the richness and composition 
of the gut microbiome. Depending on its composition, it might sometimes promote and 
other times mitigate H. pylori disease (39). Taken together, these observations from the 
literature might explain the differences between ethnic groups in the present study. 
Third, any potential protective effect of H. pylori on asthma may differ for allergic asthma 
and non-allergic asthma. However, our questionnaires did not distinguish between 
allergic and non-allergic asthma, and hence we cannot explore this issue further. Fourth, 
the effect estimates for asthma were in the opposite direction compared with wheezing 
and inhalant allergy, which are usually closely related with allergic asthma. This can be 
explained by the difference in definition between asthma, and wheezing and inhalant 
allergy used in this study. Asthma was diagnosed as having ever occurred during the 
age period of 1 to 6 years, while data on wheezing and inhalant allergy referred to 
complaints and diagnosis during the last 12 months at the age of 6 years. Ever asthma 
could reflect various phenotypes including early wheezing, mostly induced by respiratory 
tract infections and transient, and multitrigger wheezing. Current wheezing at age 6 
years most likely reflects multitrigger wheezing only. The difference in definition means 
that H. pylori acquisition could have occurred before or after the first asthma period, 
while for wheezing and inhalant allergy it is more likely that H. pylori acquisition may 
have preceded these outcomes.
In the unstratified paired group, we observed no increased risk of asthma in H. pylori-
positive children with an H. pylori-positive mother (Table 4). This finding suggests that 
maternal H. pylori carriage affects the risk of asthma, possibly by facilitating early H. 
pylori colonization in their children. Maternal IgG antibodies against H. pylori can be 
transferred to the child via the placenta, but seem not to protect the child against 
colonization (40). Direct contact between mother and child is most intense during the 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 6
148
first years of life, which may result in early acquisition of H. pylori by a child. Children 
with an H. pylori-positive mother were more likely to become colonized with H. pylori 
themselves, confirming a recent analysis of an overlapping subset of mothers and children 
(41). Whether H. pylori-positive children with an H. pylori-negative mother received the 
infection from other family members or children at day care is not known. Moreover, in 
stratified analysis according to ethnicity, the increased risk of asthma was the same both 
for European children with an H. pylori-negative and positive mother.
Strengths and limitations
The strengths of this study in comparison to prior studies include the large number 
of subjects within a birth cohort of children within the same age period, all living in 
one urban region with detailed prospectively collected information on socioeconomic 
characteristics, and numerous potential confounding factors. Limitations of the study 
include that missing data on outcomes, determinants, and several covariates might have 
resulted in biased effect estimates. The population of analysis might reflect a selection 
towards a more healthy and affluent population (18). Included subjects more often 
were of higher socio-economic status, from European ethnic background, and less often 
exposed to adverse lifestyle factors. Of all children participating in the follow-up at age 
6 years, 54.4% did not have data on both H. pylori colonization and asthma or related 
conditions. Based on the differences in characteristics between those included and not 
included in the study and previous literature (41), we speculate that the prevalence of 
H. pylori and asthma could have been higher in the excluded subjects, compared to the 
population of analysis. We have aimed to reduce the potential selection bias by the use 
of multiple imputation of covariates. Second, although both ELISAs have been validated 
in adults and children, and have been previously used in Dutch children (22), they have 
not been separately validated in Dutch children of different origins. Third, all outcomes 
largely relied on data obtained from questionnaires completed by the parents. Although 
the questions were previously validated and commonly used for epidemiological studies 
(42), we cannot rule out the possibility of misclassification or misinterpretation. Forth, 
data on antibiotic use were not available about specific types, nor validated by pharmacy 
records. Fifth, lacking of detailed data of allergic features in mothers made direct 
comparison with their children in relation to H. pylori status impossible. Finally, despite 
the large sample size of this study, the number of children with H. pylori colonization, 
especially CagA-positive strains, and asthma or related conditions was limited. In total, 
only a small proportion of the asthma risk could be attributed to H. pylori. Therefore, 
conclusions based on these numbers should be interpreted with caution. 
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Conclusions
In conclusion, we observed no significant protective association of H. pylori status at age 6 
with asthma and related conditions. Instead, colonization with a CagA-negative H. pylori 
strain at age 6 was a risk factor for asthma in children, but only in those of European 
ethnic background. Explanations of underlying mechanisms for the differences between 
ethnic groups are still speculative, and therefore need further research. Such studies also 
should include the role of the gut microbiome in relation to H. pylori colonization and 
ethnic background, which may indicate new directions for asthma prevention.
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SUPPLEMENTARY TEXT
Covariates
Information on maternal age, anthropometrics, ethnicity, socio-economic status, history 
of asthma or atopy, parity, and pet keeping were obtained by questionnaire, completed 
by the mother at enrolment. Socio-economic status was assessed using the educational 
level of mother on the basis of her highest level of completed education. Smoking during 
pregnancy was reported at enrolment, and reported smoking habits in the second and 
third trimesters of pregnancy were used to reclassify maternal smoking habits, when 
appropriate. Maternal psychological distress in the second trimester of pregnancy was 
defined using a global severity index (GSI), a measure of current level or depth of the 
symptoms, and denotes overall psychological distress. High scores represent an increased 
occurrence of overall distress, based on Dutch cut-offs (1). We used parity as a proxy for 
older siblings (2). Birth weight, gestational age, and sex of the children were obtained 
from midwife and hospital registries at birth. Postnatal questionnaires at ages of 6 and 
12 months supplied information on breastfeeding, and at age of 6 years about lower 
respiratory tract infections during the prior 12 months. Use of antibiotics in the prior 12 
months (never; yes, for 1-2 time periods; yes, for 3-4 time periods; yes, for 5 or more time 
periods) was assessed by questionnaires at the ages of 1 to 6 years, and was categorized 
into never, for 1-2 time periods, and for 3 or more time periods.
 
Statistical analyses
The prevalence of asthma and related conditions in relation to child’s H. pylori and CagA 
status were examined using Chi-square tests. We used multivariate logistic regression 
analysis to examine the association of child’s H. pylori and CagA status with asthma and 
related conditions, taking potential confounders into account, including maternal age 
at enrolment, pre-pregnancy body mass index, ethnicity, socio-economic status, history 
of asthma or atopy, parity, pet keeping, smoking during pregnancy, psychological stress 
during pregnancy, and child’s birth weight, gestational age at birth, sex, breastfeeding 
habits, lower respiratory tract infections, and antibiotic use. Confounders were included 
based on the prior literature, if they were associated with both the determinant and the 
outcome or if they changed the effect estimates with ≥10%. 
If available, child’s H. pylori status was paired with maternal H. pylori status, resulting 
into four different groups: mother and child both H. pylori negative, mother H. pylori 
negative and child positive, mother H. pylori positive and child negative, both mother 
and child H. pylori positive. We used multivariate logistic regression analysis to examine 
the association of combined H, pylori status of mother and child, with asthma and related 
conditions. Potential confounders were taken into account, including maternal age at 
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enrolment, pre-pregnancy body mass index, ethnicity, socio-economic status, history of 
asthma or atopy, parity, pet keeping, smoking during pregnancy, psychological stress 
during pregnancy, and child’s birth weight, gestational age at birth, sex, breastfeeding 
habits, lower respiratory tract infections, and antibiotic use. Due to small numbers of 
cases we were not able to differentiate between CagA-status. 
For all covariates, the percentage of missing values within the population for analysis 
were lower than 10%, except for history of asthma or atopy (18.7%), smoking during 
pregnancy (11.8%), psychological distress during pregnancy (24.6%), breastfeeding 
(32.6%), pet keeping (21.4%), and antibiotic use (24.2%). Missing values were mainly 
due to non-response. Missing data in the covariates were imputed with multiple 
imputations using chained equations (3). Ten new datasets were created by imputation 
based on all determinants, covariates and outcomes in the model plus paternal age 
and educational level, paternal history of asthma and atopy, and child’s antibiotic use 
during first 6 months of life. Data from each separate imputation were analysed, after 
which results were combined. Only the results based on the adjusted pooled imputed 
datasets are presented in this manuscript. To identify the potential modifying effect of 
covariates such as maternal ethnicity, asthma or atopy, psychological distress, and child’s 
sex, gestational age and weight at birth, and antibiotic use, we evaluated statistical 
interaction by adding the product term of H pylori status and the covariate as a variable 
to the multivariate model. We calculated the population attributable fraction of H. 
pylori colonization for asthma, using adjusted ORs estimated from logistic regression 
models (4). 
All measures of associations are presented as Odds Ratios (OR) with their 95% Confidence 
Intervals (CI). Statistical analyses were performed using SPSS version 23.0 for Windows 
(Statistical Package of Socioeconomic Sciences; SPSS Inc., Chicago, IL, USA). 
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Supplementary Table 2 (Figure 2). Prevalence of asthma and related outcomes of children according 
to child’s H. pylori and corresponding CagA status.
Wheezing (n= 3,135)
No
(n=2,866)
Yes
(n=269)
Chi-square 
(p=0.24)
Hp negative (%)
(n=2,886)
91.3 (2,635) 8.7 (251)
Hp positive
CagA negative
(n=181)
91.2 (165) 8.8 (16)
CagA positive
(n=68)
88.4 (66) 11.6 (2)
Physician diagnosed asthma (n= 3,062)
No
(n=2,864)
Yes
(n=198)
Chi-square 
(p=0.045)
Hp negative (%)
(n=2,820)
93.8 (2,645) 6.2 (175)
Hp positive
CagA negative
(n=173)
89.0 (154) 11.0 (19)
CagA positive
(n=69)
94.2 (65) 5.8 (4)
Eczema (n= 3,082)  
No
(n=2,472)
Yes
(n=610)
Chi-square 
(p=0.25)
Hp negative (%)
(n=2,834)
80.6 (2,283) 19.4 (551)
Hp positive
CagA negative
(n=180)
76.7 (138) 23.3 (42)
CagA positive
(n=68)
75.0 (51) 25.0 (17)
Inhalant allergy (n= 3,584)
No
(n=3,363)
Yes
(n=221)
Chi-square 
(p=0.32)
Hp negative (%)
(n=3,282)
93.7 (2,639) 6.3 (206)
Hp positive
CagA negative
(n=216)
94.0 (1,072) 6.0 (13)
CagA positive
(n=86)
97.7 (493) 2.3 (2)
Values are percentages (absolute numbers). H. pylori and CagA status of children related to 
childhood wheezing, asthma, eczema, and inhalant allergy. 
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Supplementary Table 3. Prevalence of asthma according to child’s H. pylori status stratified for 
ethnicity.
European
(n = 2,140)
No
(n=2,013)
Yes
(n=127)
Chi-square
(p<0.001)
Hp negative (%)
(n=2,026)
94.5 (1,915) 5.5 (111)
Hp positive
(n=114)
86.0 (98) 14.0 (16)
Non-European
(n = 922)
No
(n=851)
Yes
(n=711)
Chi-square
(p=0.32)
Hp negative (%)
(n=794)
91.9 (730) 8.1 (64)
Hp positive
(n=128)
94.5 (121) 5.5 (7)
Values are percentages (absolute numbers). 
Supplementary Table 4. Associations of children’s H. pylori and corresponding CagA status with 
asthma-related outcomes, stratified by ethnicity.
Wheezing
OR (95% CI)
Eczema
OR (95% CI)
Inhalant allergy
OR (95% CI)
European n = 2,199 n = 2,155 N = 2,388
Hp- Reference
n = 164 / 2,079
Reference
n= 313 / 2,035
Reference
n = 110 / 2,260
Hp+ 1.00
(0.48, 2.08)
n = 10 / 120
1.23
(0.76, 2.00)
n = 22 / 120
1.10
(0.49, 2.48)
n = 7 / 128
   Hp+CagA- 0.91
(0.41, 2.05)
n = 8 / 105
1.21
(0.72, 2.02)
n = 19 / 105
1.32
(0.58, 2.98)
n = 7 / 111
   Hp+CagA+ 1.65
(0.31, 8.72)
n = 2 / 15
1.42
(0.39, 5.13)
n = 3 / 15
NA
n = 0 / 17
Non-European n = 936 n = 927 n = 1,196
Hp- Reference
n = 87 / 807
Reference
n = 238 / 799
Reference
n = 96 / 1,022
Hp+ 0.49 
(0.21, 1.11)
n = 8 / 129
0.87
(0.56, 1.35)
n = 37 / 128
0.52
(0.24, 1.12)
n = 8 / 174
   Hp+CagA- 0.95
(0.40, 2.25)
n = 8 / 76
0.97
(0.57, 1.66)
n = 23 / 75
0.67
(0.28, 1.64)
n = 6 / 105
   Hp+CagA+ NA
n = 0 / 53
0.74
(0.38, 1.43)
n = 14 / 53
0.30
(0.07, 1.28)
n = 2 / 69
Values are odds ratios for wheezing, eczema, and inhalant allergy (95% confidence interval) from 
logistic regression models. n = number of cases (i.e. children with wheezing/eczema/inhalant allergy) 
per total group (i.e. according to H. pylori/CagA status). Models were adjusted for maternal age, 
ethnicity, pre-pregnancy body mass index, educational level, history of asthma or atopy, parity, pet 
keeping, smoking during pregnancy, psychological stress during pregnancy, and child’s birth weight, 
gestational age at birth, sex, breastfeeding, lower respiratory tract infections, and antibiotic use. 
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Supplementary Table 5. Prevalence of asthma and related outcomes of children according to paired 
maternal and children’s H. pylori status. 
Wheezing (n= 2,410)
No
% (n=2,205)
Yes
% (n=205)
Chi-square
(p=0.53)
mHp- cHp- 
(n=1,476)
91.7 (1,354) 8.3 (122)
mHp+ cHp-
(n= 740)
90.8 (672) 9.2 (68)
mHp- cHp+
(n= 82)
95.1 (78) 4.9 (4)
mHp+ cHp+
(n= 112)
91.5 (101) 9.8 (11)
Physician diagnosed asthma (n= 2,353)
No
% (n=2,199)
Yes
% (n=154)
Chi-square
(p=0.14)
mHp- cHp- 
(n=1,441)
94.1 (1,356) 5.9 (85)
mHp+ cHp-
(n= 726)
93.1 (676) 6.9 (50)
mHp- cHp+
(n= 79)
88.6 (70) 11.4 (9)
mHp+ cHp+
(n= 107)
90.7 (97) 9.3 (10)
Eczema (n= 2,373)
No
% (n=1,897)
Yes
% (n=476)
Chi-square 
(p=0.08)
mHp- cHp- 
(n= 1,451)
81.5 (1,183) 18.5 (268)
mHp+ cHp-
(n= 731)
77.7 (568) 22.3 (163)
mHp- cHp+
(n= 82)
79.3 (65) 20.7 (17)
mHp+ cHp+
(n= 109)
74.3 (81) 25.7 (28)
Inhalant allergy (n= 2,749)
No
% (n=2,576)
Yes
% (n=173)
Chi-square 
(p=0.32)
mHp- cHp- (n)
(n= 1,626)
94.0 (1,529) 6.0 (97)
mHp+ cHp-
(n= 888)
92.7 (823) 7.3 (65)
mHp- cHp+
(n= 94)
96.8 (91) 3.2 (3)
mHp+ cHp+
(n= 141)
94.3 (133) 5.7 (8)
Values are percentages (absolute numbers). H. pylori status of mother (mHp) and children (cHp) 
related to childhood wheezing, asthma, eczema, and inhalant allergy. 
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Supplementary Table 6. Associations of paired mother-child’s H. pylori status with asthma stratified 
by ethnicity.
Asthma
Odds Ratio (95% CI)
Asthma
Odds Ratio (95% CI)
European n = 1,642 Non-European n = 711
mHp- cHp- Reference
n = 67 / 1,1971
mHp- cHp- Reference
n = 18 / 244
mHp+ cHp- 1.08
(0.62, 1.87)
n = 19 / 353
mHp+ cHp- 0.93
(0.46, 1.89) 
n = 31 / 373
mHp- cHp+ 3.25
(1.41, 7.54)*
n = 8 / 59
mHp- cHp+ 0.57
(0.06, 5.92)
n = 1 / 20
mHp+ cHp+ 4.07
(1.47, 11.31)*
n = 6 / 33
mHp+ cHp+ 0.73
(0.26, 2.59)
n = 4 / 74
Values are odds ratios for asthma (95% confidence interval) from logistic regression models. 
Models were adjusted for maternal age, pre-pregnancy body mass index, educational level, history 
of asthma or atopy, parity, psychological stress during pregnancy, and child’s sex, gestational age 
at birth, birth weight, breastfeeding, pet keeping, lower respiratory tract infections, and antibiotic 
use. 
Overall PInteraction ethnicity
 * H. pylori: <0.05. 
1n = number of cases (i.e. children with asthma) per total group (i.e. according to H. pylori status
*p < 0.01
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Supplementary Table 7. Univariate comparisons of child’s and maternal characteristics with H. pylori 
and with asthma. 
H. pylori
N = 3,797
Asthma
N = 3,062
No Yes p-value No Yes p-value
Male sex 1819 150 0.01 1461 120 0.01
Gestational age at birth, weeks 39.9 39.9 0.49 39.9 39.3 <0.001
Birth weight, grams 3445 332 0.89 3461 3353 0.01
Ethnicity <0.001 0.07
European 2354 138 2013 127
Non-European 1111 194 851 71
Breastfeeding 0.55 0.05
Never 461 46 348 33
Ever 3004 286 2516 165
Pet keeping 0.01 0.75
No 2222 238 1857 131
Yes 1243 94 1007 67
LRTI’s at age 6 years 0.96 <0.001
No 3300 316 2771 154
Yes 165 16 93 44
Antibiotic use cumulative 0.05 <0.001
Never 479 29 461 4
1-2 periods 1463 136 1226 82
3 or more periods 722 50 577 78
Maternal education level <0.001 0.05
Primary, or secondary 1702 220 1324 104
Higher 1763 112 1540 94
Maternal age, years 31.3 29.5 <0.001 31.5 31.4 0.73
Maternal body mass index 24.6 25.2 0.03 24.5 25.3 0.01
History of asthma or atopy 0.29 <0.001
No 2132 213 1804 95
Yes 1333 119 1060 103
Parity 0.01 0.47
0 1936 164 1624 107
≥1 1529 168 1240 91
Smoking during pregnancy 0.19 0.01
No 2961 274 2483 161
Yes 504 58 381 37
Psychological distress during preganancy <0.001 0.02
No 3179 276 2661 176
Yes 285 56 203 22
Numbers are means or absolute values 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 6
162
REFERENCES 
1. de Beurs E. Brief Symptom Inventory, handleiding addendum. Leiden, The Netherlands: PITS BV. 
2009: 
2. Sonnenschein-van der Voort AM, Jaddoe VW, Raat H, et al. Fetal and infant growth and asthma 
symptoms in preschool children: the Generation R Study. Am J Respir Crit Care Med. 2012; 185: 731-7
3. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and 
clinical research: potential and pitfalls. BMJ. 2009; 338: b2393
4. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. American 
journal of public health. 1998; 88: 15-9
CHAPTER 7
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ABSTRACT
Introduction: Obesity is associated with substantial morbidity, costs, and decreased life 
expectancy, and continues to rise worldwide. While etiological understanding is needed 
for prevention, epidemiological studies indicated that colonization with Helicobacter 
pylori (H. pylori) may affect body mass index (BMI), but with inconsistent results. Here, 
we examine the relationship between H. pylori colonization and BMI/obesity in a large 
population-based cohort setting using a Mendelian Randomization approach. 
Methods: Cross-sectional analyses were performed in two independent population-
based cohorts of elderly from the Netherlands and Germany. Genetic risk scores were 
conducted based on genetic loci associated with either H. pylori colonization or BMI/
obesity. We performed a bi-directional Mendelian randomization. Results of both cohorts 
were combined for meta-analysis. 
Results: In total, 13,044 subjects were included. Meta-analysis of cross-sectional data 
revealed no association between anti-H. pylori IgG titer and BMI, nor of H. pylori 
positivity and BMI. Anti-H. pylori IgG titer was negatively associated with obesity (OR 
0.99972; 95% CI 0.99946-0.99997, p=0.03) and with obesity classes (Beta -6.91 •10-5; 95% 
CI -1.38•10-4, -5.49•10-7, p=0.048), but the magnitude of these effects was very limited. 
Mendelian randomization showed no causal relation between H. pylori genetic risk score 
and BMI/obesity, nor between BMI or obesity genetic risk scores and H. pylori positivity.  
Conclusion: This study provides no cross-sectional evidence for a clinically relevant 
association between H. pylori positivity and BMI/obesity. Bi-directional Mendelian 
randomization revealed no causal relation between H. pylori and BMI/obesity.
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INTRODUCTION
The prevalence of obesity rises worldwide. This is associated with significant morbidity, 
costs, and decreased life expectancy. The latter can be reduced with 8-13 years (1), which 
results in a huge economic burden (2). The causes of obesity are diverse and include 
excessive energy intake, lack of physical activity, but also culprits such as stress, lack of 
sleep, or exposure to chemical endocrine disruptors (3). There is increasing evidence 
from mouse as well as human studies that shows that the gut microbiome may play 
an important role in energy balance (4). Modern lifestyle, and the widespread use of 
antibiotics may affect the composition of our microbiome, which may have consequences 
for our health (5).
In this context, Helicobacter pylori (H. pylori), is of relevance. This Gram-negative, spiral-
shaped, gastric bacterium is gradually disappearing in Western populations (5, 6). H. pylori 
colonization is virtually always associated with chronic active gastritis, which can have 
various effects. This includes interference with gastric hormone regulation, including 
ghrelin and leptin. Both have multiple roles in energy homeostasis (7). Disturbance of 
their normal regulation interferes with metabolism and our energy household. H. pylori 
eradication increases serum ghrelin levels (8). 
For these reasons, several epidemiological studies have recently focused on the 
correlation between H. pylori colonization and BMI and obesity. They showed contrasting 
results, which were based on H. pylori status and BMI data, but did not include genetic 
information (9-13). Incorporation of genetic data could give unbiased information on 
the presumed association. A recent genome wide association study (GWAS) identified 
two genetic loci associated with anti-H. pylori IgG titers (14). Numerous GWAS have 
identified many genetic loci associated with BMI variation and / or obesity risk (15, 16). 
Combining these results into risk scores enables a Mendelian randomization study for 
association between H. pylori serology and BMI. Mendelian randomization is a technique 
that aims at unbiased detection of causal effects (17). 
We aimed to assess the relationship between H. pylori seroprevalence and obesity using 
both epidemiological and genetic data of two population-based cohort studies. Results 
of cross-sectional and genetic analyses were compared. In addition, we performed a 
meta-analysis of data derived from both cohorts. 
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METHODS
Study cohorts
The Rotterdam Study is a large, population based prospective study of elderly individuals 
of European ancestry consisting of three cohorts (RS-I, RS-II, RS-III), who are residing in 
a suburb of Rotterdam, the Netherlands. The study design has been described in detail 
previously (18, 19). Baseline recruitment and measurements for the RS-I study were 
obtained between 1990 and 1993. The second cohort, RS-II, was set-up in 2000-2001. A 
third cohort, RS-III, started in 2006 and recruitment ended in December 2008. 
The SHIP study comprises two independent prospectively recruited population-based 
cohorts in Northeastern Germany: SHIP and SHIP-TREND. The study design of SHIP has 
been described in detail previously (20). Participants were recruited between October 
1997 and May 2001. SHIP-TREND is an independent cohort from the same region. 
Individuals were recruited between September 2008 and summer 2012 (20). An important 
characteristic of SHIP is that it attempts to describe health-related conditions with the 
widest focus possible. 
Data from SHIP, SHIP-TREND, RS-I, and RS-II (RS from now on) were used in this study. 
Written informed consent was obtained from all participants. Both the medical ethics 
committee of the Erasmus MC University Medical Center Rotterdam and University 
Medicine Greifswald approved the study. 
Phenotype definition
Serologic H. pylori colonization in individuals from SHIP, SHIP-TREND, and RS was 
defined by measuring IgG antibody levels in serum using commercial enzyme-linked 
immunosorbent assay (Pyloriset EIA-G III ELISA; Orion). Seropositivity was defined as an 
anti-H. pylori IgG titer of ≥20 U/mL according to the manufacturer’s instructions (21). 
Seropositivity is an indicator for current or past colonization. The sensitivity of the 
Pyloriset EIA-G III ELISA is reported as 97.8%, with a specificity of 58% (22). To increase 
specificity and reduce the number of false-positive H. pylori infections, we defined 
subjects with the 25% highest IgG titers as H. pylori cases, and those with the 75% lowest 
IgG titers as controls (14). 
We further assessed the presence of H. pylori antigen in stool of subjects from SHIP-
TREND by using the H. pylori antigen ELISA kit (Immunodiagnostics). For this purpose, 100 
mg feces was stored at -20°C. An optical density (OD) ≥0.025 at 450 nm was considered 
evidence of H. pylori infection, according to the manufacturer’s recommendation. This 
test has a sensitivity of 97.7% and specificity of 96.3%. 
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Genetic risk score conduction
For the creation of the genetic risk scores (BMI risk score, obesity risk score, H. pylori risk 
score), we firstly searched the literature for publications of genome-wide association 
studies (GWAS) for these traits. A list of SNPs that reached genome-wide significance 
(P<5x10-8) with BMI or binary obesity status in populations of European ancestry was 
established. Three different strategies were used to optimize the SNP selection procedure 
using a key word search (e.g. BMI) on i) the National Human Genome Research Institute 
(NHGRI) GWAS Catalog (www.genome.gov/gwastudies/) ii) the HuGE Navigator GWAS 
Integrator (www.hugenavigator.net/HuGENavigator/gWAHitStartPage.do) iii) the 
PubMed database (www.ncbi.nlm.nih.gov/pubmed). Using this strategy, 45 independent 
loci were found to be associated with BMI variation and 48 with binary obesity status. 
We chose to analyze risk scores for BMI and obesity separately. BMI is a phenotype 
which results in a relatively clean risk score. In contrast, various different definitions 
have been used to define obesity, like BMI ≥ 25, or BMI ≥ 30. For this reason we used 
both phenotypes (e.g. BMI continuous and binary) in our analyses. A genotype score 
(GS) was calculated by summing the alleles of BMI / obesity / H. pylori status-associated 
SNPs. An unweighted GS was used as previously recommended by Dudbridge et al. (23). 
Imputed genotypes (1000G PhaseIv3) were used for the creation of the GS. All GWAS 
published before June 2014 were included. Per genetic locus, 1 SNP was selected based 
on the following criteria: 1) SNP genotyped with an imputation quality (R2) of 0.3 or 
higher in all populations; 2) Preference for A/C or G/T variants to avoid strand issues. A 
list of all studies and variants considered, as well as the variants selected can be found in 
Supplementary Table S6, S7 and S8. 
Statistical analysis
In total, we used three different approaches to assess the relationship between H. 
pylori status and BMI/obesity. First, cross-sectional analyses were performed to assess 
the relationship between H. pylori colonization and BMI/obesity at time of inclusion, by 
using linear and logistic regression. Outcomes were defined as continuous BMI, binary 
obesity (BMI ≥30 kg/m2, with BMI <30 kg/m2 as reference group), and obesity classes (lean 
BMI <18.5 kg/m2; normal-weight BMI ≥ 18.5 and <25 kg/m2; overweight BMI ≥ 25 and <30 
kg/m2; class I obesity BMI ≥30 and < 35 kg/m2; class II obesity BMI ≥35 and <40 kg/m2, class 
III obesity BMI ≥40 kg/m2). The latter outcome was defined as a continuous variable with 
value ‘0’ for lean, and value ‘5’ for class III obesity. Unadjusted effects of H. pylori titer or 
antigen (continuous) and H. pylori positivity (binary phenotype) were assessed for each 
outcome. We additionally adjusted for sex and age. All analyses were done separately 
for RS, SHIP, and SHIP-TREND. A meta-analysis was performed to observe the combined 
effect of H. pylori colonization on BMI/obesity. 
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Second, a Mendelian randomization approach was carried out to explore a bi-directional 
link between H. pylori colonization and BMI. Linear regression analysis was used to assess 
the relationship between BMI gene score and H. pylori titer and H. pylori positivity. 
Analyses were first adjusted for sex, age, and additionally for BMI at baseline. The same 
analyses were done regarding the obesity gene score. Linear regression analysis was also 
used to examine the effect of the H. pylori gene score with BMI, binary obesity status, 
and obesity classes, all defined at baseline. Analyses were adjusted for sex, and age, 
and additionally for H. pylori status (binary phenotype). Data of the three cohorts were 
combined and examined by using meta-analysis approach. 
All measures of associations are presented as Odds Ratios (OR) or Beta’s with their 95% 
confidence intervals (CI). Statistical analyses were performed using IBM SPSS Statistics 
21.0 for Windows (SPSS IBM, Armonk, New York, USA). Meta-analyses were done with 
R library meta (R Core Team (2014), R Foundation for Statistical Computing, Vienna, 
Austria). 
RESULTS
Baseline characteristics
In total, 13,044 participants were initially included in this study. Table 1 summarizes 
the baseline characteristics of each cohort. In 220 subjects (1.7%) no data on BMI was 
available. Data on H. pylori titer was lacking in 252 individuals (1.9%) of SHIP. The total 
population included in the cross-sectional analyses consisted of 12,572 (96.4%) subjects. 
According to the predefined phenotypic seroprevalence, a total of 3,147 (25.0%) subjects 
were considered as cases, and 9,425 (75%) as controls. 
Genotyping data was available for 6,883 (86.3%) subjects of RS, for 3,824 (93.7%) subjects 
of SHIP, and for 983 (99.7%) of SHIP-TREND, leaving a total population for analysis of 
11,690 (89.6%) subjects. Table 1 summarizes the mean gene risk score for each cohort 
with respect to the correlation between BMI, obesity, and H. pylori. Linear regression 
analysis within RS focusing on the BMI gene score and BMI revealed a beta of 0.10 kg/m2 
per additional BMI-increasing allele (95% CI 0.07-0.12, p=5.29•10-16). Logistic regression 
analysis focusing on the obesity gene score and obesity (BMI ≥30 kg/m2) revealed an OR 
of 1.04 per additional obesity risk allele (95% CI 1.02-1.05, p=1.09•10-4). The H. pylori 
gene score was significantly associated with H. pylori positivity (OR 1.39, 95% CI 1.27-
1.51; p=3.46•10-13). The proportion of variance of BMI, obesity, and H. pylori explained 
by the genetic risk scores ranged from 0.3% for obesity, 0.5% for H. pylori and 1% for 
BMI per 1 unit increase in score. 
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Table 1. Baseline characteristics (total cohort n = 13,044)
Cohort RS-I and RS-II SHIP SHIP-TREND
Total number (n) 7,977 4,081 986
Age (years), mean (sd) 690 (9.3) 49.7 (16.3) 50.1 (13.7)
Female sex (%) 4,391 (55.0) 2,073 (50.8) 554 (56.2)
H. pylori titer distribution, median (range) 24.3 (6.2-5587.4) 30.4 (5-500) 16.1 (5-500)
H. pylori positive (cut-off)1, % 4,372 (54.8) 2,275 (59.4) 440 (44.8)
H. pylori positive (highest 25% IgG titer)2, % 1,994 (25.0) 958 (25.0) 246 (25.0)
H. pylori antigen distribution, median (range) NA NA -0.004 (-0.151, 3.983)
H. pylori antigen (cut-off)1, % NA NA 255 (26.9)
BMI (kg/m2), mean (sd) 26.7 (3.9) 27.3 (4.7) 27.4 (4.6)
Missing, n (%) 209 (2.6)  11 (0.3) 0 (0.0)
Obesity (BMI≥30), % 1,343 (17.3) 1,042 (25.6) 252 (25.6)
Overweight (BMI≥25), % 5,027 (64.7) 2,690 (66.1) 660 (66.9)
Obesity classes (BMI), %
Lean, <18.5 79 (1.0) 42 (1.0) 2 (0.2)
Normal weight, 18.5-24.9 2,662 (34.3) 1,338 (32.9) 324 (32.9)
Overweight, 25.0-29.9 3,684 (47.2) 1,648 (40.5) 408 (41.4)
Class I obesity, 30.0-34.9 1,110 (14.3) 775 (19.0) 200 (20.3)
Class II obesity, 35.0-39.9 203 (2.6) 217 (5.3) 42 (4.3)
Class III obesity, ≥40.0 30 (0.4) 50 (1.2) 10 (1.0)
BMI risk score, mean (sd) 43.22 (3.98)
Missing, n (%) 1,094 (13.7) 257 (6.3) 3 (0.3)
Obesity risk score, mean (sd) 42.58 (3.94)
Missing, n (%) 1,094 (13.7) 257 (6.3) 3 (0.3)
H. pylori risk score, mean (sd) 3.34 (0.65)
Missing, n (%) 1,094 (13.7) 257 (6.3) 3 (0.3)
1According to manufacturer’s definition
2According to phenotype definition
NA, not applicable 
Cross-sectional analyses
Cross-sectional analyses revealed an association between H. pylori titer and BMI in RS 
and SHIP (Table S1), however with opposite direction. Meta-analysis of all three cohorts 
showed no association between H. pylori titer and BMI, nor between H. pylori positivity 
and BMI (Table 2). H. pylori titer, adjusted for age and sex, was negatively associated with 
obesity (OR 1.00; 95% CI 0.99-1.00, p=0.03) and with obesity classes (Beta -6.91 •10-5; 95% 
CI -1.38•10-4, -5.49•10-7, p=0.048) (Table 2).
Cross-sectional analyses regarding fecal H. pylori status and BMI/obesity showed no 
association (Table S2). 
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Table 2. Cross-sectional analyses regarding serologic H. pylori status and BMI/obesity – meta-analysis
Model Cohort Meta-analysis
BMI~H. pylori RS SHIP SHIP-
TREND
Beta kg/m2 (95% CI) p-value
Hp titer - crude - + + 1.19•10-3 (-1.61•10-3; 3.99•10-3) 0.39
Hp titer - adjusted1 - + - -3.09•10-4 (-6.46•10-4; 2.81•10-5) 0.07
Hp positivity - crude - + + 0.37 (-0.48; 1.22) 0.40
Hp positivity - adjusted1 - + - 0.04 (-0.34; 0.41) 0.84
Obesity2~H. pylori OR (95% CI)
Hp titer - crude - + + 1.00 (0.99; 1.00) 0.72
Hp titer - adjusted1 - + - 1.00 (0.99; 1.00) 0.03
Hp positivity - crude - + + 1.04 (0.78; 1.39) 0.78
Hp positivity - adjusted1 - + - 0.95 (0.86; 1.06) 0.37
Obesity classes3~H. pylori Beta (95% CI)
Hp titer - crude - + + 2.28•10-4 (-2.91•10-4; 7.48•10-4) 0.39
Hp titer - adjusted1 - + - -6.91 •10-5 (-1.38•10-4; -5.49•10-7) 0.05
Hp positivity - crude - + + 0.06 (-0.10; 0.22) 0.49
Hp positivity - adjusted1 - + - -0.02 (-0.05; 0.02) 0.36
1adjusted for sex and age
2Obesity defined as BMI ≥ 30 kg/m2
3 Lean: BMI < 18.5 kg/m2; normal-weight: BMI ≥ 18.5 and < 25 kg/m2; overweight: BMI ≥ 25 and < 
30 kg/m2; class I obesity: BMI ≥ 30 and < 35 kg/m2; class II obesity: BMI ≥ 35 and < 40 kg/m2, class III 
obesity: BMI ≥ 40 kg/m2
Table 3. Mendelian randomization H. pylori and BMI/obesity gene score – meta-analysis
Model Cohort Meta-analysis
H. pylori titer~BMI gene score RS SHIP SHIP-
TREND
Beta (95% CI) p-value
BMI gene score – crude + + + 0.12 (-0.63; 0.87) 0.76
BMI gene score – adjusted1 + - + 0.03 (-0.71; 0.77) 0.95
BMI gene score – adjusted2 + - + 0.04 (-0.71; 0.78) 0.92
H. pylori positivity~BMI gene score OR (95% CI)
BMI gene score – crude + + - 1.01 (1.00; 1.02) 0.14
BMI gene score – adjusted1 + + - 1.01 (1.00; 1,02) 0.20
BMI gene score – adjusted2 + + - 1.01 (1.00; 1,02) 0.15
H. pylori titer~Obesity gene score Beta (95% CI)
Obesity gene score – crude + + - 0.76 (0.02; 1.50) 0.04
Obesity gene score – adjusted1 + + - 0.73 (-0.00; 1.47) 0.05
Obesity gene score – adjusted2 + + - 0.71 (-0.03; 1.45) 0.06
H. pylori positivity~Obesity gene score OR (95% CI)
Obesity gene score – crude + + - 1.01 (1.00; 1.02) 0.12
Obesity gene score – adjusted1 + + - 1.01 (1.00; 1.02) 0.14
Obesity gene score – adjusted2 + + - 1.01 (1.00; 1.02) 0.15
1Adjusted for age and sex
2Adjusted for age, sex, and BMI
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Mendelian randomization
The BMI gene score was not associated with H. pylori titer or positivity (Table 3). Table S3 
shows the results of each cohort. Crude analysis showed a positive association between 
obesity gene score and H. pylori titer (Beta 0.76; 95% CI 0.02-1.50, p=0.04) (Table 3). H. 
pylori gene score was not associated with BMI, neither with obesity nor obesity classes 
(Table 4 and Table S4). Also, no associations were observed regarding fecal H. pylori 
status and the BMI or obesity gene score (Table S5). 
Table 4. Mendelian randomization regarding BMI/obesity and H. pylori gene score – meta-analysis
Model Cohort Meta-analysis
BMI~H. pylori gene score RS SHIP SHIP-
TREND
Beta (95% CI) p-value
Hp gene score – crude - - - -0.05 (-0.16; 0.07) 0.43
Hp gene score – adjusted1 - - - -0.06 (-0.17; 0.05) 0.31
Hp gene score – adjusted2 - - - -0.05 (-0.17; 0.06) 0.37
Obesity3~H. pylori gene score OR (95% CI)
Hp gene score – crude - + - 0.98 (0.92; 1.05) 0.60
Hp gene score – adjusted1 - - - 0.98 (0.91; 1.04) 0.47
Hp gene score – adjusted2 + - - 0.98 (0.91; 1.05) 0.56
Obesity classes4~H. pylori gene score Beta (95% CI)
Hp gene score – crude + - - -0.01 (-0.03; 0.02) 0.54
Hp gene score – adjusted1 + - - -0.01 (-0.03; 0.01) 0.37
Hp gene score – adjusted2 + - - -0.03 (-0.06; 0.01) 0.15
1Adjusted for age and sex
2Adjusted for age, sex, and H. pylori
3Obesity defined as BMI ≥ 30 kg/m2
4Obesity classes defined as lean: BMI < 18.5 kg/m2; normal-weight: BMI ≥ 18.5 and < 25 kg/m2; 
overweight: BMI ≥ 25 and < 30 kg/m2; class I obesity: BMI ≥ 30 and < 35 kg/m2; class II obesity: BMI ≥ 
35 and < 40 kg/m2, class III obesity: BMI ≥ 40 kg/m2
DISCUSSION
This study included a meta-analysis of 13,044 subjects from two large population-based 
cohorts. This analysis did not demonstrate an association between H. pylori colonization 
and BMI, neither when examined by means of serology, nor by fecal antigen, or 
Mendelian randomization. H. pylori serology, adjusted for age and sex, was negatively 
associated with obesity (BMI ≥30 kg/m2), and obesity classes. However, these effects were 
small. Active H. pylori colonization, determined by a positive fecal antigen test, was also 
not positively or negatively associated with obesity. While the unadjusted and adjusted 
effect estimates for the obesity gene score on anti-H. pylori IgG titer were positive, this 
association did not remain statistically significant after adjustment for age and sex. So, 
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the use of a Mendelian randomization method did not show a causal bi-directional link 
between H. pylori serology and BMI or obesity.
Our meta-analysis of H. pylori status as determined by serology showed a small 
negative association with both obesity and obesity classes. Considering both the small 
effect estimates, and opposite directions in the individual cohorts, we consider these 
associations as clinically irrelevant. Prior epidemiological studies have shown either 
negative (9), or positive (10, 11), or no association (12, 13) between H. pylori and BMI or 
obesity. The latter findings are most in line with our findings. A recent review of studies 
reporting data on H. pylori and obesity prevalence rates in developed countries, showed 
an inverse correlation (r=-0.29, p<0.001) between H. pylori colonization and obesity and 
overweight (24). In total, data of 99,463 subjects from 49 studies were pooled. Prevalence 
rates for H. pylori, but also for overweight and obesity were highly variable between 
included studies. Nevertheless, no additional analyses were performed to examine 
whether this correlation was related to potential significant confounders such as age. 
Age is an important confounder as it is positively correlated with H. pylori colonization 
(20), and negatively with obesity (20). This may explain the negative correlation between 
H. pylori and obesity reported in the systematic review. Other studies have observed 
weight gain following successful H. pylori eradication (18, 25-28). A clinical trial from 
Japan randomized 1,558 H. pylori-positive adults to either antibiotic treatment or 
placebo with a subsequent follow-up of 6 months. H. pylori eradication was associated 
with a mean weight gain of 0.6 kg (95% CI 0.31, 0.88) and an increase in BMI of 0.2 
kg/m2 (25). The simultaneous improvement of dyspepsia symptoms in the eradication 
group may have stimulated the appetite and subsequently caused the weight gain by 
increased food intake. Others have suggested that circulating meal-associated leptin 
and ghrelin levels, which changed after H. pylori eradication, gave rise to the increased 
BMI. US investigators observed an increase in both post-prandial levels of leptin and 
ghrelin a median seven months following H. pylori eradication in a group of 21 patients 
(29). In addition, BMI significantly increased after over 18 months of follow-up, while no 
change was observed in those who were H. pylori-negative at baseline. Although these 
studies provided evidence that H. pylori eradication may result in weight gain, it does 
not imply that there is an absolute difference in BMI between H. pylori-negative and 
positive subjects. Both our cross-sectional as well as Mendelian randomization results 
suggest that H. pylori-colonized and H. pylori-negative subjects have similar BMI. The 
congruence between the results of our cross-sectional and Mendelian randomization 
analyses is important, as the latter is based on an unbiased approach (17). 
One of the strengths of this study was the use of different methods to detect H. pylori 
colonization, by means of both serology and stool antigen. The latter is a reliable 
method to identify active H. pylori colonization. While most prior studies reported data 
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on serology, we were able to show that results for serology and fecal antigen did not 
differ. In addition, the use of SNP typing data with genetic risk scores for BMI, obesity, 
and H. pylori colonization is unique in this field. The Mendelian randomization method 
is a powerful control for reverse causation and confounding, which otherwise affects 
epidemiological studies (17). It is based on the common disease, common variant 
hypothesis, which argues that common variants with modest effects underlie many 
complex traits (30). 
As any method, the Mendelian randomization has its limitations. Although many genetic 
variants are discovered, these common variants only explain a small proportion of the 
estimated trait heritability. Regarding the H. pylori-gene risk score, we were only able to 
include two genetic variants, due to the fact that no others (as far as we know) have been 
discovered so far, and these explain only 0.5% of the variance. Finally, we did not account 
for socio-economic status in the cross-sectional analyses. Although both populations are 
similar regarding ethnicity and age distribution, differences in socio-economic status are 
associated with both H. pylori colonization and BMI, and may therefore have influenced 
our outcome. 
In conclusion, this study provides no evidence for a cross-sectional association between 
H. pylori colonization and BMI or obesity in adults. Mendelian randomization revealed 
no causal relation between H. pylori and BMI or obesity. 
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Table S2. Cross-sectional analyses regarding fecal H. pylori status and BMI/obesity 
Model SHIP-TREND
BMI~H. pylori Beta (95% CI) p-value
Hp titer - crude 0.12 (-0.24, 0.48) 0.51
Hp titer - adjusted1 -0.08 (-0.43, 0.27) 0.67
Hp positivity - crude 0.21 (-0.44; 0.86) 0.52
Hp positivity - adjusted1 -0.05 (-0.68; 0.58) 0.88
Obesity2~H. pylori OR (95% CI)
Hp titer - crude 1.00 (0.83; 1.19) 0.97
Hp titer - adjusted1 0.94 (0.78; 1.13) 0.52
Hp positivity - crude 0.95 (0.68; 1.32) 0.76
Hp positivity - adjusted1 0.88 (0.63; 1.23) 0.46
Obesity classes3~H. pylori Beta (95% CI)
Hp titer - crude 0.01 (-0.04; 0.08) 0.82
Hp titer - adjusted1 -0.03 (-0.01; 0.04) 0.39
Hp positivity - crude 0.02 (-0.13; 0.15) 0.81
Hp positivity - adjusted1 -0.04 (-0.17; 0.09) 0.59
1Adjusted for age and sex
2Obesity defined as BMI>30
3Lean (BMI < 18.5); normal-weight BMI >= 18.5 and < 25; overweight BMI >=25 and < 30; class I 
obesity BMI >=30 and < 35; class II obesity BMI >= 35 and < 40, class III obesity BMI >= 40
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Table S5. Cross-sectional analyses regarding fecal H. pylori status and BMI/obesity gene score
Model Cohort SHIP-TREND
H. pylori titer~BMI gene score Beta (95% CI) p-value
BMI gene score – crude -1.20•10-3 (-1.5•10-2; 1.27•10-2) 0.86
BMI gene score – adjusted1 -2.20•10-3 (-1.59•10-2; 1.59•10-2) 0.75
BMI gene score – adjusted2 -2.10•10-3 (-1.58•10-2; 1.16•10-2) 0.77
H. pylori positivity~BMI gene score OR (95% CI)
BMI gene score – crude 1.00 (0.99; 1.01) 1.00
BMI gene score – adjusted1 1.00 (0.99; 1.01) 0.88
BMI gene score – adjusted2 1.00 (0.99; 1.01) 0.89
H. pylori titer~Obesity gene score Beta (95% CI)
Obesity gene score – crude 2.60•10-3 (-1.11•10-2; 1.61•10-2) 0.70
Obesity gene score – adjusted1 2.20•10-3 (-1.11•10-2; 1.55•10-2) 0.75
Obesity gene score – adjusted2 2.40•10-3 (-1.09•10-2; 1.57•10-2) 0.72
H. pylori positivity~Obesity gene score OR (95% CI)
Obesity gene score – crude 1.00 (0.99; 1.01) 0.99
Obesity gene score – adjusted1 1.00 (0.99; 1.01) 0.99
Obesity gene score – adjusted2 1.00 (0.99; 1.01) 0.99
1Adjusted for age and sex
2Adjusted for age, sex, and BMI
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Table S7. Selected SNPs associated with BMI
RS1 RS2 SHIP
Gene SNP ID Coded Ref Freq Rsq Coded Ref Freq Rsq Coded Ref Freq Rsq
FTO rs9930506 A G 0,58 0,99 A G 0,57 0,99 G A 0,45 1,00
MC4R (1) rs17782313 T C 0,75 1,00 T C 0,74 1,00 C T 0,25 1,00
MC4R (2) rs7227255 G A 0,97 0,96 G A 0,98 0,96 A G 0,02 0,94
TMEM18 rs6548238 C T 0,83 1,00 C T 0,83 1,00 C T 0,82 1,00
GNPDA2 rs10938397 A G 0,59 1,00 A G 0,58 1,00 G A 0,45 0,99
SH2B1 rs7498665 A G 0,59 0,99 A G 0,58 0,99 G A 0,42 0,98
KCTD15 rs11084753 G A 0,67 0,94 G A 0,68 0,95 G A 0,68 1,00
MTCH2 rs10838738 A G 0,66 1,00 A G 0,67 1,00 G A 0,35 1,00
NEGR1 rs2815752 A G 0,59 0,97 A G 0,57 0,97 A G 0,63 1,00
SEC16B rs10913469 T C 0,80 1,00 T C 0,82 1,00 C T 0,18 0,98
ETV5 rs7647305 C T 0,79 1,00 C T 0,80 1,00 C T 0,79 0,98
BDNF rs6265 C T 0,81 1,00 C T 0,80 1,00 T C 0,20 1,00
FAIM2 rs7138803 G A 0,63 1,00 G A 0,63 1,00 A G 0,42 1,00
TFAP2B rs987237 A G 0,83 1,00 A G 0,83 1,00 G A 0,20 1,00
NRXN3 rs10150332 T C 0,79 1,00 T C 0,78 1,00 C T 0,22 1,00
GPRC5BB rs12444979 C T 0,85 0,99 C T 0,85 1,00 T C 0,15 1,00
POMC rs713586 C T 0,47 1,00 C T 0,48 1,00 C T 0,47 1,00
MAP2K5 rs2241423 G A 0,77 1,00 G A 0,76 1,00 A G 0,22 1,00
GIPR rs11671664 G A 0,90 1,00 G A 0,90 1,00 A G 0,11 0,81
FANCL rs887912 C T 0,70 1,00 C T 0,71 1,00 C T 0,73 1,00
TNNI3K rs1514175 A G 0,43 1,00 A G 0,44 1,00 G A 0,59 1,00
LRRN6C rs10968576 A G 0,69 1,00 A G 0,71 1,00 G A 0,31 1,00
FLJ35779 rs2112347 T G 0,63 0,98 T G 0,64 0,99 G T 0,37 0,99
SLC39A8 rs13107325 C T 0,95 0,94 C T 0,95 0,93 T C 0,08 1,00
TMEM160 rs3810291 G A 0,32 0,80 G A 0,33 0,82 A G 0,67 0,90
CADM2 rs13078807 A G 0,80 1,00 A G 0,79 1,00 G A 0,20 0,99
LRP1B rs2890652 T C 0,82 0,98 T C 0,82 0,98 C T 0,19 1,00
PRKD1 rs11847697 C T 0,96 0,97 C T 0,95 0,97 T C 0,04 0,96
MTIF3 rs4771122 A G 0,74 0,91 A G 0,74 0,91 A G 0,72 0,96
PTBP2 rs1555543 C A 0,58 0,98 C A 0,56 0,98 C A 0,57 1,00
TUB rs4929949 T C 0,48 0,99 T C 0,49 0,99 C T 0,49 1,00
HMGA1 rs206936 A G 0,79 0,98 A G 0,80 0,99 G A 0,19 1,00
CDKAL1 rs2206734 C T 0,83 1,00 C T 0,83 1,00 T C 0,18 1,00
PCSK1 rs261967 A C 0,60 1,00 A C 0,59 1,00 C A 0,44 1,00
GP2 rs12597579 C T 0,95 1,00 C T 0,96 1,00 T C 0,04 1,00
KLF9 rs11142387 A C 0,47 0,99 A C 0,46 0,99 C A 0,54 0,98
TOMM40 rs2075650 A G 0,85 1,00 A G 0,86 1,00 G A 0,16 0,69
FANCL/FLJ30838 rs12617233 C T 0,61 0,97 C T 0,60 0,96 C T 0,59 1,00
NTRK2 rs1211166 A G 0,79 1,00 A G 0,79 1,00 A G 0,79 1,00
GALNT10 rs7708584 A G 0,43 1,00 A G 0,42 1,00 G A 0,58 1,00
MIR148A/NFE2L3 rs10261878 C A 0,94 0,98 C A 0,94 0,99 C A 0,95 0,98
ADCY3 rs7586879 C T 0,66 1,00 C T 0,66 1,00 T C 0,33 1,00
BRE rs116612809 A G 1,00 0,82 A G 1,00 0,91 G A 0,00 0,94
MAP2K3 rs11652094 C G 0,71 0,98 C G 0,71 0,95 C G 0,71 1,00
Coded, coded allele 
Ref, Reference allele 
Freq, frequency of coded allele
Rsq, Imputation quality 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
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Table S8. Selected SNPs associated with obesity 
RS1  RS2 SHIP
Gene SNP ID Coded Ref Freq Rsq Coded Ref Freq Rsq Coded Ref Freq Rsq
FTO rs1421085 T C 0,62 1,00 T C 0,60 1,00 C T 0,43 1,00
MC4R rs17782313 T C 0,75 1,00 T C 0,74 1,00 C T 0,25 1,00
PCSK1 (1) rs6232 T C 0,93 1,00 T C 0,94 1,00 C T 0,05 0,83
PCSK1 (2) rs6234 G C 0,73 0,98 G C 0,73 0,99 C G 0,26 1,00
FAIM2 rs7132908 G A 0,62 0,98 G A 0,62 0,96 A G 0,43 0,98
MAF rs1424233 T C 0,50 1,00 T C 0,50 1,00 C T 0,51 1,00
NPC1 rs1805081 T C 0,59 1,00 T C 0,60 1,00 C T 0,43 0,99
SDCCAG8 rs12145833 T G 0,83 1,00 T G 0,83 0,99 G T 0,16 1,00
TNKS rs17150703 G A 0,90 1,00 G A 0,90 1,00 A G 0,10 1,00
KCNMA1 rs2116830 G T 0,83 0,92 G T 0,83 0,95 T G 0,18 1,00
BDNF rs988712 G T 0,77 0,98 G T 0,75 0,98 T G 0,25 1,00
TMEM18 rs4854344 T G 0,83 1,00 T G 0,83 1,00 T G 0,82 1,00
POMC rs6752378 A C 0,46 1,00 A C 0,47 1,00 A C 0,46 0,99
TNNI3K rs1040070 G C 0,44 0,99 G C 0,44 0,99 C G 0,58 0,95
SEC16B rs10913469 T C 0,80 1,00 T C 0,82 1,00 C T 0,18 0,98
OLFM4 rs9568856 G A 0,86 0,98 G A 0,86 0,97 A G 0,12 1,00
HOXB5 rs9299 T C 0,64 1,00 T C 0,63 1,00 T C 0,66 0,98
GPR120 rs116454156 G A 0,99 0,37 G A 0,99 0,42 A G 0,02 0,70
HS6ST3 rs7989336 A G 0,48 0,99 A G 0,49 0,99 A G 0,47 1,00
ZZZ3 rs17381664 T C 0,59 0,97 T C 0,59 0,96 C T 0,40 0,96
GNAT2 rs17024258 C T 0,97 0,99 C T 0,97 0,99 T C 0,04 0,98
HNF4G rs4735692 G A 0,41 0,98 G A 0,42 0,97 G A 0,41 1,00
MRPS33P4 rs13041126 T C 0,73 1,00 T C 0,74 0,99 C T 0,25 1,00
ADCY9 rs2531995 C T 0,36 1,00 C T 0,39 1,00 T C 0,62 1,00
RPTOR rs7503807 A C 0,55 0,99 A C 0,55 1,00 C A 0,45 1,00
NEGR1 rs2815752 A G 0,59 0,97 A G 0,57 0,97 A G 0,63 1,00
GNPDA2 rs10938397 A G 0,59 1,00 A G 0,58 1,00 G A 0,45 0,99
TFAP2B rs987237 A G 0,83 1,00 A G 0,83 1,00 G A 0,20 1,00
TMEM160 rs3810291 G A 0,32 0,80 G A 0,33 0,82 A G 0,67 0,90
ETV5 rs9816226 T A 0,83 1,00 T A 0,83 0,99 T A 0,82 0,98
QPCTL rs2287019 C T 0,80 1,00 C T 0,81 0,94 T C 0,21 0,74
MTCH2 rs3817334 C T 0,61 0,99 C T 0,62 0,99 T C 0,40 1,00
SH2B1 rs7359397 C T 0,60 0,95 C T 0,59 0,96 T C 0,42 0,98
GPRC5B rs12444979 C T 0,85 0,99 C T 0,85 1,00 T C 0,15 1,00
MAP2K5 rs2241423 G A 0,77 1,00 G A 0,76 1,00 A G 0,22 1,00
LRRN6C rs10968576 A G 0,69 1,00 A G 0,71 1,00 G A 0,31 1,00
TNNI3K rs1514174 C T 0,44 1,00 C T 0,45 1,00 T C 0,58 1,00
RPL27A rs11042023 C T 0,66 1,00 C T 0,65 1,00 C T 0,65 0,99
FLJ35779 rs2112347 T G 0,63 0,98 T G 0,64 0,99 G T 0,37 0,99
FANCL rs887912 C T 0,70 1,00 C T 0,71 1,00 C T 0,73 1,00
CADM2 rs13078807 A G 0,80 1,00 A G 0,79 1,00 G A 0,20 0,99
NRXN3 rs10150332 T C 0,79 1,00 T C 0,78 1,00 C T 0,22 1,00
PRKCH rs1957894 G T 0,90 0,99 G T 0,90 0,99 G T 0,91 0,95
LEPR rs11208659 T C 0,92 1,00 T C 0,91 1,00 C T 0,10 0,99
PACS1 rs564343 A G 0,41 0,99 A G 0,41 0,98 G A 0,55 1,00
RMST rs11109072 C A 0,96 0,89 C A 0,95 0,55 A C 0,04 0,99
LPIN2 rs643507 T C 0,98 0,92 T C 0,98 0,94 T C 0,98 1,00
Coded, coded allele 
Ref, Reference allele 
Freq, frequency of coded allele
Rsq, R-square 
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ABSTRACT
Background and study aims: Patients with atrophy and metaplasia of the gastric mucosa 
are at risk for progression to gastric cancer. International guidelines therefore recommend 
endoscopic surveillance of premalignant gastric lesions. However, the diagnostic yield 
and preventive effect of surveillance require further study. We therefore aimed to assess 
the incidence of neoplastic progression in patients from a low-risk area and to assess 
discriminative tests to identify patients most at risk for progression.
Patients and methods: Patients with a previous diagnosis of atrophic gastritis (AG), 
intestinal metaplasia (IM), or dysplasia from six hospitals throughout the Netherlands and 
one in Norway were offered endoscopic surveillance according to European guidelines. 
All histological specimens were assessed according to the updated Sydney classification 
and the operative link for gastric intestinal metaplasia (OLGIM) system. In addition, 
we measured serum pepsinogens I and II, and gastrin-17 obtained before surveillance 
endoscopy.  
Results: Two-hundred-and-eighty-four (mean age 57.8 year SD 11.4, M/F 142/142) patients 
were included. In 279 (98%) patients at least one surveillance endoscopy was performed. 
The mean follow-up time was 57 months (SD 36) with a total of 1,312 patient-years 
follow-up. Four subjects (1.4%) were diagnosed with high grade dysplasia or gastric 
cancer during follow-up. This occurred in 3 (2.2%) of 134 patients with OLGIM stage 
0-II disease at baseline, versus 1 (1.9%) of 54 patients with stage III-IV (p=0.87). Two of 
these patients were successfully treated with endoscopic submucosal dissection, while 
the other two underwent a total gastrectomy. Patients with normal serology markers 
and limited disease did not develop gastric cancer during follow-up, (p=0.41) (serology 
available for n=234).
Conclusions: In a low gastric cancer incidence area, a surveillance program for 
premalignant gastric lesions can detect gastric cancer at an early curable stage with 
an overall risk of neoplastic progression of 0.3% per year. Use of serologic markers in 
endoscopic surveillance programs improves risk stratification. These data strengthens 
international guidelines in their recommendations on surveillance of premalignant 
gastric lesion.
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INTRODUCTION
Gastric cancer is the third leading cause of cancer-related mortality, and the fifth most 
common malignancy worldwide (1). More than 70% of gastric cancer cases occur in 
developing countries, with highest incidences in Eastern Asia, Eastern Europe, and parts 
of central and South America. Although the global incidence and mortality rates are 
declining, the number of new cases and fatalities increase annually due to expansion 
and aging of the world population (2). In Western Europe, the age standardized rates 
of gastric cancer incidence are relatively low with 8.8 cases/ 100 000/ year in men and 4.3 
cases in women (1). Nevertheless, mortality rates remain high, as most of the cases are 
diagnosed in a late stage, leading to a 5-year survival rate of approximately 21% in the 
Netherlands, and 24% in Norway (3). 
Premalignant gastric lesions predispose to the development of intestinal type gastric 
cancer. Helicobacter pylori gastritis is considered the starting point of the carcinogenic 
pathway, in which inflammation evolves to gland loss, metaplasia, low-grade dysplasia, 
high-grade dysplasia and eventually gastric cancer in 1-2% of the infected patients (4). 
As a result, regular endoscopic follow-up is recommended in patients with premalignant 
gastric lesions (5). However, most of the patients with H. pylori and premalignant gastric 
lesions do not develop gastric cancer. Moreover, premalignant gastric lesions affect 
a substantial proportion of the population above 50 years of age (6). Furthermore, a 
proportion of patients show regression of premalignant lesions during endoscopic 
follow-up, either reflecting an effect of sampling or true regression after H. pylori 
eradication (7, 8). Therefore, identification and surveillance of subjects with an increased 
risk of gastric cancer is indicated. This will additionally result in a decrease in burden for 
patients and use of limited endoscopy resources. 
Currently, it remains difficult to identify patients with an increased gastric cancer risk, and 
to determine optimal surveillance strategies in order to prevent invasive gastric cancer. 
In 2012, the first international guideline on this topic was published (MAnagement of 
Precancerous conditions and lesions of the Stomach - MAPS guideline) (5). This guideline 
recommended endoscopic surveillance in patients with moderate to severe atrophic 
gastritis, those with marked intestinal metaplasia in both antrum and corpus, and 
patients with dysplasia. Surveillance was not recommended for patients with atrophic 
gastritis or intestinal metaplasia limited to antrum. However, prospective cohort studies 
are needed to evaluate the yield of surveillance of premalignant gastric lesions, and 
to confirm that the guideline recommendations are also applicable for low-risk areas. 
Due to a lower incidence of gastric cancer in these areas there is less experience in a 
comprehensive endoscopic assessment of the gastric mucosa, which may influence the 
yield of surveillance.    
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In this multi-center prospective cohort study, we aimed to evaluate the incidence of 
neoplastic progression during endoscopic follow-up in patients living in low-incidence 
countries. The yield and value of the operative link on intestinal metaplasia assessment 
(OLGIM) classification and MAPS guideline recommendations were evaluated. We further 
aimed to assess the potential additional value of serologic markers like pepsinogens and 
gastrin on risk stratification.  
PATIENTS AND METHODS
Patient selection
This prospective study was performed in six hospitals (one academic, 5 regional) in The 
Netherlands, and one regional hospital in Norway. Initials results of the study in 140 
patients have been published before (7). Patients were eligible for inclusion if they were 
over 18 years of age and had a previous diagnosis of atrophic gastritis, intestinal metaplasia 
and/or dysplasia of the gastric mucosa. They were identified in the histopathology 
database of each hospital or selected from the outpatient clinic. Patients were excluded 
from participation if they had previously undergone upper gastrointestinal surgery, a 
previous diagnosis of gastric carcinoma, or any other malignancy not being in remission, 
if they had severe comorbidity limiting their expected survival to less than 2 years, portal 
hypertension, or a proven CDH1 mutation. 
Eligible patients were included after written informed consent had been obtained. 
All patients underwent at least one surveillance endoscopy after the index endoscopy. 
Surveillance endoscopies were performed between April 2006 and January 2015. The 
institutional review boards of all participating hospitals approved the study. 
Baseline data collection
Data on demographic details, including age, sex and ethnicity were registered for each 
patient. In addition, all patients were asked to complete a structured questionnaire 
including several items on lifestyle factors, medical history, medication use, and family 
history of gastric cancer. 
Endoscopy procedures at baseline and during follow-up
All endoscopies were done using a standard forward-viewing videogastroscope 
(Olympus). At index endoscopy, biopsies had been taking using the local protocol, with 
non-targeted biopsies from the antrum and/or corpus, and targeted biopsies of visible 
lesions. 
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At the surveillance endoscopy, random biopsies were taken according to a standardized 
biopsy protocol from five standardized intragastric locations for histological assessment 
of the severity and distribution of premalignant gastric lesions (9, 10). Four biopsies were 
taken from the antrum, two from the angulus, two from the corpus greater curvature, 
two from the corpus lesser curvature, and two from the cardia. In case of endoscopic 
abnormalities or visible lesions in the stomach, further targeted biopsies were obtained. 
The time interval between surveillance endoscopies was 2 years, except for cases with 
low or high grade dysplasia (LGD / HGD). Those patients underwent an endoscopy within 
1 year (LGD) or 6 months (HGD).
Histological assessment of surveillance biopsies
All participating hospitals used the same histopathological protocol. Biopsy samples 
were fixed in formalin, embedded in paraffin blocks, cut into 5-μm sections, stained 
with hematoxylin and eosin and processed for routine diagnosis. Pathologists from 
the participating hospitals assessed the biopsy samples of each intragastric location 
and scored them for presence of H. pylori, atrophic gastritis, intestinal metaplasia, and 
dysplasia. A representative part of all samples was reassessed by an expert pathologist, 
who was not aware of patient data, endoscopic findings, and the baseline and follow-
up histological diagnoses of the general pathologist. If differences were observed, the 
expert score was used. 
All specimens were scored according to the updated Sydney classification system (11). 
In general, for every biopsy sample H. pylori density, acute inflammation (by means of 
neutrophil infiltration), chronic inflammation (by means of mononuclear infiltration), 
atrophic gastritis, and intestinal metaplasia were assessed (0=absent, 1=mild, 2=moderate, 
3=marked). Dysplasia was scored according to the Vienna system, which includes low 
grade dysplasia, high grade dysplasia and neoplasia (12). 
The operative link on gastric intestinal metaplasia (OLGIM) system was used to evaluate 
the severity and distribution of intestinal metaplasia throughout the stomach (13). 
This system combines the IM score (no IM, mild, moderate or severe IM) of antrum and 
angulus, with the score of the corpus lesser and greater curvature, in order to classify 
patients into 5 stages (0 to IV). 
Follow-up
The MAPS guideline recommends no follow-up in patients with mild or moderate AG or 
IM limited to antrum, as these patients are thought to have a low risk for progression to 
gastric cancer (5). In our cohort all patients were followed, at least until two endoscopies 
had shown no lesions or progression of histopathology. To evaluate the guideline, we 
categorized patients as low or high risk for developing gastric cancer. Patients with mild 
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and moderate AG or IM limited to antrum were considered as low risk, while patients 
with moderate to severe AG or IM in both antrum and corpus as well as those with 
dysplasia were considered as high risk. 
In general, patients were categorized according to their most advanced lesion. Disease 
progression was defined as more advanced histology compared to the prior endoscopic 
evaluation. Regression was defined as the opposite, meaning that histopathology of 
surveillance biopsies showed less advanced histology. Progression to HGD/carcinoma was 
defined as neoplastic progression. 
To assess the role of serological markers for identifying patients at risk, patients were 
divided into a low or high risk group, based on both histology and serology results. 
Patients were defined as low risk if histology showed AG and/or IM limited to the antrum 
and normal biomarkers and as high risk if histology showed AG and/or IM in both antrum 
and corpus and/or abnormal biomarkers.
Serological determinants 
Fasting blood samples were taken before surveillance endoscopy. Separated serum 
samples were stored at -80 °C until use for analyses. Serologic testing of pepsinogens I 
and II, gastrin-17 and H. pylori antibodies was performed by commercial enzyme-linked 
immunosorbent assay (ELISA) tests (GastroPanel, Biohit, Helsinki, Finland). All tests were 
performed according to the manufacturers guideline. 
Statistical analyses
Continuous variables were reported as mean with standard variation (SD) or median 
with 25th and 75th percentiles or range. Categorical variables were reported as counts and 
percentages. Chi-square test was applied to compare HGD/gastric cancer development 
between patients categorized at low and high risk. Analyses of variance (ANOVA) were 
used to compare means of serology markers between MAPS risk groups and OLGIM 
stages. Two-sided p-values <0.05 were considered statistically significant. Analyses were 
performed using SPSS software, version 23. 
RESULTS
Baseline characteristics
In total 295 patients consented for surveillance of premalignant gastric lesions (Figure 
1). After re-assessment of their baseline histology, 11 subjects (4%) had to be excluded 
because no premalignant lesions were observed, leaving a study population of 284 
patients. Main baseline characteristics are summarized in Table 2. The median age at 
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baseline was 58 years (range 14-79 years). At index endoscopy, 4% of patients was 
diagnosed with AG, 87% with IM, and 9% with dysplasia as most severe lesion. Histology 
showed H. pylori infection in 71 patients (26%). In 22 patients (7%) targeted biopsies 
from visible lesions were obtained. These lesions were located in antrum (n=12), corpus 
(n=6), angulus (n=1), cardia (n=1), and data were missing for the remainder (n=2). 
Histopathology of these visible lesions showed gastritis or no abnormalities in 8 patients, 
intestinal metaplasia in 10 patients, low grade dysplasia in 3 patients, and high grade 
dysplasia in 1 patient. 
Subjects with informed consent for 
surveillance 
N = 295 
N= 4 waiting for surveillance endoscopy 
N= 1 reached endpoint at index endoscopy 
 
Subjects with PGL at index endoscopy 
N = 284 
N= 35 lost to follow-up 
- N= 5 died 
- N= 4 severe comorbidity 
- N= 17 on patients wish 
- N= 9 lost to follow-up  
  
N= 11 excluded without PGL   
- N=4 no abnormalities 
- N=3 acute inflammation 
- N=4 chronic gastritis 
 
Number of subjects still in follow-up 
N = 153 
 
N= 91 excluded from regular surveillance 
- N = 4 reached endpoint 
- N = 45 no PGL anymore 
- N = 33 limited PGL (MAPS) 
- N = 9 age >75 years 
  
Subjects with at least one surveillance 
endoscopy with multiple biopsies 
N = 279 
  
Figure 1. Study flow chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Study flow chart
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The patients’ OLGIM stage at index endoscopy was available for 190 patients (stage 0: n= 
11; stage I: n=65; stage II: n=58; stage III: n=38; stage IV: n=16; Table 1). 
Table 1. Baseline characteristics of 284 patients with premalignant gastric lesions
Variable
Gender n (%)
Male
Female
142 (50)
142 (50)
Mean age (SD) 57.8 (11.4)
Ethnicity (%)
Caucasian
Non-Caucasian
    Missing
237 (84)
44 (16)
3 (1)
BMI, kg/m2 a, SD
    Missing
26.1 (4.3)
20 (7)
Smokinga (%)
No
Yes
   Missing
204 (75)
69 (25)
11 (4)
Alcohola (%)
No
Yes
   Missing
 127 (48)
136 (52)
 21 (7)
Family history of gastric cancer (%)
No
Yes
   Missing 
 183 (72)
72 (28)
29 (10)
H. pylori infectionb (%)
Negative
Positive
  Missing
201 (74)
71 (26)
12 (4)
Most severe lesion (%)
Atrophic gastritis
Slight IM
Moderate IM
Severe IM
Low grade dysplasia
High grade dysplasia
11 (4)
81 (29)
114 (40)
53 (19)
23 (8)
2 (1)
OLGIM classification (%)c
0
I
II
III
IV
  Missing
11 (6)
66 (35)
58 (30)
38 (20)
17 (9)
93 (33)
aAt T1 
bBased on histology at index endoscopy
cOnly applicable if biopsies in antrum and corpus were taken at baseline
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Progression and regression according to most severe lesion
Two-hundred seventy-nine (99%) patients underwent at least one surveillance endoscopy. 
The first surveillance endoscopy was performed after a mean time of 35 months (SD 
28.8). In total, 814 endoscopies (average 2.9 per patient, range 1-7) were performed 
within a mean follow-up time of 57.1 months (SD 35.5) and a total of 1,312 patient-years. 
Persistent H. pylori infection based on histological evaluation was present in 14 patients 
(5%). 
Table 2 shows the progression and regression by means of most severe gastric lesions 
at index endoscopy compared with last performed surveillance endoscopy. Progression 
occurred in 11 patients (4%). Progression to a visible dysplastic or early cancer lesion 
was observed in four patients (1.4%). This equals to one case of neoplastic progression 
per 328 patient years. Three out of these four patients had been diagnosed with IM 
at index endoscopy, and one with HGD (without visible lesions). Three patients (1.1%) 
progressed to LGD, which equals to one new case with LGD per 437 patient-years. In 
165 patients (59%) no progression nor regression was found. Histology in these patients 
revealed IM in 98.2% of patients, AG in 1.2%, and LGD in 0.6% of patients. Regression 
was observed in 103 patients (37%). Twenty-two patients diagnosed with LGD at index 
endoscopy regressed to IM (73%), AG (5%) or gastritis/normal histopathology (23%). 
Eight of them (36%) had positive H. pylori histology and/or positive serology. Twenty-
seven (32%) patients with IM at index endoscopy regressed to AG (13%), gastritis (40%), 
and normal histopathology (47%). Four (36%) patients with AG regressed to gastritis 
(25%) and normal histopathology (75%). No regression was observed in cases with HGD 
at baseline. H. pylori was successfully eradicated in 79% of the H. pylori positive patients 
at index endoscopy. In these patients stable disease or regression was observed in 93%, 
compared to 97% of patients who were H. pylori negative at time of index endoscopy 
(p= 0.14). 
Progression and regression according to OLGIM stage
To assess OLGIM stages over time, only patients in whom biopsies from antrum and 
corpus were available at index endoscopy, were included. The results between index 
and last surveillance endoscopy according to the OLGIM stages are shown in table 3. This 
comparison revealed regression to a lower OLGIM stage in 48% of the cases after a mean 
follow-up time of 54 months (SD 35.9). In 32% of the patients the OLGIM did not change 
over time, whereas progression was observed in 20%. In table 4 the OLGIM stages of 
the first and second surveillance endoscopy, with a planned surveillance interval of 24 
months, are shown. In all these cases (n = 211) an extensive biopsy protocol was used. The 
mean follow-up time between first and second surveillance endoscopy was 24.6 months 
(SD 5.9). 
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Table 3. OLGIM stage at index and last surveillance endoscopy in 190 patients (mean follow-up of 
54 months)
Tmax Regression Stable Progression
0 I II III IV
N=190 65 39 42 37 6 91 (48%) 61 (32%) 39 (20%)
T0
0 11 10 1 0 0 0 - 91% 9%
I 66 24 20 13 9 0 36% 30% 33%
II 58 17 11 15 14 1 49% 26% 26%
III 38 11 7 8 11 1 68% 29% 3%
IV 17 2 0 6 5 4 76% 24% -
Squares denote the patients who had the same OLGIM stage (0, I, II, III, or IV) at both index (T0) 
and last surveillance endoscopy (Tmax) (mean follow-up 54 months). Above the diagonal indicates 
patients in whom OLGIM stage became higher during follow-up. Under the diagonal indicates 
patients in whom OLGIM stage became lower during follow-up. 
Table 4. OLGIM stage at first and second surveillance endoscopy in 211 patients (mean interval of 
25 months)
T2 Regression Stable Progression
0 I II III IV
N=212 68 45 52 38 8 58 (27%) 99 (47%) 54 (25%)
T1
0 75 48 16 10 1 0 - 64% 36%
I 30 8 12 7 2 1 27% 40% 33%
II 57 9 13 20 13 2 39% 35% 26%
III 32 2 4 8 16 2 44% 50% 6%
IV 17 1 0 7 6 3 82% 18% -
Squares denote the patients who had the same OLGIM stage (0, I, II, III, or IV) at both first (T1) 
and second surveillance endoscopy (T2) (mean interval 25 months). Above the diagonal indicates 
patients in whom OLGIM stage became higher during follow-up. Under the diagonal indicates 
patients in whom OLGIM stage became lower during follow-up. 
Progression and regression according to MAPS guideline
In total 202 patients (72%) were eligible for evaluation of the MAPS guideline, as 
biopsies were available from both antrum and corpus, or histology showed dysplasia at 
baseline. In our cohort 71 patients (35%) were categorized as low risk, and 131 (65%) as 
high risk. Their overall mean follow-up time was 54.9 months (SD 36.4). Table 5 shows the 
regression and progression rate of both groups. Progression rate in the low risk group 
was 15%, compared to 2% in the high risk group (p<0.001). One patient (1%) of the low 
risk group was diagnosed with (early) gastric cancer, compared to 3 patients (2%) of the 
high-risk group (p=0.67), which equals to one neoplastic progression per 307 patients-
years vs. one case per 205 patient-years. 
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Table 5. Regression and progression according to MAPS guideline
Tmax
Low High HGD/cancer Regression
58 (29%)
Stable
131 (65%)
Progression
 13 (6%)N=202 118 81 3
T0
Low risk 71 60 10 1 - 85% 15%
High risk 131 59 70 2 45% 53% 2%
Squares denote patients who had the same risk at both index (T0) and last surveillance endoscopy 
(Tmax) (mean follow-up time 55 months) Above the diagonal indicates patients who progressed 
to the high risk group or developed (early) gastric cancer during follow-up. Under the diagonal 
indicates patients who regressed to the low risk group. Low risk means patients with mild and 
moderate AG or IM limited to antrum, while patients with moderate to severe AG or IM in both 
antrum and corpus as well as those with dysplasia were considered at high risk.
HGD/gastric cancer
During follow-up, four patients were diagnosed with HGD/gastric cancer within a 
mean time of 49 months (SD 25.3) after index endoscopy. Table 6 summarizes these 
patients. OLGIM stage at index endoscopy varied between stages I and IV. Two patients 
underwent successful endoscopic submucosal dissection (ESD) of the lesion. Histology 
of the resected specimens showed high-grade dysplasia without infiltrative growth, 
two intestinal type gastric cancers, and one diffuse type gastric cancer with signet cells. 
Histology of surrounding tissue of the lesion (assessed after surgery or ESD) showed IM 
in all specimens, except for the diffuse type carcinoma. One patient died 8 months after 
ESD, which appeared not to be related to gastric cancer or ESD. Total gastrectomy was 
performed in two patients: histology showed signet cells in one patient, and the other 
had dysplastic lesions in both antrum and cardia. The latter patient died 3 months post-
operative due to septic shock based on massive intestinal ischemia and perforation. 
Table 7. MAPS guideline, serology markers and detection of HDG/gastric cancer during follow-up
Tmax
HDG/gastric cancer
N=234 3 (2%)
T serum
Low risk 42 0 (0%)  
High risk 192 3 (2%)
Based on both histology and serology results, patients were categorized into a low risk or high risk 
group. Low risk was defined as low risk according to MAPS guideline and normal biomarkers (no 
H. pylori, normal PgI/PgII and G-17 levels). High risk group was defined as high risk according to 
MAPS guideline or abnormal biomarkers. Both histology and serology were obtained at the same 
moment. HGD/gastric cancer was diagnosed at this time point (n = 1) or during follow-up (n = 2). 
Mean follow-up was 23 months (SD 17.1). 
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Serologic markers: pepsinogens, gastrin, and H. pylori 
During follow-up, serum samples were obtained from 234 patients (84%). In 61 patients 
(26%) all biomarkers tests were normal. In this group, one patient was diagnosed with 
HGD/gastric cancer, compared to two patients with abnormal serology results (p = 0.77). 
H. pylori serology was positive in 121 patients (52%). According to the manufacturers’ 
references, antral atrophic gastritis (defined as low G17, normal PgI/II ratio), was 
observed in 58 patients (25%), while atrophic gastritis limited to the corpus (defined as 
normal G17, low PgI/II ratio) was measured in 37 (16%) patients. In only one patient an 
atrophic pangastritis was observed (defined as low PgI/II ratio and low G17). Serologic 
markers with their corresponding OLGIM stage are depicted in Figure 2. Mean serologic 
levels of PgI, PgI/PgII, and G-17 differed significantly between OLGIM categories, but 
were not consistently correlated with an increase in OLGIM stage. The mean values PgI, 
PgII, PgI/PgII, and G-17 differed significantly between low and high MAPS risk groups 
with serology and histology showing matching low and high risk categories (Figure 3). 
When patients were divided into low and high risk groups based on both histology and 
serology results, no patients in the low risk group progressed to HGD/gastric cancer, 
compared to 3 patients in the high risk group (p = 0.41). One out of the four cases who 
progressed to HGD/gastric cancer could not be included in above descripted comparison 
due to missing serologic data. 
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DISCUSSION
Although the incidence of gastric cancer has strongly declined in most Western countries 
over the past 80 years, it remains a relatively common malignancy with marked differences 
between subgroups in our populations. We have over the years come to understand 
risk factors for progression. Two recent guidelines thus recommended risk stratification 
of patients with surveillance of those at highest risk (5, 14). These recommendations 
need further support from prospective cohort studies that report on the incidence of 
disease progression, and also assess methods for risk categorization. This multi-center 
prospective cohort study helps to provide this background. It showed stable disease in 
the majority of patients during an average 4.7 years follow-up. In total, four cases (1.4%) 
showed neoplastic progression and were diagnosed with early curable HGD/gastric 
cancer during follow-up. Neither the OLGIM classification, nor the MAPS guideline were 
completely sufficient in discriminating low risk from high risk patients as a sole selection 
tool. Addition of serology markers helped to identify the subgroup without progression 
to neoplasia during follow-up. 
The majority of patients with precursor lesions will never develop gastric cancer. 
Consequently, the yield of surveillance endoscopy in all patients with premalignant 
lesions is low. This phenomenon is also known for surveillance of Barrett’s esophagus, 
and colorectal surveillance after adenoma removal. Surveillance of all patients leads 
therefore to an unnecessary burden for patient and endoscopic resources. It is known that 
the gastric cancer risk increases with progression of the lesion according to the Correa 
cascade (15, 16). The international MAPS consensus guideline therefore recommended 
endoscopic follow-up only for patients with marked AG and IM in both antrum and 
corpus, and for those with dysplasia (5). We are the first to evaluate this approach in a 
prospective study. 
The rate of neoplastic progression did not significantly differ between high and low 
risk patients, categorized according to the MAPS guideline. One patient, categorized as 
not in need for endoscopic surveillance, developed a visible lesion with HGD that was 
successfully removed by ESD. Nevertheless, the majority of patients (85%) in this low risk 
group had stable disease during follow-up. Long-term follow-up is necessary to confirm 
that indeed most patients will not develop gastric cancer in future. The same applies 
for the OLGIM classification, which has been shown as an accurate staging system for 
the extent and severity of intestinal metaplasia (13). This staging system is comparable 
with the operative link on gastritis assessment (OLGA) (17), but interobserver agreement 
for scoring IM was superior to AG (kappa 0.9 vs. 0.6) (13). High stages of OLGA and 
OLGIM are associated with a higher risk for progression to gastric cancer, and endoscopic 
surveillance may only be necessary in these patients (18). Nevertheless, three out of four 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Surveillance of premalignant gastric lesions
205
8
patients who developed gastric cancer during follow-up had a low OLGIM stage (I-II) at 
index endoscopy. It indicates that one risk stratification tool based on histopathology 
only is not sufficient for distinction between low and high risk patients.
In our study, combining histopathology data with serologic markers adequately 
discriminated between low risk and high risk patients. None of the patients with mild or 
moderate AG/IM limited to antrum (low risk according to MAPS) and normal serologic 
parameters developed HGC/gastric cancer during follow-up. Pepsinogen I and II are pro-
enzymes produced by the gastric mucosa, which can be used in the assessment of the 
functional status of gastric mucosa (19). A pepsinogen I/II ratio <3 is well related with 
corpus atrophy (20). Serum gastrin-17 correlates with the functional status of gastric 
antral glands, and levels are reduced in case of severe antrum atrophy (19). Normal 
serology levels, including a negative H. pylori test, gives greater confidence in stopping 
endoscopic surveillance in patients with moderate AG/IM limited to the antrum. Serology 
tests are non-invasive for patients and its implementation in risk stratification and 
decision making on endoscopic surveillance could help reducing the burden on patients 
and endoscopic resources. 
Regression of histopathology findings was observed in about one third of the patients. 
Remarkably, more than 90% of the cases with LDG at index endoscopy showed regression 
to less advanced lesions during follow-up. This regression occurred after H. pylori 
eradication in some patients, but may in part also have been related to sampling error, 
especially if lesions had a patchy distribution. Regression may be a reason for ending 
the endoscopic surveillance. In a large population based cohort no increased incidence 
for gastric cancer was found in patients with regression to less advanced lesions after 10 
years follow-up, except patients with dysplasia at baseline (16). 
Our study is limited by the relatively short follow-up time of 4.7 years. Gastric cancer 
development is usually a slowly ongoing process. This implies that patients at risk should 
be followed longer. A second limitation is that we used regular white-light endoscopy. The 
use of narrow band imaging (NBI) is recommended, but still not routine practice in most 
countries (5). As such, our study reflects daily clinical practice. This study is also limited 
by the small number of patients with neoplastic progression. Both The Netherlands and 
Norway represent low incidence regions for gastric cancer. The number of four cases 
with HGD/gastric carcinoma allowed to use descriptive statistics only.  
In conclusion, this multi-centre prospective cohort study in a low gastric cancer area 
showed that with a surveillance program for premalignant gastric lesions, gastric cancer 
can be detected at an early curable stage with an overall risk of neoplastic progression 
of 0.3% per year. Risk stratification only based on histopathology may result in excluding 
patients at risk for gastric cancer from follow-up. Serology markers as non-invasive tool 
for differentiation between low and high risk patients may be added. 
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SUMMARY
This thesis focused on the epidemiology of Helicobacter pylori, the association with 
extra-gastric diseases, and the surveillance of premalignant gastric lesions. It consists of 
in total four different parts. Part one provides an introductory summary on the main and 
related topics of this thesis, including gastritis, epidemiology and treatment of H. pylori, 
associated non-malignant diseases, and premalignant gastric lesions. Part one ends with 
a description of the aims and outline of this thesis. 
In part two, we showed that ethnicity is a strong predictor for H. pylori colonization 
in young women. As mothers are important for transmission of H. pylori to the next 
generation, these data show that H. pylori will remain prevalent in groups with a non-
Western ethnic background. Despite the great variance in H. pylori prevalence between 
ethnic groups, the intergenerational decline was similar for all groups. It indicates the 
importance of environmental factors in the transmission of H. pylori.
In part three we showed that H. pylori colonization is an independent risk factor for 
severe nausea and vomiting during pregnancy, leading to low maternal weight gain and 
an increased risk for the newborn of small for gestational age. H. pylori colonization in 
pregnant women appeared also to be associated with an increased risk on preeclampsia. 
This makes eradication of H. pylori in women with a complicated pregnancy an attractive 
target for future intervention studies. We observed no significant protective association 
of H. pylori status in children at age 6 with asthma and related conditions. Instead, 
colonization with a CagA-negative H. pylori strain at age 6 was a risk factor for asthma, 
but only in those of European ethnic background. The underlying mechanisms for the 
observed risk differences require further research. The Mendelian randomization study 
showed no causal bi-directional link between H. pylori and obesity or body mass index. 
Follow-up of patients with premalignant gastric lesions revealed a low incidence of 
neoplastic progression. Risk stratification may benefit from serology markers, including 
pepsinogens, for adequate differentiation between low and high risk patients. 
The final part of this thesis discusses the main conclusions from our research projects and 
directions for future research. 
EPIDEMIOLOGY OF H. PYLORI IN A MULTI-ETHNIC POPULATION (PART II)
H. pylori is a gram-negative bacterium, which colonizes more than half of the world’s 
population. The prevalence of H. pylori widely varies geographically, and is highest in 
developing countries. In Western countries, however, prevalences have been declining 
over recent decades to below 40% – supposedly as a result of improved hygiene and 
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sanitation and the active elimination by antibiotics (1). In parallel to the declining 
infection rate, incidences of H. pylori-related diseases also have shown a major decline 
(2, 3). Acquisition of infection usually occurs in early childhood, and is mainly transmitted 
within families (4). As test-and-treat strategies for H. pylori both on population as well as 
individual level are unlikely to be cost-effective in low prevalence countries, identification 
of risk groups is necessary (5). Knowledge about specific risk groups may permit assessment 
of disease risk, and will offer opportunities for targeted interventions. The H. pylori 
colonization rate is associated with factors such as age, socioeconomic status, childhood 
crowding, and non-western ethnicity (6). During past decades, many immigrants from 
developing countries with high H. pylori prevalence have settled in Western urban 
areas. In Rotterdam, a large Western city, more than 50% of the urban population 
originated from outside The Netherlands. The largest non-Dutch ethnic groups consist 
of people from Morocco, Turkey, Suriname, Dutch Antilles, and Cape Verde. Previous 
studies indicated that H. pylori colonization rates in immigrants are higher compared to 
native western populations (7-9). Some of these migrant communities have a high risk 
of gastric cancer (10, 11), in which H. pylori is involved as the major causative agent. We 
defined the presence of antibodies against H. pylori and CagA within pregnant women 
participating in a large population based cohort, called the Generation R study (chapter 
2). Overall, 46% of the 6,837 tested women were H. pylori-positive, and 35% of them 
were CagA-positive. Prevalences of H. pylori were highly variable between the different 
ethnic groups, with the lowest prevalence in Dutch women (24%), and the highest in 
Moroccan women (92%). The proportion of CagA-positive strains was also higher among 
women of non-Dutch origin. Multivariate logistic regression showed ethnicity as the 
strongest predictor for H. pylori colonization. The relatively high prevalence of H. pylori 
and CagA-positive strains found in ethnic minority groups indicates that the health risks 
imposed by H. pylori remain a significant concern. Studies comparing first and second-
generation immigrants with the native population have demonstrated a higher risk for 
non-cardia gastric cancer in first-generation immigrants (12, 13). Childhood colonization 
with H. pylori could be a possible cause (4, 14). Therefore, these migrant communities 
constitute target groups for screening of H. pylori to minimize H. pylori-related diseases.
The prevalence of colonization differs between children and adults (15). Several cross-
sectional surveys in Western countries have shown that H. pylori prevalence increases 
with age (16, 17). Since acquisition during adulthood is rare (18, 19), the higher 
prevalence in the elderly rather reflects a birth cohort effect with higher rates of 
childhood exposure to the organism in the past (1). We analysed the serum of 4,467 
children (age 6 year) participating in the Generation R study, and compared the results 
with the H. pylori status of their mothers (available for 3,185 children). These results 
are described in chapter 3. Overall, 438 (10%) children were H. pylori-positive, of whom 
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142 (32%) were CagA-positive. Independent risk factors for colonization were: maternal 
H. pylori positivity, non-Dutch ethnicity, female gender, and lower maternal education 
level. Unexpectedly, by comparing mothers and children, we found an intergenerational 
decrease of 76% and 77% for Hp+CagA- and Hp+CagA+-strains, respectively, consistent 
across all nine ethnic groups studied. Male gender, higher maternal educational level, 
and no older siblings, were independently associated with absence of H. pylori. A recent 
study from Japan independently confirms a similar decline in two generations: the 
prevalence in mothers and their children showed a reduction of 72% (20). Our findings 
imply that environmental factors and living conditions of the country in which a child 
is raised have a major impact on transmission, irrespective of ethnicity. It supports the 
hypothesis that in contemporary societies there are high prevalent factors that interfere 
with the early life acquisition and/or maintenance of H. pylori. Besides the involvement 
of socio-economic status, family size, and other living conditions, possible candidates 
include the widespread use of antibiotics, particularly in young children. The association 
of specific H. pylori types in mother and child provides further evidence supporting a 
role for maternal inheritance in early life transmission, shown in molecular typing studies 
(21). However, as one-third of the H. pylori positive tested children had an H. pylori-
negative mother, other transmission sources must also play a role, such as fathers and 
siblings (21), or grandmothers (20). Unfortunately, we were not able to test them for H. 
pylori positivity. There also is evidence for transmission from outside the nuclear family, 
including environmental reservoirs or other children in the community (22, 23), although 
these seem more likely in developing than in developed countries (24). Day-care centres 
may also act contact environment for child-to-child transmission (25). However, in our 
study we observed no association between day-care attendance and H. pylori status. 
Future perspectives
The yield and cost-effectiveness of screening and eradication of H. pylori in migrant 
communities requires further research. In particular, the focus should be on first-
generation immigrants, as their children born in a Western country already have a 
lower risk on being H. pylori positive. Due to the importance of environmental factors 
in transmission, one may expect that differences in prevalence between children of the 
next generation will be less distinct and closer to the prevalence of children from Dutch 
origin. Nevertheless, given the actual refugees movements from high endemic regions, 
this topic will remain relevant in the coming future. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 9
216
H. PYLORI, EXTRA-GASTRIC DISEASES, AND PREMALIGNANT LESIONS 
(PART III) 
H. pylori and pregnancy complications
In the Western world, severe nausea and vomiting during pregnancy (NVP) more often 
affects socially disadvantaged women and those of non-Western ethnicity (26, 27). 
To date, there is no clear explanation for the risk differences between Western and 
non-Western ethnic groups. In a recent meta-analysis, colonization with H. pylori was 
positively associated with severe NVP (28). Interestingly, as observed in chapter 2, the H. 
pylori prevalence in pregnant women of Western ethnicity is much lower than in women 
of non-Western ethnicity (29). 
In chapter 4, we investigated the association of H. pylori with vomiting severity and single 
and combined effects of H. pylori and daily vomiting on birth outcomes, in pregnant 
women participating in the Generation R study. Furthermore, we investigated whether 
H. pylori explains the marked ethnic differences in maternal daily vomiting incidence. 
In total, 5,549 women were included. H. pylori-positive women (n=2,363) were more 
likely to suffer from daily vomiting (adjusted odds ratio 1.44, 95%CI 1.16;1.78). H. pylori-
positivity reduced total weight gain in women with daily vomiting (adjusted difference 
-2.1 kg, 95%CI -2.7;-1.5) and infants born to women with H. pylori and daily vomiting 
had an increased risk of being small for gestational age (SGA; aOR 1.49, 95%CI 1.04;2.14). 
To our knowledge, this was the first prospective cohort reporting on the association 
between H. pylori and daily vomiting as well as birth outcomes. The study confirms the 
association between H. pylori and daily vomiting and adds to the existing evidence that 
the presence of H. pylori is associated with low maternal weight gain. More importantly, 
we found evidence that H. pylori contributes to SGA. It is possible that H. pylori has a local 
gastrointestinal effect leading to NVP symptoms, and a systemic placental effect resulting 
in an increased risk for SGA. The involvement of systemic inflammatory responses in 
complicated pregnancies has led to the hypothesis that maternal infections may play 
a role in the etiology and pathogenesis of these pregnancy complications (30, 31). 
Although the exact causes are still unknown, one hypothesis for their origin is that they 
each are related to suboptimal placentation in early pregnancy (32-34). In this respect, 
colonization with H. pylori may be of interest as it might be involved in the pathogenesis 
of impaired remodeling of the spiral arteries (35). It has been shown that anti-CagA 
antibodies in vitro were able to recognize β-actin on the surface of trophoblast cells in a 
dose-dependent binding activity (35). This binding resulted in impaired cytotrophoblast 
invasiveness, which is crucial for the development of placental mediated pregnancy 
complications. 
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In chapter 5 we focused on H. pylori and three pregnancy related complications 
separately, including pre-eclampsia (PE), fetal growth restriction (SGA), and spontaneous 
preterm birth (PTB). In total, 6,348 pregnant women were assessed, all participating in 
the Generation R study. Multivariate analysis showed H. pylori colonization associated 
with PE (aOR 1.51; 95%CI 1.03-2.25). Differentiation according to CagA-status revealed 
increased risk for SGA (aOR 1.34; 1.04-1.71) in CagA-positive mothers. No association was 
observed between H. pylori and PTB. Our data suggest that H. pylori colonization could 
be a risk factor for PE and that carriage of a CagA+ H. pylori strain is a risk factor for SGA. 
These findings may be helpful for a better understanding of the pathogenesis of these 
pregnancy complications and support the link with chronic inflammatory conditions. 
Although PE, SGA, and PTB are different clinical entities, all three may be caused by 
suboptimal deep placentation in early pregnancy (34) (36-39). Large numbers of non-
transformed spiral arteries are frequently observed in PE patients with or without SGA 
(34), in patients with SGA without gestational hypertension (36, 37), and in patients with 
preterm labor with or without preterm pre-labor rupture of membranes (PROM) (38, 39). 
Impaired remodeling of the spiral arteries may lead to insufficient uteroplacental arterial 
flow and episodes of irregular placental perfusion (32). Such impaired remodeling might 
be due to failure of appropriate uterine preconditioning (40), and excessive or atypical 
maternal immune responses to trophoblasts (41). Although association does not directly 
imply causation, our findings may have a biological explanation, as observed in the study 
mentioned above (35). 
Future perspectives
If these associations are confirmed by future studies and shown to be causal, screening 
and intervention (e.g. H. pylori eradication treatment) may reduce related perinatal 
morbidity and mortality. The need for such intervention studies is highlighted by the 
fact that treatment options for severe NVP are currently lacking. Several case studies 
have reported that H. pylori eradication effectively relieved symptoms in women with 
persistent vomiting, unresponsive to conventional treatment. No teratogenic effects of 
PPI use in early pregnancy, or amoxicillin, and metronidazole were described (42-45). 
These studies indicate that triple therapy consisting of PPI, amoxicillin and metronidazole 
may be safely used in pregnancy. Further evidence from a randomised controlled trial is 
needed to confirm the effectiveness of H. pylori eradication on NVP symptom reduction, 
PE, and adverse birth outcomes.
H. pylori and asthmatic conditions 
H. pylori is suggested to have not only pathogenic properties. Considered as a human 
commensal, H. pylori is thought to influence the development of the host immune 
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system (16). H. pylori has a strong interaction with the gastric mucosa. Because of the 
adaptive immunological activity of the stomach in terms of both T and B-cell function, 
it is thought that this interaction influences the maturation of the immune system. The 
“disappearing microbiota” hypothesis states that changes in our microbiota affected 
by altered ecological circumstances explain the increasing prevalence of atopic diseases 
like asthma and allergy obesity (16). H. pylori is a specific component of the human 
microbiome. In this context, several epidemiological studies showed an inverse relation 
between H. pylori colonization and asthma occurrence (46), but data are conflicting. 
In chapter 6, we examined the association between H. pylori colonization in 3,797 
children and risk of asthma and related conditions at school age. We secondly examined 
additional effects of maternal H. pylori status by pairing with children’s status. A child’s 
colonization with a CagA-negative-H. pylori strain was associated with an increased risk 
of asthma (Odds ratio 2.11; 95% CI 1.23-3.60, but this differed for European (3.64; 1.97-
6.73) and non-European (0.52; 0.14-1.89) children. When taking into account maternal 
H. pylori status, only H. pylori positive children with an H. pylori negative mother had 
increased risk of asthma (2.42; 1.11-5.27), accounting for 3.4% of the asthma risk. These 
results do not support the “disappearing microbiota” hypothesis for children at the age 
of 6. Based on our results only, we are not able to explain the risk difference between 
children of European and non-European ethnic background. Nevertheless, we have 
the following considerations. First, in the group of children with an European ethnic 
background, none of the asthmatic children were colonized with a CagA-positive strain. 
This suggests that the asthma risk may be lower in CagA-positive children compared with 
H. pylori-negatives. Due to lack of CagA-positives in asthmatic children in this subgroup, 
the overall detected effect of H. pylori-positivity might be skewed to an increased risk 
for asthma. It has been shown that CagA-positive strains have a stronger interaction 
with their hosts, leading to pronounced immune responses (47). Second, although an 
association between H. pylori and asthma was only present in children of European 
ethnic background, consistent trends were observed for wheezing, eczema, and inhalant 
allergy, either for CagA-negative or CagA-positive strains. Such differences may reflect 
variation of the gut microbiome by ethnicity, in both richness and composition. Children 
(48) and adults living in developing countries have significantly greater faecal diversity 
than those in developed countries (49). Among subjects differing in ethnic background, 
but migrating to the same country, gut microbiome composition also varies (50). Within 
this context, we speculate that the effects of H. pylori on asthma or related disease may 
depend on both the richness and composition of the gut microbiome. Depending on its 
composition, it might sometimes promote and other times mitigate H. pylori disease (51).
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Future perspectives
A diagnosis of childhood asthma is most reliable if obtained by respiratory function 
test. In future studies, including this continuing prospective cohort study, assessment 
of the association between H. pylori colonization and respiratory function test based 
asthma may contribute to the discussion on this topic. It will help physicians to decide 
whether they have to eradicate or preserve the actual H. pylori colonization in children. 
Explanations of underlying mechanisms for the differences between ethnic groups are 
still speculative, and therefore need further research. Such studies also should include the 
role of the gut microbiome in relation to H. pylori colonization and ethnic background, 
which may indicate new directions for asthma prevention. 
H. pylori and BMI/obesity 
H. pylori colonization is virtually always associated with chronic active gastritis, which can 
have various effects. This includes interference with gastric hormone regulation, including 
ghrelin and leptin. Both have multiple roles in energy homeostasis (52). Disturbance of 
their normal regulation interferes with metabolism and our energy household. H. pylori 
eradication increases serum ghrelin levels (53). Several epidemiological studies have 
recently focused on the correlation between H. pylori colonization and BMI and obesity. 
They showed contrasting results, which were based on H. pylori status and BMI data, 
but did not include genetic information (54-58). Incorporation of genetic data could 
give unbiased information on the presumed association. In chapter 7, we assessed the 
association between H. pylori and BMI/obesity among 13,044 subjects participating in two 
large population-based cohorts. Cross-sectional analysis did not demonstrate a clinical 
relevant association between H. pylori colonization and BMI, neither when examined 
by means of serology, nor by fecal antigen. By means of a Mendelian Randomization 
approach, we were able to assess a causal relationship between H. pylori and BMI/
obesity. However, bi-directional Mendelian randomization revealed no causal relation 
between H. pylori and BMI/obesity. 
Future perspectives
The causes of obesity are diverse. Amongst others, gut microbiome composition and 
diversity seems to play a role. We only tested one of the members of the ancient indigenous 
microbiome. Future studies, including a broader spectrum of the microbiome, are needed 
to further assess any potential causal relationship between the gut microbiome and BMI/
obesity. 
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Premalignant gastric lesions and gastric cancer
Premalignant gastric lesions predisposes to the development of intestinal type gastric 
cancer, with H. pylori considered as the starting point which leads to inflammation, 
metaplasia, low-grade dysplasia, high-grade dysplasia and eventually carcinoma in 1-2% 
of the infected patients (59). As a result, regular endoscopic follow-up is recommended 
in patients with premalignant gastric lesions. However, most of the patients with H. 
pylori and premalignant gastric lesions do not develop gastric cancer. Moreover, 
a substantial part of patients shows regression during endoscopic follow-up (60). 
Therefore, identification and screening of only a subpopulation at high risk of gastric 
cancer is indicated. This will additionally result in a decrease in burden for patients and 
endoscopy resources.
In chapter 8 we showed a low incidence of neoplastic progression during follow-up 
of patients participating in a multi-centre prospective cohort study. Consequently, the 
yield of surveillance endoscopy in all patients with premalignant lesions is low. Risk 
stratification according to the MAPS guideline is helpful to exclude low risk patients from 
surveillance. Nevertheless, we observed that stratification only based on histopathology 
may result in excluding patients from follow-up, who still are at risk for gastric cancer. 
We found that addition of serologic markers, including pepsinogens, was of value as 
non-invasive tool for differentiation between low and high risk patients. Regression of 
histopathology findings was observed in about one third of the patients, which can be 
result of sampling error, misclassification or true regression. The latter may be a result 
of H. pylori eradication therapy, in particular in patients with non-atrophic and atrophic 
gastritis (61). Whether eradication of H. pylori has effect on intestinal metaplasia is 
still under debate, but it may slow progression to neoplasia which is an argument for 
eradication (62). 
Future perspectives
Longer follow-up of patients with premalignant gastric lesions is necessary to confirm 
our results. The current European guideline does not take into account differences in H. 
pylori and gastric cancer incidence between different parts of Europe. Future studies are 
needed to answer the question whether widening of the screenings interval is possible 
in areas with a low gastric cancer incidence. The use of narrow band imaging (NBI) is 
recommended by guidelines, but not routine practice in most countries. Although a 
simple validated classification system is still lacking, use of NBI may enlarge the yield of 
targeted biopsies. 
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CONCLUSIONS
In this thesis, we aimed first to get insight in the current epidemiology of H. pylori 
colonization in a multi-ethnic Western population. Highly variable prevalences of H. pylori 
were observed between different ethnic groups. Nevertheless, H. pylori colonization 
rate is rapidly decreasing in the next generation, independent of ethnic background. It 
highlights the importance of common environmental factors in the transmission of H. 
pylori. 
We secondly aimed to assess the association of H. pylori with extra-gastric diseases. No 
protective effect of H. pylori colonization on asthma was observed for children at the 
age of 6. In pregnant women, H. pylori colonization was associated with an increased 
risk on severe vomiting during pregnancy, and preeclampsia. We further focused on the 
long-term effect of H. pylori colonization at higher age. We observed a low incidence of 
neoplastic progression in patients who were followed because of premalignant gastric 
lesions. At least in adults, above mentioned studies support eradication of H. pylori in 
risk groups in order to prevent associated disease in future. 
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NEDERLANDSE SAMENVATTING
Dit proefschrift richt zich op het actuele vóórkomen (epidemiologie) van Helicobacter 
pylori (H. pylori) in een multi-etnische populatie, het vóórkomen en vervolgen van 
voorloperafwijkingen van maagkanker en het richt zich op de associatie tussen H. 
pylori en ziekten buiten de maag. Het proefschrift heeft vier delen. Deel één geeft een 
introductie en samenvatting van de belangrijkste onderwerpen van dit proefschrift: 
gastritis, het vóórkomen en de behandeling van H. pylori, associaties met niet-
kwaadaardige ziekten, en voorloperafwijkingen van maagkanker. Dit deel eindigt 
met een beschrijving van het doel en de opzet van het proefschrift. Deel twee bevat 
de studies naar het actuele vóórkomen van H. pylori. In deel drie staan de studies die 
gaan over de associatie van H. pylori met ziekten buiten de maag en de follow-up van 
patiënten met voorloperafwijkingen van maagkanker. Deel vier geeft een samenvatting 
van het geheel en bevat de belangrijkste conclusies.  
HET VÓÓRKOMEN VAN H. PYLORI IN EEN MULTI-ETNISCHE POPULATIE 
(DEEL TWEE)
H. pylori is een gram-negatieve bacterie die bij meer dan de helft van de wereldbevolking 
wordt aangetroffen. Het vóórkomen van deze bacterie verschilt wereldwijd zeer, waarbij 
de meeste infecties in ontwikkelingslanden worden gevonden. In westerse landen 
wordt al jaren een dalende trend gezien, waarbij in de doorsnee bevolking minder dan 
40% geïnfecteerd is met H. pylori. Redenen van deze dalende trend zijn onder andere: 
verbeterde hygiëne, kleinere gezinnen waardoor er minder kans is op besmetting en 
het veelvuldig gebruik van antibiotica. Gelijktijdig met deze dalende trend nemen 
ook de aan H. pylori gerelateerde ziekten af in voorkomen. Dit betekent dat minder 
mensen lijden aan peptische ulcera (maagzweren) en dat ook het vóórkomen van 
maagkanker afneemt. H. pylori infectie treedt meestal op bij jonge kinderen, waarbij 
andere gezinsleden dan de bron zijn. Omdat het testen en behandelen van H. pylori 
op populatieniveau niet kosteneffectief is, is het noodzakelijk om risicogroepen te 
definiëren. Kennis van specifieke risicogroepen is belangrijk omdat dit mogelijkheden 
biedt voor gerichte interventie. Infectie met H. pylori is geassocieerd met leeftijd, 
socio-economische status, groot kinderaantal en niet-westerse etnische achtergrond. 
Gedurende de laatste decennia hebben veel immigranten uit landen met een hoog 
H. pylori percentage zich gevestigd in stedelijke gebieden van westerse landen. In 
Rotterdam, een grote westerse stad, is meer dan 50% van de bevolking oorspronkelijk 
afkomstig van buiten Nederland. De grootste groepen van niet-Nederlandse komaf 
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bestaan uit mensen afkomstig uit Marokko, Turkije, Suriname, Nederlandse Antillen en 
Kaapverdië. Eerder gepubliceerde studies geven aan dat H. pylori in immigranten vaker 
voorkomt dan in de autochtone westerse bevolking. Sommige van deze immigranten 
groepen hebben ook een verhoogd risico op maagkanker, waarbij H. pylori kan worden 
beschouwd als een belangrijke oorzaak hiervan. In hoofdstuk 2 beschrijven we de 
resultaten van ons onderzoek naar H. pylori in een grote groep van zwangere vrouwen 
die deelnamen aan de Generation R studie. Deze studie betreft een groot onderzoek 
in Rotterdam, waarbij zwangere vrouwen werden geïncludeerd met als doel om hun 
kinderen te vervolgen van foetale leeftijd tot aan het bereiken van volwassenheid. In 
dit proefschrift is bij meerdere studies gebruik gemaakt van de gegevens die binnen 
Generation R van deze moeders en kinderen beschikbaar waren. Wijzelf hebben zowel 
de moeders als hun kinderen getest op de aanwezigheid van H. pylori. Dit is gedaan door 
middel van het aantonen van antilichamen tegen H. pylori en CagA (een virulentie factor) 
in het serum van deze personen. In totaal hebben we 6837 zwangere vrouwen getest, 
waarbij 46% H. pylori positief bleek, en 35% van hen ook CagA positief. Er bleek een 
groot verschil in het vóórkomen van H. pylori tussen de verschillende bevolkingsgroepen 
met veel hogere percentages H. pylori positieven in mensen van niet-westerse afkomst. 
Migranten populaties vormen dus risicogroepen voor infectie met H. pylori en zijn een 
goede doelgroep voor gerichte screening en behandeling van H. pylori. 
De kinderen van bovengenoemde moeders werden getest op 6-jarige leeftijd, ook 
doormiddel van het aantonen van antistoffen in het serum. Deze resultaten worden 
beschreven in hoofdstuk 3. Onafhankelijke risicofactoren voor infectie met H. pylori 
waren: een H. pylori-positieve moeder, niet-westerse etnische achtergrond, vrouwelijk 
geslacht en lage socio-economische status. Bij de kinderen lag het percentage H. pylori 
positieven lager dan bij hun moeders, met opnieuw de hoogste percentages in kinderen 
met een niet-westerse etnische achtergrond. Echter, bij vergelijking van het cohort 
moeders en hun kinderen vonden we dat de daling in alle bevolkingsgroepen even groot 
is (76%), dus ongeacht hun etnische achtergrond. Dit duidt erop dat omgevingsfactoren 
en leefomstandigheden van het land waar het kind opgroeit (in dit geval voor alle 
kinderen Nederland) een grote invloed heeft op de transmissie, onafhankelijk van 
etniciteit. 
H. PYLORI, ASSOCIATIES MET ZIEKTEN BUITEN DE MAAG, EN 
VOORLOPERAFWIJKINGEN VAN MAAGKANKER (DEEL DRIE)
In hoofdstuk 4 onderzochten we de associatie tussen H. pylori en hyperemesis gravidarum 
(misselijkheid en braken) tijdens de zwangerschap in vrouwen die participeerden in de 
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Generation R studie. Een recente meta-analyse toonde een positief verband tussen H. 
pylori en ernstig hyperemesis gravidarum. We vonden een verhoogd risico op dagelijks 
braken bij H. pylori-positieve vrouwen. Verder was er een kleinere toename in gewicht bij 
H. pylori-positieve vrouwen met dagelijks braken en hadden hun kinderen een verhoogd 
risico op een te laag geboortegewicht. Deze studie bevestigt de relatie tussen H. pylori 
en dagelijks braken. In hoofdstuk 5 onderzochten we de relatie tussen H. pylori en drie 
zwangerschap gerelateerde complicaties: pre-eclampsie (PE), small for gestational age 
(SGA) en spontane vroegtijdige geboorte (PTB). Multivariate analyse liet zien dat H. 
pylori was geassocieerd met PE. Onderscheiding naar CagA-status toonde een verhoogd 
risico voor SGA in CagA-positieve moeders. Er bleek geen associatie tussen H. pylori en 
PTB. Indien bovenstaande associaties worden bevestigd bij toekomstige studies en ook 
causaal blijken te zijn, kan screening en behandeling van H. pylori mogelijk bijdragen 
aan het verlagen van de perinatale morbiditeit en mortaliteit. 
H. pylori heeft mogelijk niet alleen pathogene (ziekmakende) eigenschappen. Infectie 
met H. pylori draagt waarschijnlijk bij aan een betere rijping van het immuunsysteem. 
Binnen deze hypothese wordt gesteld dat de grote toename van mensen met astma 
en allergieën verband houdt met de verdwijning van H. pylori uit de populatie. In dit 
kader hebben we gekeken naar het vóórkomen van astma en allergie bij kinderen met 
en zonder H. pylori (hoofdstuk 6). Het bleek dat kinderen met H. pylori (maar zonder 
virulentiefactor CagA) juist meer risico hadden op astma dan kinderen zonder H. pylori. 
Deze uitkomst verschilde tussen kinderen van Europese en niet-Europese achtergrond, 
waarbij het risico alleen verhoogd was voor kinderen met een Europese etnische 
achtergrond. Mogelijk heeft dit verschil in effect te maken met de samenstelling van het 
darm microbioom, wat ook wordt beïnvloed door etnische afkomst. Vervolgonderzoek 
zal echter nodig zijn om onderliggende mechanismen te verduidelijken. 
Verschillende voorgaande studies hebben gekeken naar de relatie tussen H. pylori en 
obesitas (overgewicht). De resultaten zijn tegengesteld. In hoofdstuk 7 beschrijven 
we de resultaten van een grote studie naar het verband tussen H. pylori en obesitas. 
Hierin zijn zowel gegevens gebruikt over het dragerschap van H. pylori (antilichamen 
verkregen uit serum), alsook genetische informatie. Het voordeel van het gebruik van 
genetische informatie is dat dit een oorzakelijk verband kan aantonen. Ons onderzoek 
is gedaan in een grote groep volwassen (ruim 13000) woonachtig in Rotterdam en 
Pomerania (Duitsland). Er werd echter geen oorzakelijk verband gevonden tussen H. 
pylori dragerschap en obesitas. 
Infectie met H. pylori leidt tot een chronische ontsteking van het maagslijmvlies, wat 
een verhoogd risico geeft op het ontstaan van maagkanker. Dit verloopt meestal via een 
aantal stadia die zichtbaar worden in biopten (stukjes weefsel van het maagslijmvlies) 
die de patholoog onderzoekt onder de microscoop. Dit worden voorloperafwijkingen 
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van maagkanker genoemd. Deze worden vaak toevallig ontdekt tijdens een 
maagonderzoek (gastroscopie). Door het vroegtijdig herkennen en behandelen van 
deze voorloperafwijkingen kan maagkanker worden voorkomen. Echter, gelukkig niet 
iedereen met deze voorloperafwijkingen zal in de toekomst maagkanker ontwikkelen. 
Daarom is het belangrijk om vooraf een risico inschatting te kunnen maken welke 
patiënten het meeste risico lopen. In hoofdstuk 8 beschrijven we de resultaten van onze 
studie waarbij we 284 patiënten met voorloperafwijkingen van maagkanker hebben 
gevolgd. Er werd bij hen om de 2 jaar een gastroscopie verricht, waarbij biopten van 
het maagslijmvlies werden genomen. Binnen deze groep heeft 1,4% maagkanker 
ontwikkeld. Bij de meeste patiënten was er stabiele ziekte of juist vermindering 
van de afwijkingen te zien. Het bleek verder dat gebruik van serologische markers 
(bloedbepalingen) behulpzaam is voor het juist inschatten van het risico op ontstaan 
van maagkanker in de toekomst.
CONCLUSIES (DEEL VIER)
In deel vier worden de belangrijkste conclusies van de voorgaande hoofdstukken 
samengevat en in bredere context geplaatst. Verder worden per hoofdstuk aanbevelingen 
gedaan voor toekomstig onderzoek. Dit proefschrift had ten eerste tot doel om inzicht te 
krijgen in het actuele vóórkomen van H. pylori in een multi-etnische westerse populatie. 
Het blijkt dat H. pylori infectie in de nieuwe generatie steeds minder voorkomt, waarbij 
groepen van niet-westerse etnische achtergrond een verhoogd risico op dragerschap 
blijven houden. Het tweede doel was het onderzoek naar verbanden tussen H. pylori 
en ziekten buiten de maag. Er bleek geen beschermend effect te zijn van H. pylori op 
de astma en allergie in kinderen op de leeftijd van 6 jaar. In zwangere vrouwen bleek 
H. pylori een risicofactor voor ernstig braken tijdens de zwangerschap, alsook voor 
pre-eclampsie. Verder richtten we ons in dit proefschrift op de lange termijn effecten 
van infectie met H. pylori. Bij volwassenen werd geen oorzakelijk verband aangetoond 
tussen H. pylori en obesitas. In patiënten met voorloperafwijkingen van maagkanker 
werd bij een beperkt aantal ook daadwerkelijk maagkanker gevonden. Resultaten van 
hierboven besproken studies onderstrepen het nut H. pylori eradicatie in volwassenen, 
met als doel om zo H. pylori gerelateerde ziekten in de toekomst te kunnen voorkomen. 
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A
ABBREVIATIONS
AG  atrophic gastritis
ANOVA  analyses of variance
BMI  body mass index
CagA   cytoxin-associated gene A 
CI   confidence interval 
CMV  cytomegalovirus 
COX  cyclooxygenase
DCs  dendritic cells
EBV  Epstein-Barr virus
ELISA   enzyme-linked immunosorbent assay 
ESD  endoscopic submucosal dissection
FD  functional dyspepsia
FGR  foetal growth restriction
GERD  gastroesophageal reflux disease
GS  genotype score
GWAS  genome wide association study
HELLP  haemolysis, elevated liver enzymes, low platelets 
HG  hyperemesis gravidarum
HGD  high-grade dysplasia
IM  intestinal metaplasia
ITT   intention to treat
LGD  low-grade dysplasia 
MALT  mucosa associated lymphoid tissue
MAPS  management of precancerous conditions and lesions of the stomach
NSAIDs  non-steroidal anti-inflammatory drugs
NVP  nausea and vomiting during pregnancy
OD  optical density 
ODR   optical density ratio  
OLGA  operative link for gastric assessment
OLGIM  operative link for gastric intestinal metaplasia
OR   odds ratio 
PAF   population attributable fraction
PE  preeclampsia
PPI  proton pump inhibitor
PTB  spontaneous preterm birth
PUB  peptic ulcer bleeding
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PUD  peptic ulcer disease
RCT  randomized controlled trial
RS  Rotterdam Study
SD  standard deviation
SGA  small for gestational age
SHIP  Study of Health in Pomerania
SNP  single nucleotide polymorphism 
Tregs  regulatory T cells
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